Stock code：688363.SH

2024

Bloomage Biotechnology Corporation Limited

Bloomage Biotechnology Corporation Limited

Office Address: 33/F Building D Bloomage International Center No.A6 Jianguomenwai Street Beijing China. Sustainability Report

Email: esg@bloomagebiotech.com

Website: https://www.bloomagebiotech.com/About This Report

Report Introduction

This report is the second Sustainability Report (hereinafter referred to as "this Report") released by Bloomage Biotech-

nology Corporation Limited (hereinafter referred to as "Bloomage Biotech""the Group""the Company" or "We") follow-

ing four consecutive annual Corporate Social Responsibility (CSR) reports since the Company's listing in 2019. This

report discloses information pertinent to the Company's sustainable development and fulfilment of social responsibili-

ties.Report Scope

This Report covers Bloomage Biotechnology Corporation Limited together with its subsidiaries in line with the report-

ing period covered in Bloomage Biotech's Annual Report unless specifically stated otherwise. The reporting period of

this Report spans from 1 January 2024 to 31 December 2024. To ensure continuity integrity and comparability certain

content extends beyond the scope mentioned above with detailed explanations provided within the report.Basis of Compilation

Self-Regulatory Guidelines for Listed Companies of the Shanghai Stock Exchange No. 14 - Sustainability Reporting (for

Trial Implementation)’ with reference to the standards of the GRI Sustainability Reporting Standards (hereinafter referred

to as the “GRI Standards”) issued by the Global Commission International Financial Reporting Standard on Sustainability

Disclosure 1 - General Requirements for Disclosure of Sustainability-Related Financial Information (“IFRS S1”) the Framework

Recommendations of International Financial Reporting Standard on Sustainability Disclosure 2 - Climate-Related Disclosure

("IFRS S2") the United Nations Sustainable Development Goals (SDGs) the Ten Principles of the United Nations Global

Compact (UNGC) ("the Ten Principles of the UNGC") issues monitored by Morgan Stanley Capital International ESG

Ratings (MSCI) and issues monitored by EcoVadis Ratings. For readers' convenience a comprehensive index is provided

in the appendix for easy reference.Data Sources

All information presented in this report originates from internal official documents statistical reports third-party

questionaries and surveys and relevant public sources within Bloomage Biotech. Financial data is meticulously sourced

from the Company's annual reports with all monetary amounts denoted in Chinese Renminbi (RMB) unless explicitly

stated otherwise.Board Statement

This report has been deliberated and approved by the Board of Directors of Bloomage Biotech. The Board of Directors

solemnly assures that there are no falsifications or misleading statements within this report and assumes full account-

ability for the truthfulness accuracy and completeness of its content.Report Release

Both a Simplified Chinese and English version of this report will be officially published. In case of any ambiguity the

Simplified Chinese version shall take precedence.Electronic copies of this report in both Chinese and English are readily accessible through the Company's official

website and the Shanghai Stock Exchange's website:

https://www.bloomagebiotech.com/

http://www.sse.com.cn/

Feedback

For inquiries or feedback regarding this report and its contents you are welcome to reach out through the following

contacts:

Office Address: 33/F Building D Bloomage International Center No. A6 Jianguomenwai Street Beijing China.Email: esg@bloomagebiotech.comSustainable

2024 Sustainability Report CONTENTS Chairwoman and About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility Appendices

CEO's Message Management

Appendices

CONTENTS About This Report 00 Index of Indicators 117

Chairwoman and CEO's Message 01 GHG Verification Statement 123

ESG Key Performance Tables 125

01 Sustainable 04 Growth: Symbiosis: About Bloomage Biotech Development Talent Employmentand 05 Green Low-Carbon

Management Development and Resilience

Company Overview 03 Sustainable Development Fair and Standardized Employment 53 Addressing Climate Change 81

Management System 07

Major Honors of the Year 04 Talent Development 57 Environmental Compliance

Sustainability Strategy 09

Safety and Health Management

90

65

Stakeholders Engagement 10

Employee Rights and Benefits 75 Pollutant Emissions and Waste

Double Materiality Assessment 11 Management 94

Major Honors in Sustainability 15 Resource Utilization and

Circular Economy 98

02 Safeguard: 03 Driving Forces: Achievements: Responsibility: Compliance Governance R&D Innovation and 06 A Sustainable Value 07 Community Care and

and Risk Control Quality Management Chain Contributions

Board of Directors 19 R&D Innovation 33 Ensuring Supply Chain Security 105 Social Welfare and 115

Community Relations

Compliance Management 20 Quality Management 42 Supply Chain Quality Management 108

Internal Control and Risk 23 Product Accessibility and Supply Chain ESG Management 110

Management Affordability 47

Business Ethics 25 Customer Services and Rights

Protection 48

Cybersecurity and Privacy 28

Investor Rights Protection 30Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Chairwoman and CEO's Message

resource consumption. We actively participated in We firmly believe that in future development

To Our Esteemed Stakeholders green power market-based trading introduced enterprises must place greater emphasis on

In 2024 Bloomage Biotech was deeply committed to sustainable development. We made remarkable biomass heat energy and effectively decreased our integrating economic environmental and social

progress in ESG management and entered a new stage of development. To comprehensively showcase reliance on fossil fuels. We continuously improved values aligning profit-seeking with righteousness.our management philosophy guiding principles strategic vision and dedication to social responsibility our product packaging designs to facilitate multiple Looking ahead Bloomage Biotech will continue to

we're proud to present our second annual Sustainability Report. We sincerely invite you to read this uses and recycling. Furthermore we enhanced our uphold the concept of sustainable development

report. On behalf of Bloomage Biotech I express our deepest gratitude for your attention and support. digital energy management platform and environ- further enhance our ESG management capabilities

mental data management platform significantly and resolutely advance our sustainable develop-

improving our low-carbon and green data manage- ment strategy. We are committed to creating

ment capabilities. In line with our strategic vision greater value and contributing to the development

we have established clear pathways and targets for of society at large.Sustainable development has become a global ing upstream R&D industrial solutions and carbon emission reduction by 2030 fully integrating

consensus and ESG serves as a crucial language for brand building. Leveraging our strengths in R&D these goals into our performance management

Chinese enterprises to communicate with the global innovation result transformation and market system to ensure the comprehensive implementa-

market. As a globally influential biotechnology expansion we are advancing the development tion of our low-carbon transformation.company Bloomage Biotech driven by a strong of the biotechnology and broader health indus-

sense of social responsibility has integrated sustain- tries. We provide high-quality efficient At Bloomage Biotech we remain committed to

able development into its corporate strategy. We life-health products and services globally creating a win-win situation for all stakeholders. We

have carefully implemented it across all aspects of delivering health well-being and opportunities strictly adhere to compliant operations uphold

our operations ensuring the Company's healthy to more people. In the past year Bloomage Biotech high-standard business ethics safeguard

long-term growth while contributing to the future of has reached several significant milestones. We employees’ rights and interests fulfill our social

our planet and the sustainable development of officially opened the world's first Bio-Manufacturing responsibilities address stakeholders’ concerns

human society. 5.0 Science and Technology Museum in Tianjin; we and protect the interests of all parties. In the past

established our health food headquarters in year Bloomage Biotech officially joined the United

In 2024 the global landscape was marked by volatili- Hangzhou expanding our influence in the Nations Global Compact (UNGC) promoting the

ty with domestic and international economies large-scale health sector. The commissioning of our sustainable development of both our company and

facing formidable challenges and consumer pharmaceutical-grade pilot-scale results transfor- the entire industry. We strengthened our compli-

demand remaining subdued. These numerous mation workshop has established the world's ance risk management and audit monitoring

uncertainties posed substantial obstacles to largest platform for this purpose. Our Xiangtan systems obtaining ISO 37301 and ISO 37001

business development. However challenges and production base has officially begun operations management system certifications. We adhere to a

opportunities coexist and change is the only marking a new phase in the development of our people-centered approach and have become a

constant. Confronting dynamic challenges Bloom- medical terminal business. By integrating cross-dis- signatory to the United Nations Women's Empower-

age Biotech spearheaded sustainable innovation ciplinary technologies like AI and microfluidics we ment Principles (WEPs). By optimizing our human

and resilient adaptation. We made every effort to have developed personalized production equip- resources system we have created a fair safe and

promote and implement various management ment and introduced customized skincare services. healthy working environment that supports employ-

transformation initiatives including the establish- These innovations provide consumers with precise ees’ growth and development. In addition we have

ment of an ESG management system. This has solutions for skin health. established a supplier ESG management mecha-

enhanced our operational resilience and efficiency Low-carbon and green development is the inevitable nism. This mechanism strengthens cooperation

fostering a healthier organization and enabling the path for Bloomage Biotech. We base our efforts on with suppliers in areas such as business ethics

growth and development of our talent. the entire product lifecycle covering R&D environmental protection and labor rights promot-

procurement production and sales. We are ing high-quality development. Furthermore for theScience and technology form the cornerstone of committed to promoting the green and low-car- 14th consecutive year we have carried out the “InBloomage Biotech's development. Starting with bon transition. In the past year we successfully Cloud” Public Welfare campaign contributing to the

frontier research in basic biology particularly in initiated greenhouse gas Scope 3 accounting and inheritance of national culture rural development

glycobiology and cell biology we harness the product lifecycle assessment (LCA) for the first time and the improvement of more people's lives.power of synthetic biology to drive industrial establishing a robust data foundation for emission

transformation. We have established an reduction. We continued to optimize our production

end-to-end value chain for biomaterials cover- processes consistently reducing energy and

Chairwoman and CEO

of Bloomage Biotech

Zhao Yan

01 02CONTENTS Chairwoman and

Sustainable

2024 Sustainability Report CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

About Bloomage Biotech Major Honors of the Year

In recent years Bloomage Biotech has won the second prize of National Science and Technology Progress Award National

Enterprise Technology Centre National Manufacturing Individual Champion Demonstration Enterprise National Green Factory

China Patent Gold Medal First Prize of Shandong Province Science and Technology Progress Award Shandong Province Governor's

Company Overview Quality Prize and other national and provincial honours as well as several national association honours such as Science and

Technology Prize of China Association for the Food Industry China Association of Technology Markets' Golden Bridge Prize and

China Good Technology (China Productivity Promotion Centre) and many other national association honours.Established in 2000 and publicly listed on the A-share Science and Technology Innovation Board (Stock Code: 688363. SH) in

November 2019 Bloomage Biotech is a biotechnology company propelled by innovation in synthetic biology and a platform In 2024 Bloomage Biotech continues to communicate with the government industry associations research institutions media and

company for the whole industrial chain of biological materials dedicated to improving people's quality of life by creating healthier other related parties to maintain a good relationship and jointly promotes the industry and even the society to the good develop-

experiences with a mission of “Let every life be alive”. ment of the Company harvested a number of honours and awards some of the honours are as follows:

The R&D and business layout of Bloomage Biotech is based on the understanding of aging and the essence of all aging is cellular

aging so the Company starts from the basic research of biology focuses on two basic disciplines of glycobiology and cell biology

and relies on the advantages of industrial transformation in the field of synthetic biology to provide scientific solutions for life and

health including cellular regulation-grade raw materials medical end-products translational dermatology innovation products

and nutritional science innovation translation business through biotechnology to achieve anti-aging intervention and regeneration Honours received by Bloomage Biotech in 2024 (partial)

to extend the healthy life leading the new era of cellular anti-aging and truly achieving “let every life be alive”.Embracing the development logic of “science to technology to product to branding" Scientific and technological innovation formsthe foundational bedrock of Huaxi Bio’s enterprise development anchored in fundamental and applied research. The company's

business model comes from its three core capabilities the first most core and bottom support is the R&D innovation capability; the

second is the results conversion capability; the third is the market conversion capability. We have built a biomaterials all-chain

conversion path which opens up the whole process from material discovery to product conversion and product development and Included in the All-China Federation of

thus we are able to take the business of B-B B-B-C and B-C to serve companies and consumers around the world. Received “A” in the rating of companies Industry and Commerce's list of 500 private

listed on the Science and Technology Board

enterprises with invention patents in 2024

(2023-2024)

In the future Bloomage Biotech will always adhere to the long-termism holding an open and embracing attitude to create more All-China Federation of Industry

‘healthy beautiful and happy’ life experiences with all industry chain partners and promote the development of the global life Shanghai Stock Exchangeand Commerce

science and technology industry.National March 8

Red Flag Collective Listed Company Board Best Practice Cases

2024 Sustainability Best Practice Cases 2024

All-China Women's Federation

(PRC established 1949) China Listed Companies Association

Demonstration project on innovation and Selected for the ‘China Good

application of new materials in Shandong Province Technology’ Project Pool

(innovation platform demonstration project)

China Association of

Department of Industry and Information

Productivity Promotion Centre

Technology of Shandong Province

2024 Water Conservation

Incentive Second Prize of Jinan City China's 500 Most Valuable Brands 2024

Jinan Urban and Rural Water Bureau World Brand Lab

The 26th ‘Golden Trust and

Disclosure Award’ for Listed Companies Top 10 Innovative Biotech Companies of 2024

China Securities Journal China Times

03 04Sustainable

2024 Sustainability Report CONTENTS Chairwoman and About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility Appendices

CEO's Message Management

01

Sustainable Development

Management

Bloomage Biotech has joined the United Nations Global Compact (UNGC)

and become a global signatory to the United Nations Women's Empower-

ment Principles (WEPs). We are accelerating the integration of sustainable

development principles into our business operations and systematically

advancing our ESG management initiatives. By optimizing our ESG manage-

ment system formulating comprehensive ESG strategic plans fostering

communication and collaboration among stakeholders and enhancing our

focus on material issues we are steadily elevating the quality of our ESG

management.Sustainable

2024 Sustainability Report CONTENTS Chairwoman and About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility Appendices

CEO's Message Management

Sustainable Development Building a Sustainability CultureBloomage Biotech places significant emphasis on fostering employees' awareness of sustainable development and enhancing their

Management System capabilities in this area. In 2024 the Company organized 32 specialized sharing sessions that covered ESG concepts policies indus-try trends and professional skills. These sessions reached out to 21 departments and involved nearly 400 employees. Moreover the Company has been actively promoting initiatives focused on green office practices and low-carbon living. Employees are

encouraged to take personal responsibility by practicing sustainable development in their daily lives. For example the Company

Sustainable Development Management Framework organized awareness-raising campaigns during key observances including the International Day for Biological Diversity and World Environment Day. Furthermore an ESG literacy initiative was launched enterprise-wide. Interactive quizzes were used to deepen

employees' understanding of sustainability principles and practices.Bloomage Biotech has established a top-down ESG governance structure and an effective ESG management mechanism. This

enables the Company to synergistically promote ESG management practices in a multi-faceted manner and among multiple

departments.Bloomage Biotech's ESG Management and Governance Structure Organized Reached out to Involved nearly

Board of Directors 32 21 400

specialized sharing sessions departments employees

Governance

ESG Committee

Sustainability Performance Management

Management ESG Management Center

In 2024 Bloomage Biotech integrated ESG performance requirements into the performance evaluations of relevant senior execu-

tives and departments to ensure the effective implementation of our sustainable development initiatives. The Company assigned

a specific weight to ESG performance within the annual Personal Business Commitment for senior executives department heads

ESG Working Groups and relevant personnel. Evaluations were conducted based on two key aspects: the effectiveness of management improvements

Execution and the completion status of key projects. The assessment results directly influence the performance ratings of these individuals

Composed of various business lines which subsequently affect their salary and bonus determinations.production bases and functional departments

The Board of Directors is responsible for overseeing and coordinating all ESG-related matters. It reviews and approves

relevant recommendations from the ESG Committee ensuring that the Company implements sustainable develop-

ment principles from top to bottom while integrating ESG management into business decision-making processes

Board of Directors

The ESG Committee supervised by the Board of Directors and chaired by independent director Cao Fuguo oversees

ESG-related affairs. Established and supervised under the Board of Directors the ESG Committee reports to the

Board of Directors and aims to achieve high-quality sustainable development for the Company which also deliberates

ESG Committee on ESG-related matters and provides regular reports to the Board

Tasked with overseeing the Company's ESG management including establishing the ESG management system

assessing ESG risks formulating ESG strategic plans facilitating the implementation of key ESG initiatives evaluating

and optimizing key ESG indicators and managing ESG communication and disclosure. The center reports annually to

ESG Management the ESG Committee on its achievements of the year and future plans receiving guidance and supervision from the

Center Committee

Additionally dedicated ESG working groups have been established within each business line production base and

functional department. These teams consisting of fixed personnel are responsible for managing and executing all

ESG-related tasks

ESG Working Groups

In 2024 both the Company's Board of Directors and the ESG Committee conducted one review of ESG initiatives each while the

Chairwoman and CEO reviewed these initiatives three times. The review encompassed significant areas such as ESG management

system sustainable development strategy low-carbon transformation plan supplier ESG management system digital ESG

management sustainable corporate culture development and information disclosure practices. Furthermore the Company's

management has approved a key plan for its 2025 ESG projects. This comprehensive plan includes various aspects such as supplier

engagement in terms of their own sustainability practices environmental impact assessment throughout product life cycles

development of organizational capabilities for sustainable growth optimization of our overall ESG management system.

07 08Sustainable

2024 Sustainability Report CONTENTS Chairwoman and About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility Appendices

CEO's Message Management

Sustainability Strategy Stakeholders Engagement

Guided by our strategic vision Bloomage Biotech implements a high-quality development model that considers the interests of Bloomage Biotech earnestly listens to the ESG concerns of various stakeholders including regulatory authorities shareholders

multiple stakeholders integrates green concepts and enhances social welfare. We focus on three core pillars: sustainable opera- employees customers partners and local communities. The Company fosters mutual understanding and recognition between

tions sustainable society and sustainable products. By centering our efforts around six key areas—corporate governance ESG risk internal and external entities integrates the expectations of all parties into its operational and decision-making processes and

management sustainable innovation environmental impact management protection of employees' rights and interests and promptly discloses relevant information through annual reports and other channels. This approach is designed to continuously

social empowerment through philanthropy—we establish a series of management indicators and objectives. Conducting our enhance stakeholders' trust and confidence in the Company.operations in a systematic scientific and rational manner strengthens our operational resilience and enhances our ability to adapt

to future developments. The Company has established a sophisticated ESG audit preparation framework for its production bases. In 2024 we engaged an

internationally renowned auditing firm to conduct SMETA (Sedex Members Ethical Trade Audit) on its production bases in Jinan

Bloomage Biotech’s Strategic Framework for Sustainable Development Dongying and Tianjin. The Company successfully completed issue rectification and closure meeting the ESG management require-

Strengthening the board of directors' ments of customers and other relevant stakeholders.participation in ESG initiatives

Sustainable Operations Corporate Bloomage Biotech Stakeholder Engagement Mechanism

governance

We are committed to continuous- Implementing high-standard compliance

ly optimizing our corporate management and business ethics Stakeholder Expectations and Demands Engagement and Response

governance structures and ESG

risk management practices. This

Identifying and managing the Compliant operations

involves identifying assessing Company's ESG risks Tax compliance

Supervision and inspection

Economic development Daily managementand managing key risks while

Anti-corruption Meetings and exchangesestablishing a healthy Government and

Product responsibility Public consultation

transparent and equitable ESG risk Intensifying supply chain ESG

Regulatory Agencies

management

corporate governance mecha- management Corporate governance Shareholders' meetings

nism that supports the long-term Risk management Investor exchange meeting

stability of the Company. Enhancing internal and external Shareholder rights Information disclosure

communication and knowledge ESG performance Field investigationsShareholders

dissemination Business ethics Teleconferencingand Investors Information transparency Email and online engagement platforms

Employee rights protection Employee roundtables

Sustainable products Continuously investing in sustainable Employee compensation and benefits Employee training

product and technology research and Employee training and development Employee satisfaction surveys

We concentrate on innovation to development Employees Employees safety and health Performance evaluations

Promoting sustain-

develop more efficient and able innovation Product responsibility

environmentally friendly Fostering a culture of sustainable Client satisfaction surveysProvide excellent services

technologies and products. innovation and stakeholder collaboration Customer service hotlinesProduct accessibility

Sustainability Social media platformsThrough the optimization of Clients and Consumers Product affordability

strategy Client follow-upprocurement production and Client privacy protection Optimizing energy and

other processes we reduce resource use in production Honorable fulfillment of contracts

emissions energy consumption Managing environ- Supplier assessmentsSustainable purchasing Supplier training

and resource consumption to mental impacts Green product

Optimizing packaging and waste Supplier meetings and exchanges

achieve a sustainable product management practices Product responsibilitySuppliers and Partners Strategic cooperation

lifecycle. Intellectual property protection

Support charity and welfare Public welfare activities

Environmental protection Community events

Rural revitalization Media communication

Community Community development Public consultation

Sustainable society Fostering a safe diverse equal and

inclusive workplace environment Scientific and technological innovation Industry exchanges

We pay close attention to Protecting employ- Industry development Formulation of industry standards

employees' rights and interests ees’ rights Industry Associations and Product responsibility Field visit

and strive to create a diverse Providing a wide range of employee Chambers of Commerce

benefits and development opportunities

inclusive and fair working

Product responsibility Press conferences

environment. ESG performance Social media platforms

We also engage in social Response to climate change Public opinion monitoring

empowerment initiatives and Media Business performance Field interviews

public welfare activities Empowering society

leveraging the Company's and advancing social Carry out public welfare activities to Education assistance

technology and resources to impact initiatives support community development Scientific research innovation Academic research

create greater value for society. Universities and Talent development Technology cooperation

Research Institutes

09 10Sustainable

2024 Sustainability Report CONTENTS Chairwoman and About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility Appendices

CEO's Message Management

Based on the principles of “Double Materiality” Bloomage Biotech assessed 25 ESG issues identifying 18 high-impact material issues and 5 financially

Double Materiality Assessment material issues thereby determining key content for this report.Bloomage Biotech’s Double Materiality Matrix

Material Issue Assessment

Impact

In 2024 Bloomage Biotech conducted a materiality assessment in accordance with relevant regulatory requirements and Materiality

mainstream information disclosure standards. Building on previous assessments this evaluation incorporated a financial perspec-

tive for the first time. The specific steps of the assessment process are outlined below:

Assessment Process of Double Materiality Issues of Bloomage Biotech

Environmental Compliance Employee Rights

Management Employee Development

Water Management Occupational Health and

Corporate Governance Safety Pollutant and Waste Management

Compliance and Risk Responsible Marketing Response to Climate Change and Energy Management

Management Client Service Supplier Management

High Business Ethics Industrial Cooperation Product Quality

R&D Innovation

Identification Taking into account international standards and disclosure frameworks capital market

Intellectual Property and Development

of Material rating indicators peer performance national policies and Bloomage Biotech's business

Protection

Information Security

Topics development 25 sustainable development issues were identified which formed a

repository for material issues

Product Environmental Healthcare Availability

Impact Research Ethics

Impact Materiality:Internal and external stakeholders were invited to assess the Aver- Environmental Permits Social Welfare and Community

materiality through online questionnaires. The questionnaire survey covered 10 catego- age and Certifications Relations

ries of stakeholders including company management employees government or Circular Economy

regulatory agencies shareholders or investors clients or consumers suppliers or Biodiversity

Research of partners universities or research institutions industry associations or chambers of

Material commerce the public and sustainable development industry experts

Topics Financial Materiality: Interviews were conducted with the Company's management

team to evaluate each issue's financial materiality from various dimensions including

impact on costs and revenues industry context business model characteristics opera-

tional features and key concerns of investors Unimportant Important

Environment Social Governance Financial

Materiality

Ranking Material Issues: Survey data and interview results were analyzed to perform a

comprehensive quantitative assessment. Issues were ranked based on two dimensions:

“materiality to the Company's financial performance” and “materiality to economicAnalysis of social and environmental impacts”

Material

Topics Review of Material Issues: External experts provided feedback on the identified materi-

al issues and their rankings. Subsequently the management team reviewed these

findings

11 12Sustainable

2024 Sustainability Report CONTENTS Chairwoman and About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility Appendices

CEO's Message Management

Financial Material Issues Product Quality

For those financial material issues identified we have summarized their impact areas along with associated potential risks and

opportunities as well as their potential financial impacts. In accordance with the guidance from the Shanghai Stock Exchange's Impact Areas Company operations; downstream value chain

Sustainability Report Guidance Framework we emphasize relevant management strategies and actions within this report.If the Company fails to provide higher-quality products it may lead to customer attrition risks

Potential Risks Implementing more comprehensive product testing will incur additional investments and costs

Pollutant and Waste Management

Superior quality products will further improve customer satisfaction thereby consolidating and

expanding the customer base

Impact Areas Company operations Potential Opportunities Higher-quality products contribute to elevating the Company's reputation and image strengthen-

ing market competitiveness and help explore potential markets

Improper management of pollutants and waste may cause environmental contami- Risks: Increased operational and management costs

Potential Risks nation which may trigger compliance risks resulting in financial penalties or losses

Potential Financial Impacts

Opportunities: Increased operating revenue

and damage to corporate reputation

Please refer to the “R&D Innovation and Quality Management” section and the ESG Key

For more management content

Enhancing pollutants and waste management can improve our environmental Performance Tables

stewardship while ensuring compliance with regulatory requirements. This proactive

Potential Opportunities approach not only bolsters corporate reputation but also strengthens market

competitiveness

R&D Innovation

Risks: Increased operational and management costs

Potential Financial Impacts

Opportunities: Increased operating revenue

Impact Areas Upstream value chain; company operations; downstream value chain

Please refer to the “Green Low-Carbon and Resilience” section and the ESG Key

For more management content Delays in developing green product technologies may hinder compliance with increasingly

Performance Tables stringent environmental requirements. Furthermore if product innovations do not accurately

Potential Risks align with consumer demands this could weaken market competitiveness

Insufficient protection of intellectual property rights may lead to disputes that negatively impact

the application and promotion of the Company's innovative achievements

Adopting a customer-needs-oriented approach in R&D innovation will enable the Company to

Response to Climate Change and Energy Management adapt effectively to market trends while enhancing its competitivenessPotential Opportunities

Ongoing efforts in low-carbon product design aimed at improving energy efficiency can potential-

ly create green business opportunities

Impact Areas Upstream value chain; company operations; downstream value chain Risks: Increased operational and management costs

Potential Financial Impacts

Opportunities: Increased operating revenue

Physical risks arising from climate change such as extreme precipitation and heat Please refer to the “R&D Innovation and Quality Management” section and the ESG Key For more management content

pose threats like production disruptions and equipment damage which can Performance Tables

undermine the stability of our production and operational processes

Potential Risks Transitional risks related to climate change including evolving policies regulations

and market trends may lead to stricter compliance requirements or increased raw

material costs. These factors heighten compliance pressures on the Company while Supplier Management

raising operational expenses

Impact Areas Upstream value chain; company operations

There is an increasing customer demand for green products enhancing our product

competitiveness Factors such as climate change raw material inventory levels and turnover rates can affect supply

The ongoing development of energy-efficient technologies and low-carbon equipment chain stability. This instability may pose potential negative impacts on production operations

Potential Opportunities presents favorable conditions for cost reduction and efficiency improvements within Potential Risks Inadequate supplier auditing certification processes or performance management can reduce

our operations supply chain transparency. ESG risks including labor and environmental management issues may

By decreasing reliance on fossil fuels we can mitigate risks associated with energy adversely impact production operations and corporate reputation

supply instability

Establishing a sustainable supply chain enhances stability in product service delivery while ensuring

Risks: Asset impairment losses and increased employee and property insurance continuity within company operations

expenses Developing long-term partnerships with suppliers is crucial for improving product quality innova-

Potential Financial Impacts Potential Opportunities

Opportunities: Reduced operational and management costs; increased operating tion capabilities and market competitiveness

revenue Encouraging suppliers to enhance their ESG management practices contributes positively to our

brand image and reputation within both local markets and the global platform

Please refer to the “Green Low-Carbon and Resilience” section and the ESG Key

For more management content

Performance Tables Risks: Increased operating and administrative costsPotential Financial Impacts

Opportunities: Increased operating revenue

For more management content Please refer to the “A Sustainable Value Chain” section and the ESG Key Performance Tables

13 14Sustainable

2024 Sustainability Report CONTENTS Chairwoman and About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility Appendices

CEO's Message Management

Major Honors in Sustainability

Bloomage Biotech's Awards and Honors in Sustainability (Selected)

Bloomage Biotech places significant emphasis on communication with regulatory authorities capital markets customers leading

domestic and international ESG rating agencies industry associations and the media. Through these concerted efforts the

Company has significantly enhanced its ESG rating performance and garnered numerous honors.

2024 Best Practice Case of Sustainable 2024 ESG Best Practices in the

Development for Listed Companies Fragrance & Cosmetics Industry

Bloomage Biotech’s ESG Rating Performance (Selected) China Association for Public Companies China Association of Fragrance Flavour

and Cosmetic Industries

2024 CSR Excellence Cases by CNR 2nd Guoxin Cup ESG Golden Bull Award

(China National Radio)

China Securities Journal

CNR News

EcoVadis Global Supply Chain CDP Global Environmental Disclosure

Sustainability Rating Climate Change: B

Bronze Medal Water Security: A-

ESG Zhiyuan Award: Eco-Friendly 2024 ESG Model Enterprise &

Enterprise Pioneer Innovation Award

Cailian Press Guancha.cn

MSCI ESG Rating CSI ESG Rating Annual ESG Outstanding Practice Award 2024 Green Development Excellence Case by the

BB AA Beijing News Zero Carbon Research InstituteHexun.com

The Beijing News

SynTao Green Finance ESG Rating Wind ESG Rating

A A

In 2024 Bloomage Biotech Featured in 2024 Report on Green Transformation Practices of Chinese Enterprises and showcased at COP29

15 16Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

02

Safeguard：Compliance

Governance and Risk Control

Robust and compliant corporate governance is the cornerstone of achieving

business growth and long-term sustainability. Bloomage Biotech continu-

ously refines its corporate governance structure places significant emphasis

on risk management and compliance upholds high standards of business

ethics and establishes a comprehensive information security management

system. These efforts enhance transparency in information disclosure and

aim to create more sustainable business value for all stakeholders.SDGs Addressed in this Chapter：

Major Material Topics of Sustainability Covered in this Chapter：

· Corporate Governance

· Compliance and Risk Management

· Business Ethics

· Information SecurityChairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Board of Directors Compliance Management

Bloomage Biotech strictly adheres to relevant corporate governance laws regulations and stock exchange requirements. The Bloomage Biotech is committed to continuously enhancing its legal compliance capacity to avoid any regulatory penalties. The

Company continually strengthens its board of directors and associated committees. In 2024 the Company established the Risk Company has established an institutionalized standardized and regulated compliance management system that instills the princi-

Management Committee to enhance the board’s capabilities in managing compliance business ethics and risk. ples of “law-abiding compliance and integrity” among all employees and conducts promotional activities related to compliance

initiatives. Furthermore we adhere strictly to rigorous tax-management principles ensuring timely and lawful tax contributions

Board Structure at Bloomage Biotech necessary for stable operations.Compliance Management System

Bloomage Biotech adheres to relevant laws and regulations as well as the ISO 37301 standards to establish a robust compliance

Convened management framework. The Company has developed internal policies including the Compliance (Anti-Bribery) Management

Shareholders' Meetings

2 Regulations and the Employee Compliance and Anti-Bribery Handbook. These policies are applicable to all employees and are designed meetings

to effectively manage external partnerships.Convened The compliance management structure is coordinated by the Legal Center which is responsible for overseeing and planning all

Board of Supervisors compliance-related activities. A Chief Compliance Officer has been appointed to this role ensuring that there are no conflicts of

3meetings interest in key operational areas such as market development operations and procurement. In addition we have included the

Company's compliance system and major compliance risk prevention and control within the scope of audit supervision.Convened Bloomage Biotech Compliance Management Structure

Board of Directors 5 meetings

Board of Directors Leadership Body

Top Managers Primary Responsible Person in

Compliance Management

Risk

Nomination Remuneration Strategy

Audit Committee and Assessment Management ESG CommitteeCommittee Committee

Committee Committee Chief Compliance Officer Compliance Manager

Departments and Legal Center and Risk Audit and Inspection Center

In 2024 the Company undertook a comprehensive revision of its board management system. This includes 18 management Business Lines Management Center

regulations and working procedures such as the Articles of Association Rules for Board Meetings and Decision-Making Procedures for First Line of Defense in Second Line of Defense in Third Line of Defense in

Related Party Transactions. New regulations were also introduced including the System for Selecting Accounting Firms and Rules for Compliance Management Compliance Management Compliance Management

Conducting Risk Management Committee Meetings forming a more scientifically sound institutional framework.The Company values diversity among its board members by considering multiple factors such as gender age cultural background

educational qualifications professional experience skills and knowledge when selecting candidates. Additionally in accordance

with laws and regulatory requirements Bloomage Biotech appoints independent directors; revisions to the System for Independent

Directors were made in 2024. The directors possess diverse backgrounds in biomedicine skincare products risk management

financial accounting law and sustainability which facilitates informed decision-making in a complex market environment. All Employees

In 2024 the Company continued to provide training to all board members covering areas such as internal control management

regulatory compliance standard operational procedures and information disclosure thereby enhancing their governance capabil-

ities. To enhance its compliance management capabilities further Bloomage Biotech has implemented systematic and process-oriented

methodologies that provide clear rules and guidelines for compliance throughout all operational phases. The Company has

successfully achieved ISO 37301 certification for its compliance management system and undergoes annual surveillance audits to

confirm the ongoing effectiveness of this certification.

19 20Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Compliance Management System of Bloomage Biotech In 2024 Bloomage Biotech implemented multi-faceted compliance training programs covering various specialized topics in

alignment with business operations and systemic requirements. These encompassed Compliance Management System Develop-

Establishment of Compliance Compliance Obligations and Daily Compliance Management and ment Bribery Risk Mitigation Criminal Compliance and Interpretation of the Revised Company Law. Notably we engaged external

legal experts specializing in commercial law and anti-corruption to deliver lectures on the Revised Company Law and criminal

Framework and Policies Risk Management Compliance Culture Development compliance frameworks.Furthermore the Company formulated the Compliance Performance Data Collection Management Procedures and Compliance Assess-

ment & Evaluation Management Procedures establishing a comprehensive performance measurement mechanism. Evaluation

Identifying strategic compliance Each business department is responsible for Responsible for collaborating outcomes are systematically linked to business units individual employees and third-party partners with corresponding

priorities aligned with corporate the collection of compliance obligations within with various departments to incentives or disciplinary actions implemented to cultivate a robust compliance culture within the organization.development frameworks its operational areas to create a comprehensive develop compliance work

compliance obligation and risk list plans that include corporate

compliance inspection Key Performance

Responsible for formulating and Aggregating departmental information to processes as well as training

optimizing corporate compliance identify enterprise-level compliance risks with initiatives

management systems and relevant departments to assess risk levels and

processes developing corporate formulating response plans Launching compliance

2024

compliance management tools initiatives implementing

compliance inspections and The signing rate of Conducted Coverage for promoting compliance Conducting regular monitoring of compliance

providing relevant improve- Compliance Commitment Letter key personnelknowledge sharing plans and risk indicators along with early-warning signals

submitting annual compliance and providing ongoing reports regarding ment suggestions based on 3 compliance

management strategies compliance risk management to the manage- the inspection results to 100% training sessions 100%

ment the Risk Management Committee and ensure the compliance of

the Board of Directors business activities

Compliance Culture Development Tax Compliance Management

Bloomage Biotech has developed a comprehensive compliance training plan categorized into three programs: general compliance Bloomage Biotech strictly complies with tax laws and regulations and has established and regularly updates tax management

key personnel training and critical regulations training. This plan is designed to encompass all employees while providing special- systems such as the Tax Internal Control Manual. The Company ensures continuous oversight of tax policy implementation through

ized compliance training for key departments and critical positions. Personnel in key positions including senior management measures including a tax risk monitoring mechanism tax emergency management protocols and regular communication with tax

purchasing managers and finance and sales personnel are required to complete the training on the Employee Compliance authorities. This systematic approach underscores its proactive fulfillment of tax obligations.Handbook within 30 days of joining the Company. The Company delivers compliance training programs through diversified

channels including live webinars on-site workshops and a dedicated e-learning platform with assessments including exams Bloomage Biotech's Tax Management Measures

questionnaires and attendance checks. This multi-dimensional approach enables the organization to objectively measure employ-

ees' comprehension of compliance requirements and their ability to apply knowledge in practical scenarios.In addition to formal training programs Bloomage Biotech cultivates a compliance-oriented culture through regular awareness Establish a real-time monitoring and alert system utilizing digital platforms to oversee all tax-relat-

campaigns including compliance-themed poster promotions and compliance knowledge competitions. All employees are required ed operations including filings and compliance activities

to sign a Compliance Commitment Letter to reaffirm their adherence to the Company's ethical standards. Furthermore the

Company conducts targeted training sessions for third parties (e.g. suppliers) when necessary ensuring broader dissemination of Maintain a risk-tracking register to document and follow up on all tax alert notifications Tax Risk Prevention

its compliance principles and policies.Bloomage Biotech's Compliance Training Plan

Constitute a crisis management team composed of C-suite executives tax directors finance

managers and legal counsel to handle urgent tax contingencies

Develop tiered contingency plans and communication strategies according to incident severity levels

Tax Emergency

Management

Compliance General Targeted Training Compliance Culture Supplier Compliance

Key Systems Training

Knowledge Training Sessions for Key Personnel Development Training Programs

For all employees For employees in For all employees For all employees For suppliers

pharmaceutical raw

Covering foundational topics Conducting compliance Covering diverse Introducing the Establish a regular communication mechanism with the competent tax authorities including material

such as the employee (anti-bribery) manage- online and offline Company's compli- structured face-to-face dialogues and feedback loops

compliance handbook basic other businesses ment system training engagement ance philosophy as Designate Tax Liaison Officers (TLOs) undergoing mandatory training programs for end-to-end

knowledge of compliance Carrying out training third-party (business initiatives such as well as governance Tax Compliance coordination with tax authorities

management compliance on high-risk compli- partner) risk manage- educational poster principles applicable Coordination

warning and education non ance topics in line with ment training etc. campaigns quizzes to business partners

- compliance cases and actual business needs and festive activities

reporting channels For further insights into the Company's tax management practices please refer to the Bloomage Biotech 2024 Annual Report.

21 22CONTENTS Chairwoman and

Sustainable

2024 Sustainability Report CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Key Performance In 2024 Bloomage Biotech comprehensively

Internal Control and updated its Risk Management Regulations and formulated three critical processes including

In 2024 the Enterprise Risk Framework and the Policy

Risk Management Development Guidelines. These initiatives aim to Conducted Reaching over institutionalize a science-driven and systematic

risk governance mechanism ensuring the

Bloomage Biotech is committed to continuously refining its risk management framework and internal control systems. The Compa- 10 2000 effectiveness of the overall risk management

ny conducts regular internal audits and inspections to evaluate the effectiveness of these systems in managing compliance risks. process.risk management employees

By strengthening its risk-emergency management capabilities the Company proactively identifies potential risks while establishing training sessions

controls necessary for promoting sustainable growth and stability in its operations. To cultivate an enterprise-wide risk manage-

ment culture Bloomage Biotech has imple-

Risk Management mented a multi-tiered risk management training program across all organizational levels. This

initiative encompasses customized courses and

Risk Management System project-based learning initiatives designed for

board directors supervisory committee

In 2024 to further advance the implementation of risk management practices Bloomage Biotech formulated and publicly members C-suite executives mid-level manag-

disclosed the Rules of Procedure for the Risk Management Committee establishing a top-down governance framework. Under this ers and frontline operators with the objective

structure the Board of Directors as the supreme decision-making authority holds ultimate accountability for the efficacy of risk of enhancing the skills capabilities and exper-

management. tise of risk management personnel.Bloomage Biotech Risk Management Structure and Supervision Mechanisms Risk Identification and Response

In alignment with its business management and operational practices Bloomage Biotech categorizes risks into five primary types:

Board of Directors strategic risks financial risks market risks operational risks and legal-compliance risks. This categorization forms a comprehen-

sive risk classification framework that underpins the Company's risk management strategy. In 2024 the Company further refined

Audit Committee Risk Management Committee its risk mapping framework and established a robust risk reporting mechanism. As a result the Company produced essential

internal documents including the Quarterly Risk Monitoring Report Annual Risk Management Report and Risk Management Matrix.Bloomage Biotech maintains a dynamic risk identification process that systematically evaluates and ranks risks using quantitative

Executive Management

severity matrices. This enables the prioritization of material risks requiring immediate mitigation. Cross-functional teams are

mobilized to develop risk mitigation action plans and refine strategies for managing critical risks.In 2024 the Company implemented risk management initiatives across all business units with a dedicated focus on work safety

Risk Responsibility Departments product quality and procurement management. This strategic alignment embeds risk-conscious decision-making into core

All business departments including Bloomage

branches and subsidiaries business processes supported by systematic risk profiling analytical evaluation frameworks and continuous management optimi-

Biotech’s three zation cycles. Additionally the Company seamlessly incorporated ESG considerations into its daily risk management practices. In

lines of Defense in this regard 13 ESG-related risks were identified encompassing key issues such as climate change response; pollutant and waste

Risk Management Center Risk Management management; employee rights; product quality; and supplier oversight.Audit and Inspection Center Risk and Emergency Management

Bloomage Biotech places strong emphasis on the standardized management of emergency incidents to ensure the sustainable

The Company has implemented the Three Lines of Defense (3 LoD) model. Each line fulfills its designated responsibilities while development of the Company and maintain its corporate image. In 2024 the Company formulated and issued the Emergency

synergizing to form a multi-tiered cohesive and mutually constrained operational mechanism. This integrated approach ensures Management Measures. These measures clearly define the scope classification criteria and management procedures for various

continuous monitoring and systematic management of diverse risks across the organization. emergency incidents across multiple business domains including brand-related public opinion management product quality

assurance pharmacovigilance safety and environmental compliance and information security. Each relevant business unit is

required to develop specific emergency response plans in accordance with their respective operational requirements.Risk Responsibility Audit and Inspection

Risk Management Center

Departments Center Additionally Bloomage Biotech established a company-wide Emergency Response Leadership Team led by the CEO. This team is

tasked with actively addressing unexpected events in accordance with the Emergency Management Measures. The team is responsi-

As the first line of defence Serving as the second line of As the third line of defence in this ble for promptly implementing appropriate reward and punishment mechanisms while effectively preventing and managing

these departments are respon- defence this center coordinates model under the supervision of emergency incidents.sible for risk prevention and group-wide risk governance the Board’s Audit Committee

control within their operational through formulating institution- this center independently

scope. Key duties include al frameworks for risk manage- conducts audits and assessments Internal Control

conducting risk information ment developing risk rating on the effectiveness of the

collection and identification and criteria driving digital transfor- Group’s risk management Bloomage Biotech continuously assesses and enhances its internal control system to ensure its robustness and effectiveness. In

maintaining updates to the risk mation of risk management framework. The audit results 2024 the Company formulated the Economic Responsibility Audit Management Regulations and revised the Internal Audit Management

management matrix systems and implementing identified issues and improve- System. This marked a significant step in refining its internal audit framework and enhancing audit efficiency and quality. In 2024

daily monitoring and corrective ment recommendations are phased internal special audits were conducted across core management areas including procurement production sales R&D

action tracking periodically reported to the Audit investment performance evaluation and EHS. These audits aimed to identify any potential deficiencies that could impact the

Committee Company's operational development. Fortunately no significant deficiencies were uncovered.

23 24Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

01 Doing business with relatives that Business Ethics Falsification harms company interests 07

02 Unauthorized part-time work for remuneration 08

Bloomage Biotech remains steadfast in its commitment to upholding high standards of business ethics. The Company prioritizes Misappropriation of company property

the prevention of corruption bribery unfair competition conflicts of interest and other fraudulent activities. To this end Bloom- Misappropriation of public funds Spreading illegal or reputation-damag-

age Biotech continuously strengthens its business ethics system enhances its complaint and reporting mechanism and rigorously ing remarks that affect the Company's

03 private borrowing of funds oversees matters related to business ethics such as integrity in operations anti-corruption initiatives and complaint handling. This reputation brand image or or unauthorized guarantees organizational unity 09

comprehensive approach ensures that any form of corruption and unfair competition is avoided. Excerpt from the

Manager's Red Line Soliciting benefits from partners

Professional Ethics 04 Behavior - 12 Articles customers subordinates Unauthorized loans or credit sales or affiliated companies 10

Bloomage Biotech is committed to strict compliance with applicable laws and regulations including the Anti-Monopoly Law of the

People's Republic of China and the Anti-Unfair Competition Law of the People's Republic of China. The Company has established clear

behavioral principles and standards concerning anti-bribery anti-fraud conflict of interest anti-unfair competition responsible 05 Speculative use of enterprise funds Provocation or causing troubles 11

marketing and commercial confidentiality. This governance framework requires all employees to adhere to these standards as a

binding obligation. Bloomage Biotech requires all employees to sign a confirmation form for the Professional Ethics and Conduct

Guidelines. Any behaviour that violates relevant professional ethics regulations once discovered by the Company will be subject to

verbal warnings written warnings contract termination or other corresponding penalties. 06 Disclosure of company trade secrets Dereliction of duty or gross negligence 12

Bloomage Biotech's Business Ethics-Related Systems (Selected)

Anti-Bribery Management

Code of Ethics for Employee Personal Conduct

Code of Professional Ethics and Conduct Employee Compliance and Anti-Bribery Handbook Compliance (Anti-Bribery) Bloomage Biotech is resolutely opposed to all forms of corruption bribery and other unethical behaviors. The Company strictly

Management Regulations Bloomage Biotech Anti-Corruption and Anti-Fraud Guidelines Management Measures for Compli- complies with national policies and regulations such as the Anti-unfair Competition Law of the People's Republic of China and has

ance Reporting Investigation and Handling Manager's Red Line Behavior - 12 Articles etc. formulated systems including the Anti-Corruption and Anti-Fraud Regulations and the Anti-Commercial Bribery Compliance Guidelines.These systems cover anti-corruption anti-fraud anti-unfair competition and conflict-of-interest management guidelines. In 2024

Bloomage Biotech conducted internal audits focusing on anti-bribery anti-fraud and anti- corruption across key areas like sales

Code of Ethics in Dealing with External Partners and purchasing within its domestic subsidiaries to assess the implementation of relevant policies.Anti-Commercial Bribery Compliance Guidelines Sales Personnel and Sales Conduct Management System Business Partner

Compliance Management Measures Compliance Guidelines for Interactive Engagements (Including Conferences Exhibitions The Company has established a comprehensive business ethics management system comprising the Board of Directors Audit

and Sponsorships) etc. Committee and relevant departments. The Board of Directors assumes overall responsibility for overseeing and coordinating all

aspects related to business ethics. To ensure the continuous and effective operation of our anti-bribery framework we annually

engage a third-party certification agency to conduct an ISO 37001 Anti-Bribery Management System Certification Audit.The Employee Compliance and Anti-Bribery Handbook clearly outlines compliance norms for individual employees sales operations

and customer interactions. This handbook includes professional ethics that all employees are required to adhere to upon joining In terms of bribery risk management the Company has identified four key areas of concern: 1)

the Company and throughout their employment. Additionally it specifies ethical business conduct expectations for employees in Interactions with government officials; 2) Interactions with distributors agents and other transac-

critical roles such as sales and procurement when engaging with third-party partners. In terms of tion-influencing parties; 3) Interactions with medical institutions hospitals and other transac-

bribery risk tion-influencing entities; 4) Sponsorships and donations to hospitals or medical institutions. To

Moreover the Code of Professional Ethics and Conduct delineates the following responsibilities of all employees towards the Compa- management address these concerns the Company has clearly outlined employee conduct guidelines in the

ny customers and the market: Anti-Commercial Bribery Compliance Guidelines covering both prohibited and permitted activities

within these areas.In terms of In 2024 the Company established a conflict of interest declaration mechanism requiring all

Responsibilities Responsibilities Responsibilities conflict of employees to regularly declare their personal conflict of interest situations. During the reporting

to the Company to clients to the market interest period the coverage rate of employee conflict of interest declarations at Bloomage Biotech was management 100%.To build a culture of integrity and clean governance we regularly provide anti-corruption and

Respect for every employee Keep confidentiality of all client Fairly trade with the Company's anti-bribery training to board members management and all employees. In addition specialized

Prohibit using one's position for information customers suppliers and compet- In terms of the training programs are provided for high-risk positions such as marketing. In 2024 the Company

personal gain accepting unrea- Prohibit unauthorized disclosure; itors construction of conducted three training sessions on compliance and anti-fraud requirements for all employees

sonable hospitality from suppli- timely notify potential conflicts of Prohibit manipulation conceal- integrity culture and incorporated special lectures on anti-corruption and anti-bribery within the framework of

ers purchasing to achieve sales interest to relevant parties ment damage defamation abuse criminal compliance training. Furthermore the Company disseminates educational and aware-

or making payments for special Carefully select business partners of proprietary information or false ness-raising materials on anti-corruption and anti-bribery through its internal journals aiming to

favors and clients reporting of significant facts strengthen all employees' commitment to ethical conduct and integrity.Prohibit using company assets Prohibit providing illegal improper In terms of external In our external collaborations the Company includes compliance commitment letters (covering

for activities unrelated to work or suspicious payments or promis- collaborations clauses on good-faith cooperation financial compliance and anti-commercial bribery) in all

Adhere to safety and health-re- es to others for undue benefits procurement contracts thereby establishing clear business ethics requirements and responsibili-

lated rules and policies to ties with suppliers and other partners.maintain workplace safety

25 26Sustainable

2024 Sustainability Report CONTENTS

Chairwoman and

CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Key Performance Whistle-blowing Management

Mechanism Cybersecurity and Privacy

In 2024 Bloomage Biotech encourages joint supervision and integrity

maintenance among employees clients suppliers and other Maintaining robust information security measures and privacy protection is fundamental for fostering long-term cooperation

0 stakeholders. We've established a regular reporting and investi- between Bloomage Biotech and its business partners customers as well as employees. We are committed to continuously gation mechanism for compliance violations through our strengthening our information security management frameworks as well as our customer privacy protection mechanisms to

Embezzlement lawsuits Management Measures for Compliance Reporting Investigation and comprehensively safeguard the data security concerns related to all stakeholders involved.involving Bloomage Biotech or Handling. Reportable matters include but are not limited to

its employees were filed and violations of laws and regulations as well as breaches of business

concluded Management System

ethics such as acts of dishonesty fraud corruption unfair

competition and other unethical conduct.Bloomage Biotech strictly adheres to relevant laws and regulations and has developed comprehensive information security and

We have established a wide range of complaint and reporting data protection policies including the Information Security Risk and Emergency Management System and the Information Security

channels including telephone email and on-site complaints Control Policy in alignment with the ISO/IEC 27001 information security management standard. The Company is committed to

which are publicized to all employees distribution clients and continuously enhancing its institutional framework for information and data security thereby effectively managing data protection

suppliers. In 2024 Bloomage Biotech successfully managed the across all business operations.Conducted

response to reports and executed special investigations with a

1 100% handling rate. Essential Port-Opening Principle Strict Authentication Mechanism

company-wide anti-bribery risk To protect the privacy and security of whistleblowers effectively

assessment Only open ports that are essential for Enhance authentication processes to

the Company has standardized the management of whistleblow- business functions to mitigate guarantee that only authorized users

er information. This includes safeguarding personal details unnecessary network exposure. or services can access applications

reporting content and communication methods. Any form of thereby preventing unauthorized

retaliation against whistleblowers is strictly prohibited. A dedicat- access.ed reporting email address has been established for this

Trusted Source Access

purpose. This email is maintained by designated personnel who Principle of Least Privilege Access Control Principle

4 ensure that all communication with whistleblowers remains confidential and limited to one-on-one interactions only. For Ensure that users and services are Allow access requests solely from

Specialized anti-bribery verified reports that lead to substantiated findings against granted only the minimum privileges trusted sources or verified IP address

training sessions were held accused parties or misconducts identified through these reports necessary to perform their tasks thus ranges to strengthen network

appropriate disciplinary actions will be taken. Furthermore in reducing potential security risks. perimeter defenses.accordance with our reward system policies we may provide

Achieving whistleblowers with material or moral incentives as recognition Regular Security Audit Principle Access Log Recording Principle

for their contributions in identifying unethical behavior.

100% Conduct regular security assessments Maintain comprehensive records of all Whistle-blowing Workflow Process

coverage of key position holders to identify and rectify vulnerabilities application access activities including

promptly ensuring ongoing network access time source and target

Collect whistle-blowing File a record

information security. information for effective traceability

Excerpt from the Management Regulations for Public and auditing purposes.Specifically

Internet Access of Information Systems

11 Classify whistle-blowing records Reconsider respond and handle The Company has established an effective information security management system through five key perspectives: organization

Managers participated management technology training and supervision. The Information Security Management Committee oversees and coordinates

the Company's efforts in this regard with dedicated departments entrusted to execute information security protection strategies

Parties appeal

Analyze and sort out information and procedures. In 2024 Bloomage Biotech successfully obtained ISO 27001 certification for its information security management（if there is any objection） system. Annual reevaluations were conducted for two critical systems—the anti-counterfeiting and traceability system and the raw

materials portal system—both of which passed a second-level information security assessment.Establish an investigation team Handle the investigation result The Company actively encourages employees in relevant positions to pursue professional certifications in information security to

The signing rate of the continuously enhance their expertise. As of the end of 2024 three members of our information security team have obtained

production materials supplier

compliance commitment letter Certified Information Security Professional (CISP) national certification while one member has achieved Certified Information

Systems Auditor (CISA) international certification.

100 Reporting Channels%

Furthermore Bloomage Biotech has developed a Privacy Policy which is published on our official website. This policy outlines key

Email：jubao@bloomagebiotech.com elements such as our usage authorization strategies data retention periods as well as individuals’ rights regarding accessing

Tel：010-85670099-1503 correcting or deleting their personal information. Moreover in collaboration with third parties and business partners the Compa-

ny strictly adheres to laws and regulations requiring third parties to sign agreements and implement necessary security measures

to handle relevant user personal data in accordance with privacy policy requirements. In 2024 no incidents involving violations of

information or data security were reported within the Company.

27 28CONTENTS Chairwoman and

Sustainable

2024 Sustainability Report CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Safeguard Measures Investor Rights Protection

Bloomage Biotech has implemented a comprehensive array of measures to enhance information and data security protection

thereby solidifying the foundation of network security and ensuring the stability and security of our information systems.Bloomage Biotech strictly complies with laws and regulations such as the Measures for the Administration of Information Disclosure

Measures for Protection of Bloomage Biotech's Information Security by Listed Companies issued by regulatory authorities. In 2024 the Company revised the Information Disclosure Management System

and the Investor Relations Management System to continuously enhance information disclosure management capabilities and

protect the rights and interests of investors and other stakeholders.Use of Information-Security Technologies

We adhere strictly to principles such as authenticity accuracy completeness timeliness and fairness when disclosing information

Internally we utilize security center plugins provided by cloud service providers which are deployed on our key servers ensuring that investors can access timely updates about company activities. Multiple channels have been established ranging from

We conduct regular vulnerability scans with the assistance of external security operation and maintenance services large-scale public communication efforts through strategy meetings organized by securities firms; receiving investor research

input; conducting teleconferences; utilizing SSE e-interaction Platform; holding roadshows; all designed to foster robust communi-

We employ web application firewalls to safeguard and reinforce websites that provide public services cation between investors and Bloomage Biotech while enhancing transparency regarding company operations.Information Security Risk Assessment Key Performance

We conduct monthly penetration tests in critical plant areas covering critical servers within our network In 2024

We comprehensively identify and analyze risks and vulnerabilities across various aspects such as company network

Held earnings Hosted investor research

infrastructure data storage transmission and processing. Moreover based on assessment results we establish

Published presentation activities or conference

corresponding plans and corrective measures to continuously enhance data security announcements meetings exchanges

Monitoring of the Information Security System 93 4 272

We ensure internal applications are deployed in strict isolation from those that provide public access

Access to internal applications is granted only after rigorous identity verification processes are completed

Publicly accessible applications benefit from protective measures implemented by cloud service providers

Achieved the highest rating of Participated in compiling the 2023 Annual China

Grade A in the annual information Listed Companies Investor Relations White Paper

disclosure evaluation conducted by jointly released by Roadshow China IR Research

Information Security Emergency Management the Shanghai Stock Exchange Institute and other supporting institutions

We have established a Computer Security Incident Response Team (CSIRT) to coordinate responses to technical issues

related to computer security incidents

A reporting procedure is in place for individuals who discover violations; they can promptly report these issues to

management or the CSIRT

Promotion of Information Security Awareness

Training on port-opening procedures including procedure requirements operational guidelines and best practices

is provided for network administrators and system administrators

In November 2024 we organized an online “Data Security Awareness” training event tailored for all employees. This

training focused on key points regarding data protection practices applicable in daily work. Throughout the year

1249 employees participated in information-security training sessions

We have established independent reporting channels for complaints that are managed by a dedicated team within the Company.Strict measures ensure the protection of personal information related to reporters/complainants with guarantees against retalia-

tion:

Personal Information Protection Complaint and Reporting Channel: privacy@bloomagebiotech.com

Information Security Violation Reporting and Feedback Channel: CSIRT@bloomagebiotech.com

29 30CONTENTS Chairwoman and

Sustainable

2024 Sustainability Report CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

03

Driving Forces: R&D Innovation

and Quality Management

Bloomage Biotech is committed to advancing in fundamental biological

research focusing on glycobiology and cell biology. By leveraging the advan-

tages of industrial transformation in synthetic biology we provide innovative

scientific solutions for health and well-being. The Company initiates its

operations from the upstream R&D of biomaterials seamlessly integrating

raw material production with brand development to establish a comprehen-

sive transformation pathway for biomaterials. We rely on technological

innovation the expansion of materials and solutions achievement transfor-

mation intellectual property protection and collaborative efforts between

industry and academia to strengthen our scientific foundation. Simultane-

ously we conduct in-depth quality research while gaining insights into

market demands to deliver high-quality products and services.SDGs Addressed in this Chapter：

Major Material Topics of Sustainability Covered in this Chapter：

· R&D Innovation · Healthcare Availability

· Product Environmental Impact · Client Service

· Industrial Cooperation and Development · Information Security

· Research Ethics · Intellectual Property Protection

· Product QualityChairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Key Performance

R&D Innovation

As of the end of 2024

Bloomage Biotech places a high value on independent research and development as well as the successful transformation of

innovative outcomes. We have established a robust innovation system that prioritizes green and sustainable practices while adher- 6 1

ing to scientific ethics. Our focus also includes protecting intellectual property rights and fostering industry collaboration to National High Provincial-Level Specialized

promote high-quality development within both our company and the broader industry landscape. Rooted in the foundational Tech Enterprises (NHTEs) Sophisticated Distinctive

scientific principles of glycobiology and cell biology we are dedicated to achieving groundbreaking innovations in bioactive and Innovative (SSDI) Enterprise

substances through cutting-edge technologies such as synthetic biology and regenerative medicine. Our goal is to diversify product

offerings while expanding application scenarios that meet consumers' personalized needs realizing Smart Biomanufacturing

across six major categories of bioactive substances.R&D Investment

R&D Management System 466 4.46 % 8.68 % million RMB increase over last year of R&D investment to revenue

Bloomage Biotech has established an evolving product-planning-and-development management system that centers on market

demands as well as customer needs. We have implemented an Integrated Product Development (IPD) management system aimed

at shortening product development cycles enhancing the efficiency with which R&D results are transformed into market-ready

products and ultimately improving market performance by bridging gaps between market insights and research efforts.

39292020.70%

Innovation Platform Development invention patents of R&D professionals of total employees

directly related to our core

Bloomage Biotech has built a global R&D platform integrated innovative resources and established a system for key biomanufac- business functions

turing technologies. The Company focuses on the R&D innovation and production of 6 categories of biologically active substances

related to human health including functional sugars proteins peptides amino acids nucleotides and natural active compounds

covering the entire industry chain from cell construction to commercial applications.The Company places high emphasis on fundamental research and applied fundamental research and has eight R&D platforms

including Synthetic Biology R&D Platform Functional Saccharides R&D Platform Cell Biology Research Platform Regenerative Case the Construction of the Pilot-Scale Results Transformation

Medicine Research Platform Pilot Conversion Platform Application Mechanism R&D Platform Material Functionalization Technol- Center Completed by Bloomage Biotech

ogy Platform and Formulation Development Platform. Through AI-enabled functional integration and intelligent upgrades these

platforms span the full product lifecycle from cell construction to commercial applications. This establishes a full industry chain In June 2024 Bloomage Biotech completed the construction of its Pilot-Scale Results Transformation Center. This platform with a total

business system covering bioactive materials medical end products innovative transformation of dermatology and innovative investment of RMB several billion yuan spans an area of 30000 square meters and is equipped with 64 pilot-scale production lines. It

transformation of nutritional science solidifying competitive advantages in core technology development and commercialization. encompasses the entire process from fermentation and purification to refining enabling the Company to undertake pilot-scale and

small-scale commercial production of various bioactive raw materials for pharmaceutical-grade skincare-grade and food-grade

products.The platform is characterized by its flexibility platform-based operation and digitalization. It adopts an open cooperation model

featuring modularization and drawer-type approaches across the entire industry. Bloomage Biotech actively provides a range of services

including pilot-scale maturation experimental validation inspection and testing to universities research institutions enterprises

investment firms as well as public service sectors supporting the industrial and market transformation of research achievements.Bloomage Biotech Pilot Scale Results Transformation Center

33 34Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

R&D Management Structure and Systems Sustainable Innovation

Bloomage Biotech has established the R&D Management Committee led by our Chairwoman with participation from senior execu- Grounded in a comprehensive and advanced R&D system Bloomage Biotech prioritizes green sustainable innovation integrating

tives and core technical managers. This committee oversees all aspects of our R&D system management and has created a global concepts related to environmental protection health and safety in every phase involved in developing new substances technolo-

R&D platform to facilitate business-oriented operations through the introduction of an Integrated Product Development (IPD) gies materials and processes. The Company actively explores profound synergies between biotechnology and sustainable

management system. This approach breaks down barriers between different R&D units by establishing a project-oriented person- development. This commitment aims to promote green transformations within industries while ensuring ecological harmony.nel deployment mechanism that enables efficient human resource utilization.Product & Solution Innovation

R&D Management Structure at Bloomage Biotech

Bloomage Biotech leverages scientific principles and effective biomanufacturing technologies characterized by safety-focused

development. It aims to develop formulations/products that do not contain toxic elements and have low toxicity levels. These

formulations exhibit lower impurity levels while maintaining high purity and meeting high stability standards. We integrate sustain-

Responsible for the comprehensive ability throughout our product development process.R&D Management management of the Company's R&D system

Committee

We implement source substitution and green processes by replacing virgin materials with recycled alternatives whenever feasible.Our commitment extends to prioritizing low-toxicity and environmentally friendly reagents and consumables in our operations. We

actively utilize biobased carbon sources and innovate packaging applications to minimize negative impacts on the environment

ecology biodiversity and human health throughout the entire product life cycle. In doing so we not only contribute to environ-

mental protection but also foster the development of new quality productive forces. Additionally we harness artificial intelligence

Integrated Coordination and Information

Cascading technology to predict substance efficacy screen potential active ingredients develop differentiated products unlock new function-

Global R&D Platform alities and expand solution scenarios.Implementation and Contributions of Major Green Key Performance

Technology Innovations in 2024

Our upgraded emulsification technology reduces energy In 2024

consumption by approximately 10% while cutting chemical

reagent usage (e.g. methylene chloride & ethanol) by over

50% further enhancing both product safety and environmen- 310

tal sustainability.Integrated Medical Device & Raw Material R&D Center Skin Science Innovation Innovation Research Institute Frontier Research Institute

number of R&D projects

Pharmaceutical R&D Center R&D Center for Scientific Insights (FRISI) The introduction of COP pre-filled syringes (a drug-device

combination product) into our pharmaceutical production line

has completed pilot-scale testing. This innovation reduces

medical waste processing costs and achieves an approximately

Insights and analysis of 80% reduction in energy consumption during manufacturing. 2

new technologies &

materials By adopting serum-free formulations with chemically defined participated in national and

Conducting R&D management and operations across business lines Exploring innovative Insights and studies on

frontier science compositions we have significantly reduced reliance on

provincial key R&D projects

business models that animal-derived materials thereby mitigating potential ecologi-

expand commercial

applications cal risks associated with traditional biopharmaceutical produc-

tion processes.R&D Sharing Center（Providing technical services & support through a shared service delivery platform） Case Research on Biodegradable Materials in Single-Use Packaging

Bloomage Biotech focusing on environmental protection and quality enhancement conducted a systematic study on the potential

Intellectual Property (IP) Center（Management of IP protection utilization and development efforts）

issues of biodegradable material Bio-PE during prolonged contact with cosmetics. Through dedicated material modification studies the

Company successfully optimized Bio-PE for application in single-use packaging materials. This innovation significantly reduces the

consumption of non-biodegradable plastics and advances the sustainable development of the beauty industry.The Company strictly complies with laws and regulations including the Law of the People's Republic of China on Promoting the

Transformation of Scientific and Technological Achievements Safety Management Measures for Biotechnology Research and Develop- Case Development of Eco-Friendly Packaging to Empower Customer Sustainability

ment Measures for Drug Registration and Regulations on the Supervision and Administration of Cosmetics. We consistently update and

implement internal systems such as the Pilot-Scale Testing and Trial Production Control Procedures R&D-to-Production Technology

Transfer and New Product Introduction (NPI) Governance Framework Design and Development Control Procedures Patent Management In 2024 Bloomage Biotech developed an eco-friendly polyolefin film packaging that complies with international standards. This packag-

Regulations and Patent Incentive Measures. These efforts contribute to establishing a robust and standardized R&D project manage- ing utilizes a single-material design achieves over 90% recyclability and generates no toxic or harmful emissions during incineration. The

ment framework continuously refining evaluation criteria for scientific achievements and talent incentive mechanisms. Further- successful development of this packaging has accelerated the Company's sustainable innovation and development enabled customers

more the Company has developed a series of research project management regulations to ensure that relevant activities are to embrace the green concept and set an example of sustainable development for the industry.conducted legally and compliantly throughout project initiation development review and other stages.

35 36CONTENTS Chairwoman and

Sustainable

2024 Sustainability Report CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Ingredient Sustainability Ethics in Technology

Bloomage Biotech strictly adheres to domestic and international regulations such as the Cosmetic Safety Technical Specifications and

the Regulation on Registration Evaluation Authorization and Restriction of Chemicals (REACH Regulation) ensuring products are Bloomage Biotech strictly complies with domestic and international regulations and guidelines for biomedical research including

registered or certified for ingredient safety mildness efficiency and natural organic properties. The Company extensively referenc- Ethical Review Measures for Life Sciences and Medical Research Involving Human Subjects Regulations on the Management of Laboratory

es authoritative industry and market standards to develop systems such as the Chemical Use List for Research and Development. Animals (aligning with the 3R principles of Replacement Reduction and Refinement in animal studies) Good Clinical Practice (GCP) for

We have established comprehensive chemical use management mechanisms to standardize the selection of raw materials for our Drugs Guidelines for Registration and Review of Animal Testing in Medical Devices Clinical Trial Guidelines for Sodium Hyaluronate-based

products. Facial Injectable Fillers. To ensure systematic compliance we have developed internal governance documents such as the Technical

Guidelines for Cosmetic Consumer Usage Testing. We also strictly adhere to the World Medical Association's Declaration of Helsinki and

region-specific ethical frameworks to ensure legal and regulatory conformity of testing activities whether conducted internally or

The Company is committed to ongoing hazard identification processes implementing measures to reduce substitute or prohibit

externally. The Company’s R&D Management Committee oversees global R&D operations to coordinate issues related to technolo-

controversial ingredients and minimize the use of preservatives. These actions enhance the safety sustainability and biodegrad-

gy ethics. Additionally we have established the Cosmetic Efficacy Evaluation Ethics Committee responsible for reviewing and super-

ability of our ingredients thereby significantly reducing their negative impact on both human health and the environment. To

vising ethical concerns during efficacy assessments of functional skincare products. In 2024 the Company did not incur fines from

achieve a balance between efficacy and safety we select active ingredients based on scientific principles. Our approach focuses on

regulatory bodies for violating ethical technology testing guidelines.delivering precisely targeted solutions while minimizing unnecessary active additions ensuring a superior combination of compre-

hensive efficacy with fewer components. In addition Bloomage Biotech conducts radioactive substance testing on products from

our MedRepair brand that contain marine-sourced raw materials. This proactive measure ensures product safety for consumers. Guided by the principles of scientific rigor ethical integrity and corporate accountability we have established rigorous assessment

In 2024 the Company did not receive any penalties from regulatory agencies for non-compliance with chemical usage in products. frameworks that leverage cutting-edge technologies and innovative alternative testing methodologies to ensure product safety and

efficacy. Our commitment extends to systematically minimizing and ultimately replacing animal testing and human trials. We have

Manufacturing Innovation developed AOF (Animal Origin-Free) medium technology that is serum-free with no animal-derived components significantly

decreasing our dependence on animal-sourced materials. We use cell testing ex vivo skin testing and 3D skin model testing.Bloomage Biotech has established a refined technical system for biomanufacturing hyaluronic acid alongside green preparation Additionally we have a subject-testing model that is entirely based on voluntary participation with a freely exercisable withdrawal

methods. Our commitment involves continuously enhancing production designs and processes investing in state-of-the-art equip- mechanism which is used in place of animal testing for efficacy trials on functional skincare products. When designing trials for

ment establishing efficient process systems and elevating digitalization & automation levels throughout production stages. By medical device efficacy we prioritize alternative methods to minimize the frequency of conducting animal and human clinical trials.integrating sustainable principles such as environmental protection & safety into every aspect of manufacturing operations we

ensure that sustainability remains at the core of our practices. We are also dedicated to exploring & deploying technologies related Bloomage Biotech does not directly conduct animal or human testing and therefore has no staff involved in animal testing or any

to Industry 4.0. Our AI-powered platform for rapid screening of active ingredients is widely utilized across production lines. By requirements for the management of care or welfare for test subjects. The Company conducts thorough in-vitro evaluations on key

optimizing workflows and improving management models we drive technological upgrades and innovations within product manu- raw materials related to product efficacy to replace animal testing while enhancing overall product safety. All the Company's neces-

facturing processes thereby leading the advancement of intelligent manufacturing trends. sary animal and human clinical trials are entrusted to qualified Contract Research Organizations (CROs) or hospitals. Contracts are

in place to stipulate compliance with national regulations on trial ethics and related measures for the welfare of human and animal

subjects. They also ensure compliance with the Company's management regulations for third-party animal-testing and inspection

institutions thereby ensuring that the company's responsibilities of respecting life ethics and safeguarding welfare are effectively

fulfilled. In 2024 Bloomage Biotech conducted regular training sessions aimed at enhancing R&D personnel's awareness concern-

ing experimental ethics.Case Standardization of Engineered Epidermal Models and Their Applica-

tion as Alternatives to Animal Testing for Skin Irritation Assessment

Bloomage Biotech has developed a standardized reconstructed human epidermal model specifically designed for functional evaluation

of cosmetics and pharmaceuticals serving as an alternative to conventional animal testing methodologies. This innovative model

addresses ethical dilemmas associated with such practices while overcoming human-testing bottlenecks. It shortens evaluation cycles

with precise and highly repeatable data thereby advancing skin irritation-related applications within China’s framework for reducing

reliance on animals. Additionally this model serves as an essential platform facilitating toxicological evaluations along with pharmacolog-

ical studies alongside molecular biology research focusing both raw materials and finished products. This initiative significantly enhances

the safety assessments of raw materials and finished products while ensuring the effectiveness of cosmetics and pharmaceuticals.Furthermore the Company follows and implements requirements related to AI ethics and information ethics. We use AI responsi-

bly in our business operations. When utilizing AI systems we adhere to a human-centered approach. When adopting generative-AI

solutions we implement manual controls and conduct comprehensive evaluations of the results. Moreover we treat data as a

crucial asset and install encryption software on the office equipment for all R&D personnel to further enhance the full-process

compliance control of data and information. In 2024 the Company organized three training sessions related to information ethics.Bloomage Biotech Creates a Fully Production and Linked Unmanned Operation Production Workshop

37 38Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Collaborative Development Intellectual Property Protection

Bloomage Biotech leverages its technological innovation capabilities and technical platform advantages to implement open Bloomage Biotech integrates intellectual property management into the entire product operation process. The Company has built

cooperation actively collaborating with governments industry organizations research institutions etc. to promote joint scientific a standardized and effective intellectual property management system by clarifying management policies and objectives improv-

research the establishment of standardized norms and industry knowledge popularization driving the sustainable and healthy ing management structure and resource elements and strengthening lifecycle management of intellectual property. The Company

development of related industries. has been certified by GB/T 29490 intellectual property management system. As of 2024 the Company has accumulated a total of

587 authorized patents and 580 valid patents.

Industry-Academia-Research Collaboration

The Company places significant emphasis on the in-depth integration of The Executive Director of the Company’s R&D Committee is responsible for overseeing the operation and continuous improvement

industry academia and research for collaborative technological innovation. of the intellectual property management system. The Intellectual Property Center is tasked with providing professional expertise

Through strategic cooperation agreements joint establishment of research and implementing specific initiatives related to IP management. The Company reviews the suitability and effectiveness of the

centers the development of advanced pilot-scale conversion platforms as intellectual property management system every year.well as applied basic research and academic discussions in related fields of

technology and manufacturing Bloomage Biotech facilitates a seamless Bloomage Biotech strictly adheres to current laws and regulations referring to standards such as the Intellectual Property Manage-

connection among industry stakeholders that accelerates the transforma- ment System Standard for Enterprises to formulate and enhance its intellectual property protection policies and procedures. These

tion from R&D to commercial application. In 2024 we deepened our collabo- measures are effectively implemented in all aspects of IP management activities. The Company has clarified its principles and

ration within the realm of industry-academia-research partnerships result- division of responsibilities for intellectual property management in patents trademarks copyrights and business secrets. We have

ing in substantial achievements. We conducted 29 projects in collaborationBloomage Biotech participated in the “2024 China-Korea established clear procedures for the application registration utilization management transfer and protection of intellectualwith 12 universities and research institutions across diverse areas such as Cutting-edge Biotechnology Exchange and Cooperation Symposium” property rights.small-scale process development for substance creation quality inspection co- hosted by the Chinese Embassy in South Korea and the Korean

protocols and efficacy studies on various applications involving functional National Institute of Green Technology Bloomage Biotech's Measures on Strengthening Intellectual Property Protection

sugars and amino acids.Industry Popularization and

Standard Setting Communication Risk Identification and Management

To promote the adoption of new materials technologies and In 2024 Bloomage Biotech inaugurated its Bio-Manufactur- Bloomage Biotech has implemented a comprehensive patent search and competitor patent monitoring mechanism to

processes as well as advanced management concepts and to ing 5.0 Science and Technology Museum in Tianjin marking conduct systematic analyses including Freedom to Operate (FTO) at various stages such as project initiation R&D

remove technological barriers that hinder the transformation of the completion of three landmark industrial exhibition progression project completion and pre-market launch. This mechanism enables the Company to proactively identify

scientific and technological achievements Bloomage Biotech halls: the World Hyaluronic Acid Museum the Synthetic and mitigate infringement risks throughout the entire product lifecycle

takes the initiative to attend various industry associations and Biology Science Pavilion and the Bio-Manufacturing 5.0 We have paid attention to the regional characteristics of intellectual property protection and have actively applied for

lead and participate in the formulation and implementation of Science and Technology Museum. These facilities employ international patents to fully protect our intellectual property and enhance our ability to respond to supply chain risks.national group and industry standards. This not only enhances cutting-edge interactive technologies such as simulated We allocate necessary budgets every year to respond to possible intellectual property risks

its own influence and discourse power but also promotes the models three-dimensional holographic projections and

establishment of clear guidelines and standards for the industry dynamic light-shadow installations. Through these technol- Awareness-raising Training and Exchange

to follow. Bloomage Biotech has led or participated in the formu- ogies they offer panoramic demonstrations of hyaluronic

lation of 8 industry standards and 48 group standards. Among acid applications synthetic biology innovations. They also

these 12 group standards were released in 2024 including the showcase the pivotal role of bio-manufacturing in advanc- The Company carries out intellectual property training activities for its employees every year such as professional

industry standard QB/T 4576-2023 for Sodium Hyaluronate which ing carbon peaking and carbon neutrality strategies. Collec- internal training and bi-weekly sharing sessions. In 2024 the Company carried out 9 intellectual property-related

was led by Bloomage Biotech in its revision and officially came into tively they serve as an educational portal for the public to publicity and training sessions with more than 1800 participants and more than 18 training hours

effect on July 1 2024. Additionally the Company is currently explore the scientific frontiers and industrial implications of In addition we have actively participated in relevant external exchange activities and received investigations and

involved in the development of 16 national industry and group biotechnology. Since their respective openings these three research from relevant supervisory and management departments on our intellectual property management. We

standards. museums have hosted over tens of thousands of visitors. have also been involved in various seminars training classes and other activities

Performance Evaluation

We have clearly defined the requirements for rewarding and penalizing intellectual property-related matters and

decomposed the intellectual property management objectives and conducted regular assessments. In 2024 the

Company provided intellectual property-related performance incentives to 240 employees with a total bonus

amounting to RMB 1.49 million

Protection of Rights and Interests

A delegation comprising the Deputy Chair of the International Federation of

Societies of Cosmetic Chemists (IFSCC) and faculty members from the The Bio-Manufacturing 5.0 Science and

University of S?o Paulo Brazil conducted an official visit to Bloomage Technology Museum Was Inaugurated in Tianjin We have actively cooperated with police and judicial authorities in many places by assisting in handling cases of

Biotech World Hyaluronic Acid Museum counterfeit production and sale to protect intellectual property rights

Bloomage Biotech has established exhibition halls in its main offices factories and R&D centers to conduct science popularization We have entrusted professional third-party organizations to follow up on infringements of our trademarks patents

activities for visiting groups. Additionally the Company actively participates in industry exhibitions and exchanges and integrates and other intellectual property rights. In 2024 the Company filed 16 rights protection litigation cases. The Company

has not been punished by relevant competent authorities or held liable by court judgments for infringement of

internal and external professional resources to conduct online public education. In 2024 the Company conducted 145 scientific

others' intellectual property rights. There have been no major infringement litigation cases of intellectual property

popularization campaigns focusing on bioactive ingredients throughout the year. Meanwhile the Company jointly developed and (including abuse of a dominant position counterfeiting and piracy)

published the 2024 Scientific Skincare Guidelines for Oily Skin in collaboration with academic institutions and dermatology experts.This initiative delivers comprehensive solutions for consumers while advocating science-based skincare principles.

39 40CONTENTS Chairwoman and

Sustainable

2024 Sustainability Report CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Additionally the Company respects the outcomes and spirit of the Declaration on the TRIPS Agreement and Public Health and abides

by compulsory licensing requirements for public interests public health and other purposes in the Patent Law of the PRC. We

involuntarily transfer relevant patents when necessary to popularize and promote technologies. In this way the Company can Quality Management

benefit more people with its innovative achievements.Bloomage Biotech follows the quality management policy and principles of "leading technology standardized management safe

Bloomage Biotech's intellectual property licensingUnit: Item and reliability and professional service" with product quality always prioritized. Bloomage Biotech enhances its “OperationalExcellence and Lean” globally aligned quality management system through lifecycle management by establishing quality standards

and objectives that surpass national regulatory requirements and industry standards with an unwavering commitment to deliver-

ing premium-quality products for global consumers. Each year we set goals related to product inspection pass rates first-inspec-

??? tion pass rates for finished products customer satisfaction with product quality ex-factory pass rates and on-time delivery rates. ??? ??? In 2024 the Company successfully achieved all these established goals.???

??? ??? Quality Management System

????

Quality Management Structure

The Chairwoman of Bloomage Biotech holds overall responsibility for product quality and safety. This includes strategic planning

the formulation of quality policies review of quality objectives and oversight of their implementation. Relevant quality manage-

ment departments and employees collaborate closely within the Company to fulfill their respective responsibilities effectively.Together they form a robust quality assurance network that safeguards product quality and safety.??

????

??

? ? Bloomage Biotech’s Architecture for Integrated Product Quality & Safety Management

Total patents Domestic patents Overseas patents Patents Number of invention Utility model Design patents

for invention patents applied to core patents

business operations

Number of licenses in ???? Number of applications in ???? Board of Directors

Monthly Reporting

Bloomage Biotech's annual trademark status

Unit: Item

Supply Chain Platform

??? Monthly Reporting

Quality Center

??????

??? ??? Customer Quality Quality Management Quality System Management R&D Quality Management Supplier Quality Management Departments across All

Department Department Department Management Department Production Bases

???

Quality Management Systems Processes and Measures

Trademark rights Domestic trademarks Overseas trademarks Bloomage Biotech strictly adheres to comprehensive legal frameworks including the Law of the People's Republic of China on Product

Number of licenses in ???? Number of applications in ???? Quality the Drug Administration Law of the People's Republic of China the Food Safety Law of the People's Republic of China the Regula-

tions for the Implementation of the Food Safety Law the Good Pharmacovigilance Practices (GVP) the Cosmetics Production Quality

Management Standards and the Medical Device Operation Quality Management Standards. The Company has established and imple-

mented a systematic quality governance system encompassing the Quality Food Safety and HACCP (Hazard Analysis Critical Control

Point) Integrated Management Manual and Product Monitoring & Measurement Control Procedures. This system enforces full life-cycle

quality management spanning product design R&D manufacturing and post-market surveillance with clearly defined quality

accountability across all stages to ensure regulatory compliance safety and efficacy of products.

41 42Sustainable

2024 Sustainability Report CONTENTS

Chairwoman and

CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Quality Audits and Certifications Key Performance Bloomage Biotech’s Lifecycle Quality Control

Bloomage Biotech has established and continuously improved a Supplier quality is rigorously assessed during the onboarding process. We sign quality assurance agreements with qualified In 2024 the Company

product life-cycle quality management system with the construction suppliers establishing clear quality standards.of a quality management information system to drive the implemen- In addition from mold development sampling testing to mass production we work collaboratively with suppliers to

tation and application of digitalized and intelligent systems across all Conducted internal audits of the address bottlenecks as well as any quality or safety issues that may arise. On-site communication is employed when

product lines. This initiative aims to advance comprehensive quality production-based quality manage- necessary for the immediate resolution of issues. We implement monthly tracking management processes that ensure ment system at least

Supplier Quality non-compliance issues are resolved in a closed-loop manner.management practices ensuring end-to-end quality control and

1 For more detailed information regarding supplier quality management practices please refer to the “Achievements: safety throughout the product life cycle. a year Sustainable Value Chain” section.

Bloomage Biotech has established a dedicated Quality Inspection & A comprehensive mapping of the R&D platform's quality management system has been developed with an established

Audit Team that standardizes quality review processes including

Carried out over framework for R&D documentation. A total of 66 specific quality control requirements and management procedures have

self-inspections and preparations for external audits. This team been formulated to standardize our product development process effectively.systematically conducts internal audits of the quality management 120000 We have established a robust cross-departmental communication mechanism that enhances collaboration across six key systems at production facilities. Alongside rigorous product testing systems: quality assurance materials management equipment facilities oversight analytical laboratory control and R&D

protocols and actively collaborates with external regulatory authori- product tests R&D Quality production/preparation processes. This holistic approach ensures stringent adherence to quality control throughout every

ties accredited certification bodies and customer audits. Through stage of product development.continuous improvement the Company has received exemp-

tion-from-inspection evaluations from some customers and has Undergone Bloomage Biotech implements strict controls through various measures including raw material testing equipment manage-

passed MDR audits conducted by certain customers with zero ment standardized operations process and flow optimization lean production techniques and environmental controls.defects. In 2024 Bloomage Biotech completed a total of 147 custom- 168 We have established comprehensive regulations such as the Product Monitoring and Measuring Control Procedure to

er-factory inspections and third-party audits organized by custom- official and customer audits standardize the acceptance and inspection processes for materials water usage intermediate products and finished

ers. All of these were successfully passed with no major quality risks with no major quality risks or goods. Additionally we ensure meticulous management of device calibration. Throughout each stage of production we

detected. General defects were promptly rectified. defects identified conduct thorough performance evaluations as well as functionality assessments alongside comprehensive quality testing.Production This integrated approach enables us to achieve all-around control over product process quality.The Company has obtained the following certifications: ISO 9001 Quality After production products are subject to internal or external quality testing. Qualified products are cleared for release

Quality Management System ISO 13485 Medical Devices Quality Obtained based on an inspection report. Otherwise an unqualified inspection report is issued and non-conforming products are

handled under company regulations. This ensures the quality efficacy and safety of products before they leave the factory.Management System ISO 22716 & GMPC (US) Cosmetic Good Manu-

facturing Practices EFfCI GMP Standard for Cosmetic Ingredients 2

Kosher Certification Halal Certification HACCP Food Safety Manage- Monitoring and Auditing Management: We conduct at least one routine audit for all products each year and collaborate with new drug/API (Active

ment System FSSC 22000/ISO 22000 Food Safety Management regulatory authorities customers and other parties for special and routine supervision and inspection. In 2024 no major Pharmaceutical Ingredient) product quality defects were identified indicating manageable quality risks in the operational phase.System and Laboratory Accreditation. Its high-standard production registration certificates

lines comply with the requirements of US Current Good Manufactur- Product Traceability Management: Bloomage Biotech has established and updated the Product Identification and Traceability

ing Practices (cGMP) China's GMP and ICH Q7 Guidelines for Active Control Procedures in line with ISO 9001 and ISO 22000 standards creating a comprehensive product traceability system. Obtained

Pharmaceutical Ingredients. Additionally the Company has success- This system ensures that product outer packaging is intact and clearly labeled. Records are kept truthfully accurately and

fully passed quality audits and on-site inspections conducted by 2 standardly for easy access review and traceability of product information. Regular simulations are conducted to quickly trace products using batch numbers and labels.regulatory authorities including the EU Medical Device Regulation

(MDR) US Food and Drug Administration (FDA) South Korea's Domestic class III medical Non-Conforming Products Management: Bloomage Biotech has set up regulations like the Non-Conforming Products

Ministry of Food and Drug Safety (MFDS) Japan's Pharmaceuticals device registration certificates Management Rules and Cosmetics Quality Release Procedure. Non-conforming products are clearly labeled stored separately

and Medical Devices Agency (PMDA) and China's National Medical Management and undergo investigation handling correction and inspection. Products that can be reworked are corrected to meet

Products Administration (NMPA) for GMP compliance. Obtained Quality quality standards while those that can't are disposed of under supervision to prevent them from entering the market.Quality Emergency Management: Bloomage Biotech has developed management systems including the Emergency

7 Preparedness and Response Control Procedures and the Food Safety Emergency Response Plan to effectively manage product

Class II medical device safety incidents. These measures aim to prevent product safety incidents proactively and ensure quick control if they occur.registration certificates The Company continuously refines its handling processes for product safety incidents by incorporating monitoring early

warning systems reporting mechanisms emergency response protocols post-incident handling procedures and

safeguard measures. An annual emergency drill focusing on drug and food safety incidents ensures relevant departments

Life-Cycle Quality Control can respond promptly protecting public health.Bloomage Biotech establishes internal product quality and safety management procedures and systems in accordance with Aftersales Tracing: Bloomage Biotech has established the Product Release Authorization Procedure and the After-Sales

applicable laws and regulations. We implement quality risk assessment and control measures to effectively address and manage Monitoring and Governance Procedure to ensure only qualified products leave our facilities. A Customer Quality Management

quality risks thereby enhancing Bloomage Biotech's brand reputation through high-quality standards. The Company consistently Department has been set up for front-line quality management collecting feedback on business quality issues and tracking

identifies assesses controls communicates audits and minimizes quality risks throughout its product's lifecycle to decrease the their resolution effectively. This department ensures timely market feedback for necessary product adjustments.likelihood and impact of risks to an acceptable level while protecting consumer safety health and rights. The Company conducts Products Recall: Bloomage Biotech has implemented regulations like the Product Recall Management Standard Operating

comprehensive quality risk assessments annually and rectifies any defects identified. After-Sales Procedure Returned Product Control and Handling Procedure and Medical Device Mock Recall Management Standard Operating

Quality Procedure. Recall management is executed based on product categories with defective items handled appropriately. A

In 2024 the Company did not experience any significant safety or quality-related liability incidents concerning our products or summary of recall situations is documented with corrective actions to prevent recurrence of issues identified during recalls. Management

Separate recall plans exist for pharmaceutical and non-pharmaceutical product lines with at least one mock recall drill

services. There were no fatalities linked to the use of Bloomage Biotech products nor were there any enforcement actions taken

conducted annually in each category. In 2024 no recalls were required due to safety or health concerns related to sold or

due to violations of the current Good Manufacturing Practice for Pharmaceuticals (cGMP). tested products.

43 44Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Pharmacovigilance and Adverse Reactions Cultivation of Quality Culture

Bloomage Biotech has established a vigilance system covering products such as pharmaceuticals medical devices and functional Bloomage Biotech clearly defines quality management goals promotes lean production and encourages cross-site collaboration

skincare products along with procedures for reporting and handling adverse reaction events. Monthly literature research related and empowerment. Additionally the Company advocates quality training and education values practical drills on quality manage-

to product adverse events is regularly conducted and relevant regulations are collected. Internal training and health-and-safety ment and implements quality assessments and incentive mechanisms. All these efforts contribute to building a distinct quality

awareness campaigns are organized periodically. The Company also maintains communication with regulatory agencies and other management culture. At Bloomage Biotech we actively nurture our employees' quality concepts and awareness by organizing

stakeholders to continuously enhance pharmacovigilance and product adverse reaction management thereby safeguarding public quality monthly activities providing quality training and promotion participating in the construction of quality standards maintain-

health and safety. ing cooperation and communication with external parties etc. In 2024 we conducted hundreds of offline/online trainings related

Pharmacovigilance Adverse Reaction Management for Func- to quality control and product safety covering all relevant personnel involved in product quality management.The Chairwoman of the Board of Directors leads drug safety tional Skincare Products Bloomage Biotech’s efforts to foster an atmosphere of quality culture

management and has established the Drug Safety Committee

and a leading group for monitoring medical device adverse Bloomage Biotech adheres to the management principles ofevents. Other committee members are managers from depart- “safety first openness and transparency scientific valida-ments related to drug safety including pharmacovigilance tion and risk notification” in developing and continuously

quality management production sales R&D and registration. refining its adverse reaction management system for Synergized Internal-External Strategies

We ensure pharmacovigilance and adverse reaction manage- functional skincare products. In compliance with relevant for Effective Implementation

ment throughout the product lifecycle. laws regulations and industry standards the Company

regularly updates and revises the Cosmetic Adverse Reaction Internal Efforts External strategies

Bloomage Biotech strictly follows national local and internation- Monitoring and Reporting Standard Operating Procedure (SOP).al pharmacovigilance regulations and guidelines. In line with This process optimizes information collection monitoring

external policies regulatory directions stakeholder expectations and analysis emergency response procedures and

and internal compliance requirements the Company continuous- feedback mechanisms to safeguard consumer rights while

ly revises a series of pharmacovigilance and medical-device enhancing product quality and safety control capabilities. Launching the “Quality Month” initiative featuring 33 Participating in the “2024 Cosmetics Industryvigilance management mechanisms procedures and standard themed activities such as: Quality Culture Campaign High-Quality Development Symposium” organized

operating procedures covering the entire product life-cycle The Company conducts relevant tests during product Quality Control Team Competitions Visual Storytelling by the Shandong Provincial Medical Productsincluding the Drug Safety Committee Operating Bylaws and the development based on industry standards as well as internal Photography Competition “Innovative Quality AdministrationPharmacovigilance Quality Management System. In 2024 Bloomage procedures including the Human Skin Patch Testing Protocol Excellence in My Eyes – Bloomage” Essay Series

Biotech revised and implemented 21 procedural documents for Cosmetics In Vitro 3T3 Neutral Red Uptake Phototoxicity Participating in the “Quality Month” Campaign

related to its pharmacovigilance system and the medical device Assay and Skin Sensitization Assessment: Direct Peptide Implementing a series of training and awareness organized by Hainan Provincial Medical Products

adverse event monitoring system. Reactivity Assay (DPRA). These measures help mitigate poten- campaigns including: Job-specific knowledge training; Administration

tial adverse reactions on human skin caused by functional Quality process dissemination; Thematic training on

Attending external workshops and training

The Company actively participates in training sessions organized skincare products. The Company has analyzed and evaluat- quality enhancement; Compliance-focused training

by regulatory authorities to enhance vigilance awareness and ed reports and monitored data of adverse product reactions activities("Strengthening Quality and Compliance"); Monthly

improve management capabilities. Additionally we disseminate before and after marketing which have been actively and training on quality regulations and procedures Attending Jinan City quality typical exchange

professional knowledge internally to strengthen employees' passively collected and ensured product traceability. speech

understanding of pharmacovigilance and their skills in handling Collaborative Training on Hands-On and Professional

adverse reactions. Throughout the year Bloomage Biotech Through internal audits external inspections training Skills for Compliance Risk Management Showcasing smart factory practices through video

organized and completed seven internal audits and self-inspec- sessions and effective communication channels we ensure presentations by the Provincial Medical Products

tions of the pharmacovigilance system. The Company also under- that assessments related to suspected or confirmed adverse Organizing the “Building the Great Wall of Quality” Administration

went nine official inspections related to pharmacovigilance reactions are conducted in a timely manner while remaining Knowledge Contest 2024: Adapting to Industry

practices specifically focusing on medical device adverse event efficient and compliant with legal standards. In 2024 Bloom- Transformation Showcasing exemplary works from Shandong's

monitoring. Furthermore we received one audit from a customer age Biotech was subjected to four external audits concern- quality - driven brand storytelling campaigns

related to our pharmacovigilance systems and conducted 15 ing the monitoring of adverse cosmetic reactions while Conducting Quality Scenario Simulation and Technical

internal and external training sessions on pharmacovigilance and hosting five internal training sessions focused on managing Skills Competition Organizing media tours to promote regionally

medical device adverse reactions. these reactions related specifically to functional skincare certified products under the "Quancheng Good Interactive Quality & Safety Engagement Campaigns:

products. Notably in that year one case of a suspected Products" initiative

Bloomage Biotech is committed to continuously optimizing its adverse reaction was reported concerning our functional

Gamified Learning for Operational Excellence

pharmacovigilance risk management system. We formulate skincare line. In accordance with our established regulations Participating in the “2.25 Skin Care Day” eventNarratives of Resilience: Quality-driven Production

comprehensive pharmacovigilance plans that involve monitoring on cosmetic adverse reaction monitoring management we Recovery and Employee Dedication Attending the Second Medical Device Innovation

and analyzing drug safety signals. Regular risk assessments carried out thorough collection processes alongside report- and Development Conference

concerning adverse reactions are conducted leading to insightful ing measures. And analysis evaluations were conducted

reports that inform us of our control measures. To enhance swiftly followed by an investigation into this occurrence. Inviting regulators and industry associations to

stakeholder engagement we have established accessible Effective risk control measures were implemented ensuring base their training courses in the Bloomage

feedback channels that allow for the active addressing of that no widespread adverse reaction events occurred. Biotech

feedback regarding adverse events. We maintain close communi-

cation with provincial/municipal drug reaction monitoring Participating in the construction of international

centers as well as other regulatory agencies. Adverse events are national industrial and group quality-related

reported promptly enabling collaborative efforts in testing Adverse reaction feedback standards actively

procedures and risk assessments. telephone number of the Company

In 2024 the Company received and handled 171 reports of 0531-82685091

adverse drug reactions and 65 reports of adverse medical device

reactions. There were no product-related deaths or violations of

the current Good Pharmacovigilance Practices.

45 46Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Product Accessibility Customer Services and

and Affordability Rights Protection

Driven by making products and services of better quality more accessible more inclusive safer and longer-lasting Bloomage Bloomage Biotech has established a dedicated service team committed to responsible marketing practices. The Company has

Biotech has always been expanding product application areas and consumption scenarios to bring healthy beautiful and happy developed diverse communication channels that enable prompt responses while addressing customer feedback and inquiries

life experiences to mankind. The Board of Directors remains actively engaged in making informed decisions regarding issues accurately. Through rigorous quality control measures and reliable after-sales support we effectively safeguard consumer rights

impacting enterprise development within the context of healthcare accessibility among other relevant considerations. and interests thereby fostering positive relationships with customers over the long term.Product Accessibility Responsible Marketing

Bloomage Biotech rigorously complies with laws and regulations in terms of responsible marketing such as the Law of the People's

Bloomage Biotech is committed to expanding applications for hyaluronic acid products across various fields while enhancing Republic of China on the Protection of Consumer Rights and Interests the Advertising Law of the People's Republic of China. The Company

accessibility for diverse populations globally. The Company continuously explores broader applications for medical sodium has devised policies like the Code of Conduct for Advertising Release Compliance Guidelines for Live Streaming Promotion Sensitive

hyaluronate beyond dermatology into areas like gynecological health while progressively increasing application areas for Term Base for Cosmetics and Daily Chemical Products to regulate marketing and communication practices. Additionally we establish

micro-crosslinked hyaluronic acid extending from facial applications to body areas such as hands or necks. marketing compliance procedures and regularly organize internal training. The Company's legal center conducts a comprehensive

review of product promotion information and related marketing language to ensure legal compliance. In 2024 Bloomage Biotech

Our range which includes various bioproducts featuring hyaluronic acid is distributed across over 70 countries worldwide promot- did not face any legal disputes related to false marketing claims.ing both industry growth and enhanced market penetration efforts thereby facilitating safe and effective solutions accessible

globally. In 2024 Bloomage Biotech established a Southeast Asia Regional Centre formed a localized team and actively developed Enhancing Product Information Transparency

and expanded emerging markets.Bloomage Biotech closely monitors the latest regulatory developments regarding product manuals labeling and packaging. The

The Company is committed to improving drug accessibility and medical levels in underdeveloped areas. We have actively cooperat- Company promptly updates its internal management procedures and conducts regular self-audits to rectify any discrepancies.ed with sectors of society such as governments medical institutions and non-governmental organizations to carry out the Patient Committed to the principle of information transparency Bloomage accurately labels product ingredients usage instructions

Care Charity Campaign. For example the Chairwoman leads her charity walk campaign to help solve the health problems of people contraindications and shelf life to ensure full compliance with applicable laws and regulations. All claims regarding product efficacy

in underdeveloped areas. are substantiated by results from external authoritative testing and validation processes. To further enhance transparency the

Company clearly communicates product ingredients and their sources during promotional activities. Comprehensive ingredient

information is publicly disclosed across multiple platforms including the Company's official website. Moreover ingredient explana-

A Clinical Trial on the Treatment of Genitourinary Syndrome of tion seminars are organized for interested parties. This approach fosters an open environment where customers and consumers Case

Menopause with Hyaluronic Acid Conducted by Bloomage Biotech can provide oversight. Additionally Bloomage Biotech regularly educates consumers about product shelf life and proper usage

methods through various channels such as social media platforms advertising campaigns and customer service hotlines.Genitourinary syndrome of menopause (GSM) significantly impacts women's health and quality of life. Hyaluronic acid recognized for its Compliance in Marketing Key Performance

excellent biocompatibility offers potential advantages in enhancing tissue hydration and lubrication. Bloomage Biotech in partnership

In its external marketing collaborations Bloomage Biotech incorpo-

with Beijing Hospital has pioneered a clinical trial to evaluate the use of hyaluronic acid in treating GSM. This research aims to assess the

safety and efficacy of this treatment approach within the Chinese population. The findings will provide valuable guidance for clinicians rates marketing risk clauses in its promotional contracts. These Bloomage Biotech responsible

and offer technical support in developing safe and effective treatment options for menopausal patients. clauses require partner agencies and influencers to sign a Commit- marketing training overview

ment Letter for Marketing Compliance ensuring strict adherence to

laws regulations company policies and the guidelines of promo-

tional platforms related to internet marketing activities. Prior to

Product Affordability initiating partnerships we conduct comprehensive background

22243

checks and audits of online influencers and major V-streamers. We participants

provide training to ensure they are well-versed in relevant regula-

Bloomage Biotech strives to provide customers and consumers with high-quality raw materials and terminal products at reason- tions and prohibited terms as well as review the promotional

able prices. To continuously improve the affordability of our products in the global market we fully consider the level of economic content they intend to use for product advertising. During 15312

development in each region in product pricing. live-streaming events we implement manual monitoring across training hours

multiple platforms to closely track any negative public sentiment in

While abiding by the market pricing mechanism the Company has considered factors such as the affordability and amount real-time.purchased from different countries and regions for all its products. Adhering to business ethics rules such as anti-monopoly and

anti-unfair competition the Company has priced fairly in accordance with the local market industry pricing and regulatory require- Online platform stores and e-commerce livestreams serve as the primary sales channels for Bloomage Biotech's functional

ments. skincare and food products. To raise employees' awareness of responsible marketing and ensure compliance during the sales

process the Company conducts training on compliance in promotion and advertising practices for key marketing employees

At present the Company owns one ophthalmic pharmaceutical product and one orthopedic drug both of which have been includ- promptly summarizing and sharing regulations and policies related to compliant product promotion and advertising. External

ed in the medical insurance to benefit the whole country reducing the economic burden of patients and benefiting more patients. experts are occasionally invited to conduct compliance promotion training for sales personnel. Furthermore the Company regular-

ly reviews prohibited marketing keywords and other online sales risks reinforcing the compliance and operational capabilities of

relevant personnel through post-event analysis weekly exchanges and special training so as to avoid providing consumers with

negative experiences due to violations.

47 48Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

In 2024 all brands under Bloomage Biotech maintained high DSR1 scores on major mainstream online platforms such as Tmall

JD.com and TikTok without content moderation alerts comment suspension and serious violations. Customer Feedback and Complaints

Improving Customer Satisfaction Key Performance To respond to customer feedback on time and handle customer complaints efficiently Bloomage Biotech formulated the Customer Complaint Handling Standard Operating Procedure as well as Customer-Related Processes and Closed-Loop Feedback Management

In ???? Procedure. Also we have established handling and feedback procedures customer service standards and specifications and

Bloomage Biotech has established management documents such as the emergency handling procedures. We have optimized its service quality through daily inspections research and analysis and timely

Operating Procedures for Customer Satisfaction Survey and Analysis which The Company has conducted a training for relevant employees.clearly define customer service objectives. The Company continuously satisfaction survey on

conducts training programs aimed at enhancing customer service 935 Upon receiving feedback and complaints the Company conducts thorough cause investigations along with risk assessments where capabilities while establishing quality inspection standards linked direct- customers applicable. The company may take actions such as sampling or initiating product recalls based on the findings and the company

ly to customer service staff performance assessments. Bloomage develops corrective action plans accordingly and implements preventive measures aimed at effectively resolving various types of

Biotech has established a dedicated consumer research team that with a satisfaction rate of feedback. We have established distinct handling procedures based on the nature of customer feedback. If a complaint pertains to

collaborates with external data analysis firms to conduct satisfaction product quality the customer complaint handling process is initiated. Feedback involving adverse reactions triggers the Adverse

surveys regarding product quality and company services both before 99.4 Event (AE) support process. For feedback related to product usage experiences or consumer demands our Product Management and after product launches. The results of these surveys are analyzed in % Department will assess the possibility to develop new products and services.depth enabling timely updates and iterations of our products while achieving the 2024 satisfaction

target

continuously optimizing our operational methods and content. In The Company welcomes feedback from B2B customers via WeChat email phone calls and interviews. In 2024 the Company

addition Bloomage Biotech promotes awareness of its products while received a total of 38 complaints from B-end customers through various channels with a response rate of 100% and a complaint

building trust among customers through various outreach initiatives Additionally the Tmall customer service teams resolution rate of 100%.such as publishing scientific articles and white papers organizing associated with our major

skincare-related seminars providing online educational content hosting brands have been recognized The Company welcomes queries requests and suggestions from B2C consumers via online or offline channels. The Company has

sessions featuring industry experts and partner training workshops. with “Golden Wangwang”& provided online customer service on e-commerce platforms such as Tmall JD.com and TikTok and participated in the “Hassle-Free“Silver Wangwang” titles Return Protection” program promoted by the platforms. If consumers have any questions or complaints they can contact us

through customer service channels. Furthermore we consistently engage private-domain fans alongside recruiting public-domain

consumers by inviting them into trial runs featuring new products to gather valuable perspectives covering diverse aspects like

In 2024 we established a centralized customer feedback collection mechanism alongside standardized monitoring processes for

user experience efficacy weight packaging material and fragrance. In 2024 the Company received a total of 53 complaints from

service delivery. By integrating information from multiple channels into clear standards at each interaction step we effectively

B2C consumers via various channels with a response rate of 100% and a complaint resolution rate of 100%.addressed issues related to information fragmentation or processing delays while significantly boosting response times. We also

enhanced technical support by assembling a specialized expert team capable of conducting targeted training that refine usage

scenarios enriching our knowledge base while updating raw material labeling standards to comprehensively improve customer

experience.Customer Privacy Protection

Bloomage Biotech places a high priority on customer privacy and security. To safeguard customer information and trade secrets

while preventing privacy breaches the Company encrypts data related to user privacy and enforces strict permission isolation at

the original layer of its Operational Data Store (ODS). We have established a hierarchical access system for customer information

based on departments job levels and positions accompanied by a rigorous data access approval process. This structure ensures

the secure and compliant use of customer information. Bloomage Biotech has required employees to strictly control and manage

documents and other materials according to relevant provisions and administrative regulations. It is forbidden to arbitrarily leak

any documents and materials of the Company to outsiders. In addition the Company organizes special training on trade secret

protection on an irregular basis to enhance employees' confidentiality awareness.The Company strictly protects the privacy and data security of B2B customers. We have confidentiality clauses in all contracts

signed with customers. We do not disclose privacy without his or her knowledge and consent. The Company abides by the Personal

Information Protection Law of the People's Republic of China and the data protection policies of online shopping platforms. We have

strengthened our internal self-discipline and autonomy. Based on legality and compliance the Company has handled B2C consum-

ers' personal information following the principle of personal information notification and consent. Regarding medical aesthetic

products and services Bloomage Biotech has implemented management measures such as the Image Rights License Agreement and

the Facial Injectable Treatment Informed Consent to protect the privacy rights of distributors and patients.The Company continuously develops specific processes for identifying assessing prioritizing monitoring and managing risks

related to customer privacy protection. These measures provide comprehensive safeguards for securing customer privacy

information. In 2024 Bloomage Biotech did not experience any incidents involving leakage of customer privacy or verified

complaints related to invasion of privacy or loss of customer data. Furthermore there were no complaints arising from inadequate

management of customer data security.

1DSR score is the detailed evaluation score given by buyers on e-commerce platforms to

sellers reflecting the performance of sellers in aspects such as product description

logistics service communication and transaction experience.

49 50Sustainable

2024 Sustainability Report CONTENTS

Chairwoman and

CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

04

Growth: Talent

Employment and Development

Bloomage Biotech firmly believes that talent is a crucial cornerstone for the

Company's sustainable development. We are dedicated to fostering an

equitable diverse inclusive and safe working environment for all employ-

ees. Our commitment includes providing a comprehensive full-cycle talent

training system that supports professional development and broadens

career advancement opportunities while facilitating the personal growth of

our employees. We will continue to enhance our occupational health and

safety management practices ensuring the safeguarding of our employees'

occupational safety as well as their physical and mental well-being. By doing

so we aim to collectively achieve our goals for sustainable development.SDGs Addressed in this Chapter：

Major Material Topics of Sustainability Covered in this Chapter：

· Employee Rights

· Employee Development

· Occupational Health and SafetyChairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

The Company strictly prohibits the use of child labour. We have established and implemented work management procedures for

Fair and Standardized Employment the prohibition of child labour and the protection of underage workers. Identity and background checks are carried out on employ-ees and the following measures are taken to ensure effective management:

Bloomage Biotech adheres to the principles of legal and equal employment. The Company is committed to comprehensively Statement and Principle

respecting and protecting human rights as well as safeguarding laborer rights and interests through standardizing employee The Company firmly opposes any form of child labour use and will never collaborate with suppliers who knowingly employ

recruitment and hiring processes continuously improving employment management systems and clarifying ethical codes of children

conduct.Compliance in Employment Recruitment and Hiring

Prior to employee onboarding we employ a multi-tiered verification approach that combines third-party background checks

Bloomage Biotech is committed to upholding the principles outlined in the Universal Declaration of Human Rights and strictly with manual reviews. Personnel files are meticulously created and we conduct in-depth verification and authentication of

adheres to national and local laws and regulations including the Labor Law of the People's Republic of China Labor Contract Law of employees' true identity details. This comprehensive process is designed to prevent the inadvertent recruitment of child

the People's Republic of China and Regulations on the Prohibition of Child Labor in all its operational regions. In alignment with labour especially in cases where employees might submit false information

standards such as the SA 8000 Social Responsibility Standard ISO 26000 Social Responsibility Management System Standard and

Ethical Trading Initiative (ETI) Base Code we have developed and implemented an Employee Handbook along with several associat- Protection of Underage Workers

ed management policies. The Company is dedicated to treating all employees fairly and equitably regardless of their race skin

color ethnicity gender age religious beliefs or cultural background. We have a strict zero-tolerance policy towards child labor in For underage workers between the ages of 16 and 18 we strictly adhere to legal and ethical guidelines. They are not permitted

any form. Additionally forced labor including any use of violence threats or illegal restrictions on personal freedom is expressly to engage in nor will they be assigned to work in high-risk environments such as high-altitude jobs underground operations

prohibited. Corporal punishment intimidation harassment abuse or any form of discrimination against employees is likewise radioactive highly toxic flammable and explosive work areas. Additionally they are excluded from tasks involving the

strictly forbidden. fourth-level physical labour intensity as defined by national regulations and other internship work with inherent safety risks.In compliance with legal requirements regular health examinations are arranged to safeguard their well-being

We have made employee recruitment and management standards including but not limited to:

Child Labour Rescue Procedures

Recruitment Process In the event that child labour is detected immediate action is taken. The child's work is halted without delay and a compre-

hensive health check is arranged. Subsequently the child is safely escorted home and both the child's guardian and relevant

authorities are promptly notifiedThe Company has formulated the Recruitment Management Regulations. Recruitment is carried out under the principle of “openness andfairness” ensuring that recruitment decisions are not influenced by discrimination based on factors such as ethnicity religion disability

gender or marital status

Necessary background checks are conducted with the informed consent of candidates to prevent issues such as identity fraud and conflicts

of interest The Company categorically prohibits all forms of forced labour and abuse including sexual coercion sexual assault threats

unwarranted body searches maltreatment humiliation exploitation and harassment. A comprehensive management system has

been established. This system clearly outlines employees' rights and interests sets explicit requirements for management person-

During Employment nel and provides a well-defined complaint channel. A dedicated department is responsible for conducting investigations to ensure

effective supervision and continuous improvement of management quality.Bloomage Biotech has established the Attendance and Leave Management Policy to implement standard working hour systems and compre- Bloomage Biotech continues to expand its talent pool and build a well-structured talent pipeline. By the close of the reporting

hensive time-keeping procedures. This ensures the smooth operation and production order of the Company while safeguarding employees' period the Company had a workforce of 4444 employees. The labour contract signing rate reached 100% and the employee

legal rights to rest and time off

turnover rate stood at 28.75%. All employees were adults above 18 years old. There were no incidents of child labour employment

forced labour or other severe human rights violations such as debt-bondage labour labour trafficking or transfer.Position Changes Terminations and Resignation

Employee-Initiated Termination of the Labor Contract:

The Company respects employees' voluntary decisions to resign and adheres to established resignation procedures

Company-Unilateral Initiation of Position Changes or Termination of Employment Contracts:

Compliance with Law and Labor Contract：Bloomage Biotech is committed to complying with local employment laws regulations and

labor contracts ensuring that termination or layoff procedures are conducted legally and fairly

Unimpeded Communication and Transparency：Employees are informed in advance about terminations. The specific reasons for

termination along with detailed processes and follow-up arrangements are clearly conveyed

Support and Compensation：Employees' rights are fully respected throughout this process. Appropriate financial compensation is

provided in accordance with legal requirements. Additionally Bloomage Biotech offers support for re-employment through various means

such as career counseling training opportunities internal referrals and job transfer options

53 54Sustainable

2024 Sustainability Report CONTENTS

Chairwoman and

CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

The Company has provided equal opportunities for all employees. We have fully utilized the respective advantages of gender

Diversity and Inclusion differences and capability differences at work. In 2024 awareness training on diversity discrimination and harassment and forced and abusive labour was newly developed and incorporated into the Employee Onboarding Guidebook for new employees.Bloomage Biotech respects employees of different ages races genders nationalities and physical conditions. To ensure the Female Employees

fairness and justice of the Company's procedures and processes in recruitment salary incentives training and promotion we have

We respect and protect the rights and interests of female employees and clarify the scope of work for female employees:

formulated and implemented the Professional Code of Ethics and Conduct and other systems. In this way we ensure that employees

- We forbid arranging female employees in super labor-intensive positions

enjoy equal rights prohibiting any form of discrimination and accepting employees' complaints when necessary.- We prohibit arranging pregnant and lactating female employees to engage in any work that may endanger their and their

children's health and safety

- Provide diversified care to our female employees by setting up a dedicated lactation room in the Company and organizing

regular care activities

Employee Structure of Bloomage Biotech in 2024 Unit: person/%

Retired and Re-employed Employees

We have formulated the Management Regulations on Retirement and Re-employment. We have not restricted the

???? ???? ???? ???? opportunities for employees to develop old employees' abilities. Oriented to personal expertise and industry

??.??% ??.??% ??.??% ??.??% experience we fully protect the rights and interests of re-employed employee

Employee Employee In 2024 Bloomage Biotech has had 11 re-employed employees

Gender Structure Age Structure

??

Employees of Different Races and Ethnicities

?.??%

We are highly attentive to the lives of employees from diverse racial and ethnic backgrounds showing full respect for

their emotions cultural and dietary customs. In our company cafeteria we make distinctions in food offerings

Male Female Aged 51 or above Aged 31 to 50 Aged 30 or below according to the religious beliefs of ethnic-minority employees

In 2024 Bloomage Biotech has employed a total of 9 foreign employees and a total of 120 minority employees

???? Disabled employees

????

??? ??.??% The Company supports the employment of special groups such as people with disabilities. We have prohibited

??.??%

??.??% discrimination against the disabled in the recruitment and appointment process. When conditions permit we provide Employee ??? Employee suitable positions for such individuals to protect their legitimate rights and interests

Hierarchical ?.??% Education In 2024 Bloomage Biotech has employed a total of 17 disabled employees

Structure Structure

???????

?.??%?.??%??.??%

Case Bloomage Biotech's Signing of the United Nations Women's Empowerment Principles (WEPs)

Senior management Middle management Doctor’s degree Master's degreeGeneral staff Bachelor's degree Below bachelor's degree ”“True gender equality should transcend the over-emphasis on gender. Gender equality is not only an indicator of social progress butalso a linchpin for the sustainable development of enterprises. Bloomage Biotech is committed to doing its part to assist more

women in realising their self-worth enabling them to shine with wisdom and radiance and contributing to the creation of a more

Key Performanceequitable social environment.”

As of the end of the reporting period the proportion of female employees at Bloomage Biotech was as follows:Zhao Yan Chairwoman and CEO of Bloomage Biotech “

48.96 50.00 41.45 62.72 In May 2024 Bloomage Biotech officially became a signatory member of UN Women's Women's Empowerment Principles (WEPs). This % % % % initiative aims to empower women in the workplace marketplace and community thereby promoting the realization of gender equality.

of the total number of in senior management in middle management among R&D staff The signing of the WEPs also signals international recognition of Bloomage Biotech's commitment and efforts in promoting gender

employees

equality and women's empowerment. Looking ahead Bloomage Biotech will further deepen its practices in gender equality and women's

empowerment. By establishing a high-level leadership mechanism and strengthening education and training for female employees the

Company aims to enhance the personal and social values of its female workforce.

55 56Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Bloomage Biotech's all-round employee training system

Talent Development Diversified Promotion Channels OpenDevelopment Platform

Management track Professional track Management Talent Pipeline Internal job competition system

Bloomage Biotech attaches great importance to attracting and retaining talents. We have striven to make career development R&D track Job Rotation System Management trainee system

channels smooth continuously optimized employee training systems and built a complete performance incentive mechanism. By

doing so we provide a broad platform for employee development. Management training Professional Training New Employee Training General training General training

Talent Introduction For all managers For all employees For new hires For all employees For R&D platform members

Bloomage Biotech approaches talent development and management from a strategic perspective. The Company has established Design tiered leadership For each professional Provide training on Provide training on For R&D personnel

an efficient talent recruitment management mechanism and scientifically forecasts talent development requirements. We prompt- programs tailored to track covered by corporate culture knowledge that all establish a learning

ly engage external human resources service agencies to assist in building our talent pool in technology management and profes- management hierarchies marketing R&D company system job employees of different platform that enhances

sional fields. We conduct social and campus recruitment activities on mainstream social and recruitment platforms. Additionally Include leadership production and functions basics knowledge and tracks are required to the exploration of new

the Company has drawn attention to talent acquisition by actively participating in industry activities conducting training with training for senior Provide professional skills enabling new hires master substances technologies

schools promoting employer brands and providing competitive benefits. managers and middle skills training courses to integrate into new Include training courses materials and processes

managers as well as including three stages of positions and grasp the on general management enabling them to quickly

management skills beginners intermediate basic knowledge required general qualities general embrace cutting-edge

When recruiting talent Bloomage Biotech adopts a diversified talent acquisition strategy. The Company has established a scientific

training for junior and advanced levels by the position in a short skills and other related perspectives and

objective and comprehensive evaluation system. By utilizing diverse assessment tools such as scientific evaluations and situational

managers and newly time knowledge and skills stimulate R&D motivation

simulations and integrating professional and systematic interview processes we thoroughly assess the capabilities of candidates promoted managers

thereby strengthening our talent development strategy. Furthermore Bloomage Biotech continuously refines the Internal Referral

Management Regulations. For referrers who successfully recommend management-level candidates for employment the Company

offers bonuses to encourage employees to continuously support the Company in attracting high-quality talent.In recent years Bloomage Biotech has received prestigious employer awards such as the ECHO 2023 King’s Ark·Most Talent-Centric Offline Courses Online Platform (E-learning)Lecturer Resources

Employer Award and the China HR Venus Grand Awards: Talent Management Benchmark Enterprise. These recognitions signify the Covering various categories such as management Case videos learning courseware Internal lecturers external experts

technology operation and general knowledge. knowledge base resources etc.Company's continuous exploration of employee development pathways and the achievements it has attained.Sharing of educational resources

Talent Cultivation

Employee training performance of Bloomage Biotech in 2024

Bloomage Biotech has improved employee qualities and fueled their career development through training. The Company has

established talent cultivation systems such as the Training Management System and the Internal Job Posting System which clearly

define its talent cultivation strategy. By developing diversified promotion channels and establishing an open development Training participation Training participation rate by gender

platform we have provided employees with more opportunities for training and further study. rate by hierarchical level

??.??%??.??%

Employee Training System ??.??%

Bloomage Biotech has built a systematic talent training system framework. To facilitate the internal talent pipeline development

we have provided multi-field and multi-level training programs covering management training professional training new staff ??.??%

training and general skills training. In addition we provide rich academic resources and platforms such as various AI office tools

and CNKI accounts to help employees make efficient use of office and learning resources and support their development.General staff Management Male employees Female employees

Key Performance

Training hours by

Average training hours by gender

hierarchical level

In 2024

??.????.????.????.??

Traning sessions Training hours per employee Overall investment in employee training

6279 participants 26.61 hours 2.67 million RMB

General staff Management Male employees Female employees

57 58Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Case Bloomage Biotech’s New Employee Onboarding Camp Case Vocational Skills Training Conducted by Bloomage Biotech

Bloomage Biotech conducts a comprehensive 5-day onboarding training program for newly hired employees. This training integrates In 2024 the Company organised 7 vocational skills training sessions with around 500 participants. These trainings employed thematic

various formats including classroom lectures group discussions on-site visits outdoor team-building activities and practical drills. The instruction alongside group competitions and situational interactions to assist employees in clarifying their thought processes from user

program aims to impart essential knowledge regarding corporate culture product information and quality and safety management. This needs to improving business performance. This approach deepened employees' understanding of market dynamics and enhanced the

approach not only deepens employees' identification with the corporate culture but also enhances their professional skills and fosters a success rate of new product development as well as market promotion.spirit of teamwork thereby facilitating the smooth integration of new employees into the workplace.

4 Flagship Products Market Concepts and Plans in the Strategy Program

Development for the

Second Session 1

Biomanufacturing

Pilot-Scale Platform

HRBP Strategic Partner-

5 ship Boot camp

Training Program on the

Development Plan for the

Second Session 2

Biomanufacturing

Pilot-Scale Platform PMP Certification &

6 Project Management

Excellence Initiative

Bloomage Biotech 2024

Consultative Marketing

Training Camp 3 Vocational Skills Training

7 Presentation Skills

New Employee Onboarding Camp Jinan Production Base

This year marks Bloomage Biotech formally initiated the Reserve Cadre Nomination Process for Tier 1 (Including 1.5) and Higher

Management Team. Managers are encouraged to nominate candidates who demonstrate exemplary character and performance

Case Bloomage Biotech has launched diversified leadership training programs while aligning with organizational development needs. This effort lays a foundational framework for systematic long-term talent

reserve within the Company’s talent management strategy.In 2024 the Company organized 4 leadership training sessions across different business lines engaging approximately 200 participants The Company has continued to enhance the Implementation Rules for Learning and Growth Welfare which encompasses vocational

in total. The training adopts a thematic approach combined with situational interaction to promote in-depth and amicable collaboration qualification training projects and educational programs for all employees including part-time and contract workers. The initiative

among departments. This initiative contributes to the optimal allocation and efficient utilization of resources. encourages employees to pursue relevant professional qualification certificates or upgrade their academic education. It also clearly

outlines reimbursement policies for personal academic advancement expenses and provides subsidies for obtaining certificates. In

2024 the Company invested a total of RMB 196.4 thousand in subsidies to support employees in achieving educational qualifica-

tions and professional certificates.Active Ingredient Business Line & Pharmaceutical & Global R&D Platform - Raw Material R&D Center & Active

Medical Device Business Line: “Driving Growth through Development” Ingredient Business Line: Specialized Horizontal Leadership Training Centered on

Management Leadership Training “Value Linkage: Synergy for Win-Win Results”

Personal Health Consumer Goods Business Line & Global R&D Platform - Global R&D Platform - Raw Material R&D Center: “Fusion-Innovation”Personal Care R&D Center: “Boundary-less Communication: Win-Win First Phase Project Management Capacity-Building Training CampCooperation” Horizontal Leadership Training Project

59 60Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Employee Training Model Innovative Talent Cultivation Key Performance

Bloomage Biotech continuously expands its talent development models including internal tutoring external expert teaching and Bloomage Biotech actively explores innovative talent - cultivation In 2024 Bloomage Biotech

college-enterprise cooperation. Besides the Company has continued to enrich the existing teaching resource library to meet models and promotes the transformation of scientific and

employees' diverse growth needs. technological achievements. In 2024 the Company continuously

refined the innovative talent management model. The R&D The Company employs approximately

In 2024 the Company further refined internal documents such as the Interim Regulations on the Management of Tutoring New and Management Committee takes the lead in overall planning

Interim Regulations on the Management of Internal Trainers. By doing so we have clarified the tutoring process tutor qualifications supervision and guidance while various departments collabo-

and appointments teaching responsibilities and assessment methods. We have regulated internally established tutorial systems rate in management each performing its own duties. Bloomage 920R&D professionalsand apprenticeship to build a stable and high-quality team of trainers. Biotech places significant emphasis on attracting innovative （around 50% hold postgraduate degreesor higher）

talent and optimizing the structure of its talent pool. The Compa-Additionally Bloomage Biotech improved employee development paths in terms of three directions: “experiential and practical ny actively encourages R&D personnel to engage in internallearning” “feedback and instruction” and “courses and skills training”. transfers and job rotations thereby establishing pathways for the represents about

cultivation and development of innovative talents. We regularly

formulate and update our talent assessment and incentive mech-

Talent training practices of Bloomage Biotech anisms to align with best practices. In doing so we continuously 20.70%

enhance our model for the cultivation and management of of our total workforce

innovative talents. Currently we boast a multidisciplinary profes-

Leveraging its training system and learning platform the Company has provided teaching resources and sionally structured industry-experienced deeply capable and

Courses and online and offline courses in management professional general and other knowledge efficiently collaborative talent team providing fundamental

skills training support for the Company's technological innovation. 2

experts enjoying special

Bloomage Biotech places a strong emphasis on providing various government subsidies

training opportunities for R&D personnel to empower innovative from the State Council

Tutorial system：establish an internal teaching mechanism develop a team of internal lecturers and researchers. In 2024 the Company conducted a total of 43

provide personalized instruction training sessions focused on innovative talent development with

Daily communication：each department holds regular meetings to encourage communication and 2931 participants accumulating 128 hours of training. Among

Feedback and learning between old middle-aged and young employees between current employees and new employ- these seven sessions were specifically designed for core staff 2

instruction ees and between employees in relevant departments. This aims to pass on excellent experience and help and team leaders engaging a total of 382 participants. Addition- Provincial Experts with Outstand-

employees independently access to training resources needed ally the Company arranged for relevant personnel to attend ing Contributions

external technical training programs to enhance industry techni-

cal exchanges.Job-specific learning: match suitable positions according to personal abilities and continue to accumulate 3

skills and management experience at work Case Conducted Business Competency Taishan Industry Leading Talents

Job rotation mechanism: provide three-year rotation opportunities for the head of first-line business to Training Conducted by Bloomage Biotech

Experiential and promote internal mobility of talents

practical learning Personal improvement: provide learning subsidies to encourage employees to improve their academic

level or professional and technical abilities and obtain relevant qualifications and academic certificates In 2024 the Company organized 6 training sessionsthemed “R&D Personnel Understanding Business 3Operations” for all R&D staff involved in raw materials and

Municipal Leading Talent

pharmaceutical and medical device research. A total of 952

person-time participated in these sessions. The training

aimed to enhance capabilities in knowledge transfer

This year the Company has initiated a pilot rotation program designed to cultivate mid-to-senior-level composite leadership talents management cognition organizational awareness project

and enhance cross-functional management competencies thereby building a robust talent development ecosystem. management and self-growth among R&D personnel. 30

Through thematic instruction case studies interactive Key technical personnel in critical

discussions and simulated problem-solving scenarios the fields such as senior/deputy

program improved employees' business awareness as well engineers and pharmacists.as their problem-solving skills and collaborative thinking

supporting the continuous optimization of the Company's

R&D system in alignment with its strategic objectives.Training rate of our

innovative talent

100%

61 62Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Honor and recognition system of Bloomage Biotech

Talent Development

Teams or individuals excelling in our quarterly recognition program

Promotion Mechanism Objects of Benchmark Models: Recognized role models within each business line

Key Performance recognition Employees who have made significant contributions to critical projects or tasks

Bloomage Biotech provides a growth framework that aligns with job require- Employees involved in key milestone events for the Company

ments and career planning objectives while establishing scientific evaluation In 2024

criteria for employees' promotion pathways. The Company has implemented a

Performance Management System that standardizes key performance manage-

ment processes including setting performance indicators conducting perfor-

mance communication and coaching evaluating performance and facilitating 100 % Spiritual Incentives: We enhance employees' sense of honor and achievement through

interviews with feedback. This system combines quarterly and annual evalua- employees received awards such as medals of honor or prestigious titles

tions to regularly assess employee performance while providing a basis for salary performance evaluations Material Incentives: We conduct annual evaluations to identify outstanding projects

distribution as well as talent promotion and development decisions. We are providing bonus incentives to both teams and individuals recognized for their contri-

committed to eradicating any form of discrimination during career advancement butionsForms of

processes to ensure equal promotional opportunities for all employees. Talent Development Incentives: Key accomplishments are documented in personal recognition

development file. Include employees in the core reserve echelon for special training

In 2024 Bloomage Biotech initiated the Personal Business Commitment (PBC)

performance assessment across all employee levels. Additionally we have 322 opportunities. Provide promotion opportunitiesEquity Incentives: We implement long-term incentive measures for the Company’s

continuously optimized our Employee Performance Evaluation Grievance Redress internal promotions directors senior management and key personnel. Outstanding individuals are given

Mechanism. Employees who have questions or concerns regarding their perfor- priority access to equity and other medium-to-long-term incentive programs

mance results can initiate an appeal at any time and we guarantee that respons-

es will be provided within 2-3 days. Internal promotion rate

In 2024 Bloomage Biotech issued the Interim Regulations on Internal Job Posting 7.25 %

Recognition

Management V2.0. This update introduced an evaluation mechanism for the Awards will be given in the annual/quarterly summing-up meeting

adaptation periods of Tier 1 Organizational Unit Leaders Senior Management frequency Awards will be given timely after important projects/tasks are completed

and Core Technical Personnel through a Dual-Tier Evaluation process comple-

mented by a 360-Degree Assessment approach. These mechanisms comprehen-

sively evaluate the compatibility between employees and their roles while

encouraging individuals to seek more suitable career development opportunities

within Bloomage Biotech. Furthermore the establishment of standardized Case Commendation activities on Bloomage Biotech's anniversary

internal job posting processes enhances our ability to effectively allocate and

manage talent resources across the organization.In celebration of our anniversary in 2024 Bloomage Biotech honored benchmarked model employees at our celebration event by

awarding a total of 16 prizes (eight categories) comprising individual awards such as 1 Chairwoman's Special Award 7 Excellent

Incentives Teamwork Award and 8 Outstanding Contribution Award. This not only expresses gratitude towards our dedicated workforce but also

aims to motivate outstanding performers to continue achieving excellence alongside us.and Recognition

Key Performance

In 2024 Bloomage Biotech imple-

mented the Management Measures of

Honors and Recognition V2.0 for all In 2024

employees further enhancing our

selection mechanism for honors and Employee stock ownership Representingplan (ESOP) covered

recognition. Additionally we estab-

lished an assessment and incentive 1%framework that focuses on “product 339 of the total stock valuedevelopment projects as individualunits” guided by the “goal of meetingmarket and customer demands”. By

leveraging project-based perfor-

mance evaluations along with bonus 4800000

structures we aim to enhance shares issued under this plan

employees' motivation for progress

and accelerate high-quality innova-

tive research and development of Group Photo of the Commended Employees at the Company Anniversary Celebration

products.

63 64Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Safety Goals

Safety and Health Bloomage Biotech sets goals related to occupational health and work safety every year as a guide to promote various work safety

management tasks. In 2024 the Company adjusted the safety production goals of 2024 by combining the safety audit rectification

opinions and national laws and regulations related to safety production. We have finally developed 19 annual goals and distributed

Bloomage Biotech places paramount importance on employee occupational health and safety. The Company adheres strictly to them to each subsidiary and branch ensuring their implementation at each production base. In 2024 all of the Company's safety

legal regulations such as the Work Safety Law of the People's Republic of China and the Law of the People's Republic of China on Preven- objectives were successfully achieved.tion and Control of Occupational Diseases. We have established a comprehensive work safety management system alongside

occupational health protocols that focus on enhancing safety practices across all operations ensuring compliance with work safety Minor injury rate ≤ ?%

In 2025 Bloomage Biotech will continue Completion rate of the“ three simultaneous” regulations while safeguarding employee well-being. requirements for new renovated and expanded to centre its efforts on the development projects: ???%

of the safety system aiming to compre-

Safety Management Number of major incidents: ≤ hensively enhance the Company's safety

The pass rate of occupational hazard

management level. Through systematic factor detection: ???%

By benchmarking against ISO 45001 standards and international best practices we have further refined our policies governing The number of accidents is ? management and continuous innovation

safety and health management including the Work Safety Management System and Occupational Health Management System. As of we strive to elevate its safety manage-

the end of this reporting period Bloomage Biotech's production bases in Jinan Tianjin and Dongying have all achieved ISO 45001 ment to a higher standard. The Compa- Coverage rate of safety audits

The pass rate of hidden

certification for their occupational health and safety management systems. Regular internal audits are conducted alongside ny's work safety objectives for 2025 are (inspections): ???%hazard rectification ≥ ??%

external audits to ensure adherence across all production bases. as follows:

Timely reporting rate of Establishment of the Group's professional

Security Structure accidents/incidents: ???% auditing standards for occupational health and

environmental protection

Bloomage Biotech emphasizes standardized development for work safety through a top-down organizational approach that To achieve its safety production targets successfully the Company has broken down the targets and delivered them to subsidiaries

directs coordinates and implements safety tasks across subsidiaries while regularly convening meetings focused on work safety. departments manufacturing workshops teams and individuals. We have completed the targets from top to bottom by standardiz-

The Company's Work Safety Committee serves as the supreme authority for safety-related affairs. The Chairwoman and CEO of the ing the production system improving the safety management structure developing a safety culture and assessing safety perfor-

Company assumes the role of director while the heads of various departments and safety heads of production bases are mance.members.Key Performance

In 2024 Bloomage Biotech newly established the Safety and Environmental Protection Management Center. This center is tasked

with formulating and implementing the Company's safety and environmental protection strategies ensuring the effective opera-

tion of the safety and environmental protection systems. The Group has set up an internal safety expert panel and collaborated

with a third-party to form an external expert panel. By conducting audits alternately between the internal and external expert

panels the Company further strengthens the foundation of its safety system management and continuously improves its safety -

management standards. This approach supports activities such as formulating work safety regulations conducting safety audits 10.82 million RMB 135.2 thousand RMB 100%

and engaging in academic discussions on work safety. Invested in work safety and occupational health2 allocated to employees' work safety related positions' work safety

liability insurance liability insurance3

Safety production management structure of Bloomage Biotech

Based on its realities each production base has formulated its management measures for performance appraisal which are

related to vocational health and safety. These measures stipulated safety performance appraisal standards and procedures cover-

Production Safety Committee ing all relevant employees. We also require general managers of all production bases and employees to sign a safety target respon-

sibility letter. In 2024 the signing rate of employee safety target responsibility letters in all production bases of Bloomage Biotech

reached 100%. Besides the work-related injury insurance purchase rate also stood at 100%.Production Safety Committee Office Safety Expert Group

Employees' occupational health and safety conditions of Bloomage Biotech

Departments

Indicators Unit 2023 2024

Number of work-related deaths person 0 0

Number of work-related injuries count 3

Production bases 0

Number of working days lost due

to work-related injuries day 53 0

Work-related accidents per million 0

work hours / 0.32

02

Workshops

2 The statistical scope encompasses the entire Bloomage Biotech Group including safety investments employee health check-ups occupational disease

check-ups detection of occupational disease hazard factors and other occupational health and safety investments as well as investments in employees' work

safety liability insurance and work-related injury insurance.

3 This is not a mandatory requirement for the industry in which Bloomage Biotech operates.

65 66Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Work Safety Work Safety Management Key Performance

Work Safety System The Company implements a dual-prevention system that combines the classification and control of work safety risks with the investigation and In 2024

Bloomage Biotech has formulated and continuously refined a comprehensive set of regulations including the Hazard Identification and management of accident hazards. Safety education and training activities

Risk Assessment System and the Safety Inspection and Hidden Danger Investigation Management System. These systems encompass all aspects are carried out regularly. Through annual internal and external safety The internal safety audit

of work safety management such as risk identification safety hazard investigations chemical management occupational health manage- audits the Company sorts out the list of safety risk factors each year and coverage rate of Bloomage

ment equipment management contractor management operational safety management emergency response protocols and incident implements safety management measures thus achieving standardised Biotech was

management. Additionally we integrate safety culture development with safety monitoring and internal/external audits to consolidate closed-loop management throughout the entire production life cycle.our achievements in safety management. 100%

Each production base of Bloomage Biotech has established a risk classifi-

Bloomage Biotech Safety Management System (Selected): cation and control system and a system for the investigation and manage-

ment of accident hazards. These systems are reviewed annually to ensure Covering

their effectiveness. The production bases have established risk control

Safety Management lists including risk ledgers records of hazard identification and analysis. 12

Work Safety Responsibility Management System Work Safety Meeting Management System They also organise comprehensive inspections seasonal inspections elements such as work safety

Management System for the Withdrawal and Use of Safety Performance Appraisal Management System special inspections holiday inspections monthly inspections and irregu-

objectives and indicators

Work Safety Expenses lar daily inspections. Potential hazards discovered during inspections are

organisational structure and

promptly issued to the responsible parties via the OA system for rectifica- responsibilities production equipment and facilities

tion within a specified time limit and the relevant responsible parties are management operation

evaluated. safety risk classification and

control hazard investigation

Risk Assessment and Control The Company also attaches great importance to the safety management and management in all

Management System for the Classification and Control of Work Safety Risks departments and production of engineering contractors and other suppliers within the production workshops.Identification of Hazards and Risk Analysis of Operational Activities bases. It strictly implements the Safety Management System for Contractors

and Suppliers. Compliance checks are carried out on contractors' qualifica-

The rectification completion

tions. Before the entry of all engineering contractors safety requirements rate was

and the responsibilities of both parties are clearly defined. Safety training

assessment and technical disclosure are provided for external construc-

Hidden Danger Investigation tion workers. Safety supervision and management are carried out 100%.Management System for Safety Inspections and the Investigation and Treatment of Hidden Dangers throughout the process to promptly identify and rectify potential safety

hazards of contractors preventing safety risks during the contractors' and

suppliers' operations within the park. In 2024 all production bases of

Bloomage Biotech conducted a total of 467 safety education sessions for

suppliers contractors and other personnel with 27823 participants. In

Chemical Management addition we care about the safety of employees' daily lives. System

Safety Management System for Hazardous Chemicals Safety Management System for Major Hazard Sources documents such as the Canteen Management Regulations and the Employee

Safety Management System for Precursor and Explosive Apartment Management Regulations have been formulated to ensure the

Chemicals safety and hygiene of employees' food and accommodation.The Company also actively promotes the automation and digitisation of work safety and strengthens safety monitoring in the

Occupational Health Management following ways:

Management System for Labour Protection Equipment

Occupational Health Management System

Equipment Management Configure automatic alarm systems including combustible gas detectors automatic fire alarms temperature

Contractor Management detectors and audible and visual alarms.Management System for Special

Safety Management System for Contractors Equipment

and Suppliers Safety Management System for

Production Facilities In daily management we issue rectify and eliminate hazards through the OA system to improve work efficiency.Emergency Response and Operation Safety Management Production bases have built security integration platforms equipped with intelligent systems. Real-time dynamic

Incident Management Management System for Special monitoring is obtained through electronic maps achieving comprehensive safety monitoring of the park.Incident Management System Operations

Emergency Rescue Management System Safety Management System for Confined

Spaces

67 68Sustainable

2024 Sustainability Report CONTENTS

Chairwoman and

CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Chemical Safety Laboratory Safety

To prevent hazardous chemical accidents Bloomage Biotech adheres to relevant laws and regulations such as the Work Safety Law As Bloomage Biotech's core to promote its continuous innovation and development the laboratory also serves as a centralized

of the People's Republic of China and the Regulations on the Regulations on the Safety Management of Hazardous Chemicals. The place for hazardous chemicals. To standardize laboratory safety management the Company has formulated and implemented

Company has developed a series of internal regulations including: Safety Management System for Hazardous Chemicals and Precur- strict laboratory safety procedures clarifying standard operating procedures for the management of chemicals biological materi-

sor Chemicals; Management System for Highly Toxic Chemicals; Safety Management System for Explosive and Drug Precursor Chemicals. als and laboratory equipment. We have taken multiple measures to ensure the safe operation of the laboratories.These regulations clarify departmental responsibilities and management approaches throughout the entire life cycle of hazardouschemicals. The Company standardizes the management process for hazardous chemicals including procurement storage loading Safety measures of Bloomage Biotech's laboratories (partial)）

and unloading transportation usage disposal and accident handling. Regular emergency drills are conducted based on estab-

lished plans such as the List of Hazardous Chemicals and the Special Emergency Response Plan for Accidents of Hazardous Chemicals

(Major Hazard Sources).System construction

In the development of the institutional system for the global R&D platform the Company has drafted and continuously

Chemical Safety Management Measures refined the general guideline including Global R&D Platform Laboratory Management Procedures and issued special

systems such as the Global R&D Platform Hazardous Chemicals Management Regulations the Global R&D Platform Hazard-

ous Waste Management Regulations and the Equipment and Facilities Safety Management System

Identify chemicals before warehousing and establish chemical labels and Safety Data Sheets (MSDS) For the first time the R&D platform has established platform-level management systems a safety performance manage-

ment mechanism and a safety mutual-inspection mechanism to boost the participation of all employees

Classify and store hazardous chemical storage cabinets in separate warehouses as required and manage them with a

double-lock system by two persons

Identify high-risk chemicals and reduce or replace their usage

Risk Identification and Control

Obtain safety technical specifications from suppliers when purchasing chemicals Identify safety risks in R&D laboratories and rectify them in a timely manner to reduce the exposure of personnel to risks

Determine the inventory with the warehouse before procurement to reduce storage risks

Reduce the risk of exposure to hazardous chemicals by installing explosion-proof cabinets accident fans and combus- Hazardous chemicals management

tible gas detectors We properly classify label store and dispose of all biological materials and chemicals to reduce the risks of cross-con-

tamination and accidental exposures

Regularly train employees on the properties storage retrieval use protection and emergency response of chemicals

Conduct a comprehensive survey of hazardous chemicals and establish an inventory of hazardous chemicals.Personal Protection Management

Provide employees with labor protection equipment such as protective gloves protective face shields goggles acid- We provide necessary personal protective equipment such as lab coats safety glasses gloves and masks and ensure

and alkali-resistant clothing and filtering gas masks according to the properties of the chemicals that employees can use them correctly

Set up safety warning signs hazardous chemical information cards and operating procedures for positions involving

hazardous chemical operations testing and inspection Facility and equipment management

We regularly maintain and inspect all laboratory equipment to ensure it is in good condition

Formulate emergency response measures for hazardous chemical leakage and equip accident emergency facilities

such as chemical adsorption cotton fire sand boric acid and drenchers

Emergency preparedness

We have assigned safety commissioners responsible for preparing laboratory emergency plans and conducting drills

Case Drills for On-site Disposal Plans of Hazardous Chemical and Hazardous

Waste Leakage Conducted at Production Bases in Jinan Dongying etc.Personnel training

In 2024 production bases in Jinan Dongying and other places simulated hydrochloric acid leakage scenarios and carried out emergency We regularly organized training on laboratory operations and equipment use

response plan drills. After the hazardous chemical keeper discovered the leakage he notified the members of the disposal team to wear In 2024 the R&D platform organized a total of 7 EHSand safety training sessions with 541 participants in total and a

acid- and alkali-resistant chemical protective suits gas masks goggles and other personal protective equipment. Then the leaked cumulative training duration of 19 hours

hydrochloric acid was adsorbed with sand and the adsorbed sand and the damaged containers were transferred to the waste chemical

warehouse. Finally the hydrochloric acid containers were replaced. This drill helps improve employees' ability to coordinate scientific

on-site disposal when there is a chemical leakage reducing the possible impact of leakage incidents.Occupational Health Examination

Conduct physical examinations for R&D personnel to screen for occupational diseases promptly

In 2024 a total of 191 occupational health examinations were carried out for R&D personnel in the platform

69 70Sustainable

2024 Sustainability Report CONTENTS

Chairwoman and

CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Safety Culture Safety Emergency Drills

Bloomage Biotech is dedicated to creating a safety culture atmosphere through measures such as strengthening safety training In 2024 Bloomage Biotech has optimized comprehensive emergency plans special emergency plans and on-site disposal plans

and drills building safety culture demonstration workshops releasing safety knowledge posts and organizing safety knowledge such as the Work Safety Incident Emergency Response Plan the Special Emergency Plan for Fire and Explosion Accidents Mechanical

competitions. Moreover Bloomage Biotech encourages employees to put forward reasonable safety suggestions and actively Injury Incident Response Plan Typhoon Preparedness Special Emergency Plan On-site Response Plan for Heatstroke in High-Temperature

participate in the Company's safety construction. Environments Earthquake (Evacuation) Special Emergency Plan. The plans cover a total of 13 categories including fire vehicle injuries

electric shocks alcohol accidents and scalding accidents and the relevant plans have been registered for the record. We carry out

safety emergency drills in various production bases and offices every year based on relevant emergency response plans to help

Safety Training employees apply the knowledge and skills learned in safety training to practice.Bloomage Biotech formulates and implements internal documents such as the Safety Training and Education System. The safety

training plan is updated regularly every year. The main responsible persons safety management personnel and employees on

specific positions of each production base are required to receive safety education. Special operators and operators of special Case A Variety of Safety Drills Conducted by Each Production Base of Bloomage Biotech

equipment must hold relevant professional qualifications. New employees must receive three-level training for work safety.In 2024 each production base of Bloomage Biotech carried out various types of drills including comprehensive emergency drills special

Case Safety Training Conducted by Each Production Base of Bloomage Biotech emergency drills for major hazard sources and special emergency drills for fires and special equipment accidents. The themes of these

drills covered aspects such as fires simulated leakage in ethanol tank areas abnormal boiler conditions confined space operations fire

drills and emergency responses during the flood season. These activities comprehensively enhanced employees' emergency response

In 2024 Bloomage Biotech regularly educated and trained employees on safety and health regulations. Diverse training methods were capabilities to safety incidents.adopted including classroom training simulation drills and case analysis to enhance the training effect by combining theory and

practice. Additionally each production base established a question bank of essential safety knowledge and urged departments to

regularly assess employees to ensure that every employee masters the necessary safety knowledge.Case “Work Safety Month” Activities Carried Out by Bloomage

Biotech in Multiple Locations

In June 2024 several production bases of Bloomage Biotech launched “Work Safety Month” activities with the theme of “Safety for AllEmergency Ready Clear Lifelines Always”. Activities such as emergency evacuation drills simulating fire and earthquake scenarios online

public classes on risk avoidance and escape and quizzes on risk avoidance and escape were organized to enhance employees' ability to

respond to emergencies and avoid risks.Case Special Training on Hazard and Operability (HAZOP) Analysis Conducted by

Bloomage Biotech Fire Drill at the Production Base

In 2024 to continuously improve the Company's design review level regarding the safety and operability of facilities Bloomage Biotech

organized special training on Hazard and Operability (HAZOP) analysis at the group level. This training enhanced employees' ability to

identify and analyze potential hazards in engineering projects or production facilities in advance ensuring safety from the perspective of

the overall equipment system.Occupational health and safety training of Bloomage Biotech4

Indicators Unit 2023 2024

Number of occupational health times 640 1755

and safety training

Number of employees trained on

participants 16675

occupational health and safety 34080

Total hours of occupational 02

hour 23533

health and safety training 36629

4 The statistical caliber covers all of Bloomage Biotech's all operating production bases in China.

71 72Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Occupational Health Case Occupational Health Training Conducted by Each Production Base of Bloomage Biotech

Bloomage Biotech strictly complies with laws and regulations such as the Law of the People's Republic of China on the Prevention and

Control of Occupational Diseases. During this year we updated and implemented occupational health-related management

systems including the Occupational Health Management System and the Management System for Labour Protection Equipment. The In 2024 Bloomage Biotech provided education and training on occupational health for employees. The training covered topics such as

Company regularly hires external institutions to detect occupational hazard factors at production bases and provides comprehen- the Company's occupational health management system and operating procedures the use of occupational disease prevention facilities

sive protection against occupational disease risks for employees from aspects such as personal safety protection environmental at their positions the wearing of labour protection equipment and the knowledge and skills of emergency response to occupational

disease hazards. By combining theoretical learning with practical operations the training effectiveness was enhanced.and engineering measures. This is to address the Company's major occupational disease risks such as dust high temperatures

noise and chemicals. During this reporting period the health examination coverage rate of Bloomage Biotech employees has

reached 100%.The Company has adopted a series of measures to reduce or eliminate occupational disease hazards:

Engineering Control and Equipment Management

Minimize employees' exposure to occupational hazard factors through measures such as isolation zoned

operations ventilation dust removal noise reduction and the sealing and piping of production equip-

ment

Management Measures

Practical CPR Training at the Hainan Production Base Occupational Disease Knowledge Training at the Tianjin Production Base

In terms of risk prevention identify the risks of occupational hazards in the workplace and formulate

preventive and control measures In addition Bloomage Biotech attaches great importance to preventing the risk of repetitive strain injuries that may be caused to

Implement management control measures such as reducing working hours and improving operation employees during daily operations. By improving the working environment and operation methods such as using robotic arms

methods to control the extent of employees' exposure to harmful factors and mitigate the potential automated guided vehicles (AGVs) and electric vehicles and upgrading manual packaging processes to automatic or semi-auto-

health impacts matic packaging machines the Company reduces the pain or injuries that employees may suffer from repetitive movements and

Set up warning signs and instructions in prominent locations in workplaces job positions equipment overuse of muscles. We also install fans to exchange air alleviating the impact of high temperatures in the workshop and prevent-

and facilities where occupational hazards exist or are generated ing negative health effects on employees during their work.Set up the “Hazard Snap” Mini Program in the OA system enabling employees to report any discovered

occupational health and safety hazards risks and issues at any time and ensuring that these reports are

promptly addressed

Conduct regular occupational health training and organize a series of emergency drills to enhance

employees' awareness and capabilities of health protection

Regular Occupational Health Checks

Organize occupational health examinations for employees engaged in work involving exposure to

occupational disease hazards before taking up their posts during their employment and upon leaving

their posts. Inform employees of the results of the occupational health checks and the suggestions

provided by the occupational health examination institutions

Personal Protection

Provide employees and other personnel entering the production site with a full set of labor protection

equipment for free and guide and supervise employees to use and wear them correctly

73 74Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Employee Rights and Benefits Employee Benefits

In 2024 Bloomage Biotech continued to optimize the Benefits Management System enhancing the employee benefits system to

cover three categories: statutory benefits supplementary benefits and position-based benefits. Based on employee feedback we

refined our benefits structure to meet diverse employee needs. Moreover the Company strengthened its care for employees by

Bloomage Biotech has continued to refine its compensation and benefits system and establish standardized management policies. establishing a lactation room for female employees and a gym and organizing activities such as holiday celebrations periodic

The Company provides employees with excellent working conditions ensures smooth communication and complaint channels condolences and team-building events to help employees balance work and family life. Additionally we have made the office

and strives to create a respectful fair and friendly work atmosphere. These efforts are aimed at continuously enhancing employ- environment more comfortable to provide employees with a more pleasant and humane workplace.ees' sense of happiness and belonging.Key Performance

Employee Compensation

In 2024

Bloomage Biotech adheres to the principle of equal pay for equal work. This year the Company updated the Salary Management

System and the Performance Management System and introduced a broadband salary model for the first time. To match salary with The social security contribution rate The coverage rate for supplementary medical insurance for all employees and physical examination for regular employees

employees' contributions and performance and to boost their motivation we have optimized the income distribution structure

and clarified the salary incentive orientation. The Company pays salaries on time and in full and provides pay stubs to employees

enabling them to understand the details of their compensation structure bonuses and benefits. Each year the Company uses 100 % 100 %

annual performance ratings as the basis for salary adjustments combining individual salary levels in the market performance

ratings and total compensation to form a salary adjustment plan.Bloomage Biotech benefits system

The Company's remuneration payments are based on the following principles:

Provide benefits to employees to meet national statutory requirements based on the Leave and Attendance

Management System and the Benefits Management System:

Social insurance (medical insurance pension insurance unemployment insurance work-related injury insurance maternity

insurance)

Housing provident fund

Principle of perfor- Statutory

mance results payment Benefits Statutory holidays annual leave sick leave marriage leave maternity leave parental leave nursing leave paternity leave

and funeral leave

Labor protection

Education and training

Principle of job Principles of openness

value payment fairness and transparency

Provide additional benefits to all regular employees to enhance welfare benefits and satisfaction including:

Care benefits: commercial insurance annual physical examinations high temperature subsidies

Warmth benefits: holiday gifts condolence allowance birthday benefits

Supplementary

benefits Economic benefits: lunch allowances overtime meal allowances transportation allowances work-type residence permit

employee purchase program

The Company's salary structure includes the following components:

Learning and growth benefits (for professional qualifications and certifications)

Salary type Contend

Fixed cash income Base salary position salary and seniority salary

Provide meal allowances based on job nature and support employees in advancing their education:

Monthly performance bonus quarterly performance bonus project bonus sales

Variable cash income

bonus annual bonus and special bonus Transportation allowances

Overtime pay Overtime pay for hours beyond standard working hours and holiday overtime pay Communication allowancesPosition-based

General subsidies such as meal allowance transportation subsidy and high-tempera- benefits Shift allowances

Allowances and subsidies

ture allowance as well as subsidies for employees stationed in other locations

02 Learning and growth allowances (for education advancement)

75 76Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Case Bloomage Biotech carried out Women's Day activities Employee Communication

Bloomage Biotech attaches importance to communicating with employees and has established multiple and open channels

In March 2024 Bloomage including face-to-face activities like employee meetings and departmental meetings as well as online feedback channels such as

Biotech's subsidiaries and email and suggestion boxes. In 2024 the Company further democratized its systems and processes by publicizing new policies on

branches held Women's Day internal communication platforms and soliciting suggestions.activities themed "Achieving a

Better Self" featuring flower To protect employees' legitimate rights interests and privacy the Company has established an anonymous complaint and report-

arranging flower gifting and DIY ing channel and kept employees' complaints and reporting information confidential. Employees can anonymously report any

handicrafts for female violations workplace misconduct or health and safety issues to their superiors or the Human Resources Department. Then the

colleagues. These activities relevant responsible departments conduct follow-up investigations and handling based on employees' complaints or reports.promote employee happiness

and work-life balance.Bloomage Biotech’s flower arranging and flower gifting activities on the Women's Day

Bloomage Biotech’s employee channel for rational suggestions and opinions:

Case Bloomage Biotech's Children's Day activities hr@bloomagebiotech.com

In June 2024.Bloomage Biotech helChildren's

Dayactivities to strengthenthe bond betweene-

mployees and theirchildren and enhancethe Bloomage Biotech regularly conducts employee satisfaction surveys anonymously covering five dimensions: job duties manage-

sense ofidentification ofemployees'

ment process working environment career development salary and benefits. We have also analyzed data with a third-party

familieswith the workplacefurther fostering

aharmonious and warmworking environment. professional research platform to ensure objective and professional survey results. Currently the Company's employee satisfac-

tion score stands at 85 points. Additionally Bloomage Biotech has conducted surveys on the hygiene meals environment and

service quality of the company cafeteria with satisfaction rates exceeding 97%. Based on the survey analysis the Company has an

Bloomage Biotech's family fun activities on the Children's Day understanding of employees' work conditions thus providing care and developing plans to improve employee satisfaction.Furthermore Bloomage Biotech fully respects employees' rights to freely associate and refrains from interfering with the legal

Case Bloomage Biotech's "Happiness Proposal" plan establishment operation or management of collective bargaining thereby facilitating effective communication between labor and

management. Each of Bloomage Biotech's production bases has established its trade union. According to the Trade Union Manage-

ment System we listen to employees' opinions safeguard their legitimate interests and democratic rights and regularly carry out

Bloomage Biotech has launched its "Happiness Proposal" plan offering union welfare activities to improve their lives.congratulations and gifts to employees on holidays and birthdays and other

key dates. In 2024 the Company organized various activities including fun In 2024 all major production bases of Bloomage Biotech signed the Collective Labor Agreements with the company’s trade union.sports meet dumpling-making activity and the Loong Year celebration to The agreements cover principles of diversity non-discrimination and non-harassment as well as working hours salaries occupa-

convey care and gratitude enhancing employees' sense of belonging and tional safety and health women's rights employee insurance benefits and training ensuring the protection of employees' legal

happiness. rights and reasonable treatment.Bloomage Biotech’s employees and their children

attended the Loong Year celebration

Besides to promote employee health the Company has implemented diverse measures including organizing sports activities fun sports meets and

building a gym. Additionally the Company has organized free medical activities to help employees monitor their health in a timely manner.Bloomage Biotech's health benefits

Workplace gym Free medical services provided by hospital staff Fun sports meets

77 78Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

05

Symbiosis: Green Low-Carbon

and Resilience

The genes of green technology have been deeply embedded in every aspect

of Bloomage Biotech's operations. The Company actively practices the

concept of green manufacturing continuously improves its environmental

management system refines product design and processes in an effort to

reduce resource consumption and pollutant emissions. To address climate

change we proactively drive green production through technological

innovation and the adoption of clean energy. Furthermore we focus on

resource recycling and reuse to advocate for a green and low-carbon lifestyle

in society.SDGs Addressed in this Chapter:

Major Material Topics of Sustainability Covered in this Chapter：

· Environmental Compliance Management · Water Management

· Environmental Permits and Certifications · Response to Climate Change and Energy Management

· Pollutant and Waste Management · Biodiversity

· Product Environmental ImpactChairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Addressing Climate Change Climate Strategy and Goals

Bloomage Biotech has integrated climate change response into its sustainable development strategy and conducted carbon

emission accounting from dimensions of both organization and product. We have set a special budget for greenhouse gas manage-

ment and implemented low-carbon transition along two paths: energy conservation and emission control.Bloomage Biotech actively explores the development path of green manufacturing. The Company has been less dependent on

fossil-based materials and continuously reduced resource consumption and GHG emissions. While reducing its own emissions the Additionally the Company proactively discloses its climate change management and performance on platforms like CDP demon-

Company strives to provide green manufacturing solutions. strating its determination to address climate change and contributing to the mitigation of global warming.To scientifically and effectively disclose the Company's efforts in addressing climate change we follow the recommendations of the

Task Force on Climate-related Financial Disclosures (TCFD) and disclose our climate change risk management system and actions Bloomage Biotech’s climate strategy framework

from four dimensions: governance strategy risk management as well as metrics and targets. The Company continuously seeks

solutions to address climate change and strives to achieve sustainable low-carbon development goals through emission reduction

planning energy-saving technology applications and renewable energy utilization.Strategic measures Specific measures

Climate Governance

Conduct greenhouse gas accounting

Bloomage Biotech has established a top-down sustainable development management mechanism and assembled a dedicated Continuously implement energy-saving

team with professional knowledge industry background and experience. Regular specialized training was conducted to empower technological upgrades

the organization to effectively drive climate change and energy-saving initiatives. Additionally the Company has incorporated ESG Optimize energy and resource use Constantly build a low-carbon corporate culture

performance evaluation requirements including climate change into the annual personal performance commitments of relevant Production and in production Deploy renewable energy infrastructure

senior executives department heads and specialized positions. To effectively implement relevant initiatives we have utilized a operations optimization Participate in green electricity market

salary-based incentive mechanism. transactions

Bloomage Biotech’s climate governance structure

Carry out life cycle assessments (LCAs) on

Continue to focus on sustainable products to evaluate their environmental impacts

products and technology R&D Pay attention to sustainable ingredients and

Product upgrades packaging innovation

Oversee and make decisions on climate-related matters such as formulating strategies related to

climate change setting emission reduction targets and pathways managing climate risks and

Board of Directors monitoring progress toward emission reduction goals Perform greenhouse gas (Scope 3) accounting

across the value chain

Supply chain ESG management

Supply chain Encourage suppliers to improve their greenhouse gas management levels

enhancement

ESG Review and supervise the identification and assessment of risks and opportunities related to climate

change as well as the completion of specific projects

ESG Committee under

the Board of Directors

Case Conducting life cycle assessments (LCAs) on multi-category products to

evaluate their environmental impacts

Tasked with overseeing the daily management of climate change issues conducting policy research

and training developing climate change strategies and targets leading the implementation and

ESG monitoring of climate-related projects and supervising carbon management and information disclo- During the reporting period in order to strengthen its management of product sustainability Bloomage Biotech conducted life cycle

ESG Management sure assessments (LCAs) on multi-category products including pharmaceutical-grade cosmetic-grade and food-grade Sodium Hyaluronate

Center as well as cosmetic-grade Ectoine and BIOHYALUX HA Barrier Conditioning Single Use Essence. The Company calculated key indicators

such as product carbon footprint resource consumption and water consumption and engaged authoritative auditing institutions to

conduct verifications obtaining compliance statements in accordance with ISO 14040 ISO 14071 ISO 14064 ISO 14067 standards.Follow the Company’s climate strategy and targets implement climate-related action plans strength-

en energy resource management and regularly report progress on these actions

ESG Working Groups

Aware of the urgency and necessity to accelerate low-carbon transition the Company aims to reduce total group-wide carbon

emissions (Scope 1 + Scope 2) by 50% by 2030 (compared to that in 2023). We strive to scientifically and efficiently reduce emissions

to the best of our capabilities.

81 82CONTENTS Chairwoman and

Sustainable

2024 Sustainability Report CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Risk and Opportunity Management List of Climate Risks and Opportunities

Physical Risks

Bloomage Biotech places great emphasis on identifying and managing climate-related risks and opportunities. Under the review

and guidance of the Company’s Board of Directors and the ESG Committee the ESG Management Center has led the development We have conducted the scenario analysis based on the two Representative Concentration Pathways (RCPs) of the Intergovernmen-

of risk and opportunity assessment and response plans and coordinated with functional teams such as production procurement tal Panel on Climate Change (IPCC) namely RCP4.5 (low carbon emissions scenario) and RCP8.5 (high carbon emissions scenario).energy and finance to implement specific tasks. Additionally during this reporting period we incorporated climate risk manage- We have comprehensively identified our potential physical risks in the short medium and long term as follows:

ment into the Company’s overall risk management system conducting quarterly risk assessments and reporting.Climate Risk and Opportunity Management Process Expected Risk Risk Occurrence

Type Level Potential Impacts ResponseTime

The climate risks and opportunity management process of Bloomage Biotech is as follows:

Acute Risks

Possible damages or faults to devices and infrastruc- Develop the Preparedness Plan to Respond to Natural

Short

Extreme ture resulting in production interruption and reduced Disasters the Emergency Plan for Environmental

High medium Precipi- production efficiency as well as more additional costs Emergencies and the Production Safety Accident and long

tation terms in device maintenance and replacement Response combined with regular drills to continuously

An increase in short-term wastewater disposal improve emergency response mechanisms

burdens leads to larger external drainage volumes Pre-emptively stockpile flood control materials

and severer water pollution risks affecting production optimize water supply and drainage facilities and

stability install cutoff valves at discharge points

Short

Identification Evaluation The normal operation of logistics and supply chain

Tropical medium Medium and long may be affected with logistics delays inventory Cyclone

terms shortages and overdue delivery incurring a big threat

Based on our production and In combination with our actualbusi- to business continuity and client satisfaction

operational insights we identify ness operations we evaluate the

climate-related risks and opportunities applicability and importance of each

by integ rating industry trends risk and opportunity and comprehen- A need produced to equip more refrigeration Develop the Preparedness Plan to Respond to Natural

domestic and international policy sively determine the risk level and equipment in an increased operational cost Disasters combined with regular drills to continuously

landscapes and benchmarking against material opportunities from perspec- Some raw materials and products go bad during improve emergency response mechanisms

Short

best practices ultimately forming a tives including the probability of storage and shipment affecting the quality and Keep the ventilation temperature and humidity Extreme medium

comprehensive list occurrence business development Heat Medium and long marketability of products under control at a reasonable level in storage and

Fire and explosion risks rise in the warehousing transportation

financial impact and reputational terms

Strengthen fire prevention including regular

impact

inspections and maintenance of fire-fighting

equipment and facilities and fire drills

An increase in short-term wastewater disposal Develop the Preparedness Plan to Respond to Natural

burdens leads to larger external drainage volumes and Disasters combined with regular flood drills to

Short severer water pollution risks continuously improve emergency response

medium

Floods Low Possible damage or faults to devices and infrastruc- mechanismsand long

terms ture resulting in production interruption and reduced Pre-emptively stockpile flood control materials

production efficiency as well as more additional costs optimize water supply and drainage facilities and

in device maintenance and replacement install cutoff valves at discharge points

Response Monitoring

Chronic Risks

We develop response plans for risks We continuously engage in communi-

and opportunities including but not cation with relevant parties and

Long-term drought may cause a water shortage in Stick to optimization of production processes and

limited to formulating low-carbon regularly conduct reassessments to Short and production and affect production stability employ water-saving devices instead of old ones for

transition plans and implementing a ensure that the risks opportunities Water Medium medium

Shortage highly efficient water resource utilization

series of adaptive measures appro- and response measures are suitable terms Scientifically arrange production plans and strictly

vedby the management for the Company’s actual situation implement water usage plans

Seawater intrusion in coastal areas can damage Strengthen the resilience of buildings and

infrastructure and production equipment and cause infrastructure to disasters such as a design of higher

erosion and flooding of factories warehouses and building foundation and more efficient drainage

Sea- Low office buildings leading to production suspension and systemsLong term

Level Rise relocation Assess risks related to sea-level rise in coastal sites so

Damage to coastal ports and transportation channels as to adjust investment and development plans in a

resulting in supply chain disruptions or logistics delays timely manner that potential risks are addressed

83 84Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Transition Risks and Opportunities Low-Carbon Transition and Emission Reduction Achievements

We analyze climate-related transition risks and opportunities facing the Company with two shared socio-economic pathways (SSPs)

of the Intergovernmental Panel on Climate Change (IPCC) namely SSP1-1.9 (low carbon emission scenario) and SSP2-4.5 (high Energy conservation and emission reduction emerge as key measures to address climate change. Bloomage Biotech has continu-

carbon emission scenario). ously carried out low-carbon transition initiatives from three aspects: improving energy management capabilities enhancing

production and operational energy efficiency and promoting value chain carbon reduction.Type Risk/Oppor- Potential Impacts Response

tunity Type Energy Management System Improvement

If the Company is included in the national or regional Pay close attention to global market conditions and changes in Bloomage Biotech actively advances the institutionalization of energy management to lay a solid foundation for ongoing energy

carbon market the associated compliance operating costs laws regulations and policies involving carbon emissions. Carry efficiency improvements and energy consumption reduction. The Company sets annual energy management targets and has

may increase out annual organizational carbon inventories and audits along formed a multi-level full-production-base energy management network. The energy management network comprises leading

As stricter national policies and regulations are enacted to with product carbon footprint certifications

Policies and

regulations mitigate climate change enterprises are faced with more Strengthen internal management by setting low-carbon

groups at each production base the Engineering and Equipment Department related departments workshops and teams all of

compliance pressures and related litigation risks transition targets and plans and implementing a series of actions whom have worked together to implement these targets. In 2024 we updated several procedural documents including the Energy

The Company's exported products may face policies Management Energy Saving and Consumption Reduction Regulations and the Energy Management Implementation Plan to achieve

related to carbon tariffs and carbon footprint and other scientific standardized and procedural energy management.During the reporting period Bloomage Biotech pursued ISO 50001

restrictions in the future Energy Management System certification. The Jinan and Tianjin production bases successfully obtained the certification.Technological cost in low-carbon transition Monitor the rationality and applicability assessment of related Energy management measures of Bloomage Biotech mainly include:

Technologies Investments in low-carbon technology failed and the technologies

Company lagged behind peers in low-carbon transition Energy-consuming equipment management

Forbid the use of equipment phased out by the state and use the latest energy-saving products recommended by the state

Raw material costs may rise due to the climate- affecting Monitor raw material markets to anticipate price fluctuations Carry out regular equipment maintenance repair and optimization to ensure that equipment operates at optimal conditions over

quality and quantity Strengthen supply chain management by developing diverse the long term

Client/consumer demand for low-carbon products and suppliers and promoting suppliers’ carbon reduction

Risk growing ESG requirements for suppliers may reduce Engage in energy conservation and emission reduction increase

Market

product demand the use of clean energy and communicate with stakeholders in a Energy metering statistics

Climate change may trigger regional power and water timely manner Establish and improve energy measurement systems. Equip with certified measuring instruments and professionally qualified

restrictions or increased electricity prices leading to Integrate the concept of sustainability into product R&D measurement personnel as required and conduct regular energy statistics to meet the requirements for energy classification

higher production and operating costs production and sales to meet the demand for green products grading and itemized measurement

Build an energy management platform to continuously enhance digital energy management capabilities of the organization

As the Company's ESG performance remains a focus for Engage with stakeholders on climate-related concerns through

stakeholders failure to address climate change risks or various means Energy performance management

fulfill environmental responsibilities may damage its Plan carbon offset transactions strategically and control Engage professional agencies to assist production bases in energy audits

reputation leading to a deterioration of its brand image transaction costs Implement daily energy management inspections and a joint inspection system. Reward and punish individuals and departments

and market position

Reputation based on their performanceIf emission reduction targets are not met the Company Encourage employees to put forward rationalized proposals and participate in technological transformations of energy-saving and

may need to purchase carbon offset products to fulfill consumption- reducing. Provide positive incentives based on cost savings when the proposals are implemented and evaluated to

voluntary emission reduction commitments resulting in be effective

increased operating costs

Energy cascading utilization

Incentive policies involving carbon reduction subsidies and Actively engage in the development and implementation of

support are formulated by the government carbon reduction projects and timely apply for relevant subsidies Collect steam and thermal energy from the fermentation process and apply for factory heating hot water supply and thermal

Deploy renewable energy applications access green electricity

Policies energy consumption in the employee cafeteria

supply and construct distributed photovoltaic and biogas power

generation facilities at production and operational sites

Energy audits

The Company can count on new financing channels and Build the capability of advancing green transformation and Conduct energy audits regularly

support policies attributable to the development of green expand funding sources

Oppor- financing and sustainable investment Achieve non-hazardous disposal and low-carbon production of

tunity Market The demand of clients for green products increases products by means of R&D innovation process optimization etc.and try to obtain product carbon footprint certification and Energy measurement audit at Tianjin production base to

environmental declaration for higher product competitiveness Case

further strengthen energy management

Opportunities are provided by industrial energy- saving Employ high-efficiency production equipment to improve

Technologies technologies and equipment for companies to reduce resource recovery and utilization and further reduce costs In July 2024 the Tianjin production base conducted a self-inspection based on relevant regulations covering the Company's energy

costs and increase production efficiency related to energy and resource consumption measurement organizational structure objectives personnel and relevant instrument management and calibration as well as the

management system energy utilization and energy flow. This ensured that the entire process remained under control resulting in the

Self-inspection Report on Energy Measurement for Key Energy-Consuming Units. Based on the self-inspection results the Tianjin production

base achieved a 100% equipment rate for energy measurement devices and all energy measurement staff passed their job training

During this reporting period the Company effectively managed the above risks which did not have a significant impact on normal assessments.operations and development. Additionally the Company remained committed to low-carbon transition and continuously

enhanced the low-carbon competitiveness of the organization and its products.

85 86Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Energy Use Advancing Energy Transition

The energy use of Bloomage Biotech is as follows: Bloomage Biotech has accelerated the transition to renewable energy increasing the proportion of renewable energy usage.Building on existing distributed photovoltaic and biogas power generation facilities the Company constructed new biomass boilers

Energy Use of Bloomage Biotech5 in 2024 and introduced purchased renewable electricity (wind power) and biomass heat and achieved an equivalent emission

reduction of approximately 26913.24 metric tons of carbon dioxide equivalent (CO2e).Indicators Unit 2023 2024 Renewable Energy Consumption of Bloomage Biotech6

Natural gas cubic meter 15686836 13073453

Indicators Unit 2023 2024

Gasoline litre 21706 30112

Diesel oil litre 8939 7934 Purchased renewable electricity (wind power) kWh /

13375618

Purchased heat from fossil fuels GJ 174331.73 245503.80 Self-generated renewable electricity kWh 3521913 3745485

Renewable electricity

Purchased heat from biomass fuel GJ 38282.69 153263.05 Photovoltaic electricity generation kWh 2401725 2312192

Total electricity consumption kWh 70453123 94746874 Biogas electricity generation kWh 1120188 1433293

Purchased electricity (thermal power) kWh 66931210 77625771

Renewable heat Purchased heat from biomass fuel GJ 38282.69 153263.05

Purchased renewable electricity

(wind power) kWh / 13375618

Self-generated renewable electricity kWh 3521913 3745485 Advocating Green Office

Total comprehensive energy consumption tons of standard coal 35071.79 35346.54

Bloomage Biotech actively promotes low-carbon operations in office settings through various measures including energy manage-

ton of standard coal/revenue in

Comprehensive energy consumption intensity 5.77 6.58 ment consumables management and digital office practices to enhance resource efficiency in office operations.RMB 1000000

Purchase high-efficiency office equipment

Production and Operational Energy Use Optimization Prohibit the use of lighting and air conditioning in unoccupied areas. In occupied areas only necessary lighting

and air conditioning facilities will operateIn 2024 Bloomage Biotech continued to expand and deepen efforts in emission reduction actions based on two pillars: “improving Set summer air conditioning temperatures at 26°C and winter temperatures at 23°Cenergy efficiency” and “advancing energy transition”. Energy Encourage employees to turn off power sources when not in use cut off power to certain areas during statutory

conservation

holidays and post energy-saving slogans at lighting switch locations

Improving Operational Energy Efficiency Arrange for dedicated personnel to conduct inspections and promptly address wasteful practices

Bloomage Biotech set goals to continuously enhance operational energy efficiency. Production bases actively explore and analyze

energy-saving potential and encourage all employees to provide suggestions for energy conservation and consumption reduction. In

2024 the Company focused on the usage optimization and upgrade of energy-consuming equipment to improve energy efficiency.

Implement digital office platforms and encourage electronic reporting and online meetings

Production bases Energy efficiency improvement measures (partial) Promote fully electronic invoicing and paperless operations achieving online and paperless approval processes

Require double-sided and black-and-white printing set up A4 paper recycling bins and repurpose printed waste

We implemented a compressed-air networked operation project for pharmaceutical machinery air compressors refrigerant Paper conservation paper for secondary use

dryers and instruments. By optimizing equipment operation modes energy efficiency was improved and energy consumption

was reduced with an estimated annual electricity savings of around 470000 kWh and approximately RMB 370000 in electricity

Jinan production base

costs

We set fixed stirring times for dissolving tanks to avoid unnecessary electricity consumption from ineffective stirring with an

estimated hourly electricity savings of close to 45 kWh and annual electricity cost savings of RMB 20000–RMB 50000

We upgraded sedimentation tanks to save ethanol usage while achieving estimated savings of approximately 330000 kWh of Replace office fuel vehicles with hybrid or electric vehicles

Tianjin electricity and 6000 tons of steam annually Install charging stations in parking areas

production base We modified the outlet pump of the buffer tank by adding an exhaust port and enhancing valve control to avoid repeated Green

operations resulting in electricity savings of 1485 kWh transportation

Chaohu We optimized warehouse temperature and humidity control settings arranged warehouse layouts more efficiently reduced Bloomage Biotech organizes annual training programs on energy conservation and environmental protection and conducts

production base artificial lighting and replaced traditional light sources with LED lamps to lower energy consumption environmental activities during National Low-Carbon Day (May 15) World Environment Day (June 5) and National Energy Conserva-

tion Week. These activities convey to employees the contributions of water conservation reduced detergent use electricity savings

paper reduction decreased single-use products waste sorting and recycling low-carbon travel and green diet to resource conser-

5 The increase in total consumption of fossil energy heat and electricity this year was attributable to increased production capacity at the Tianjin production bases vation and environmental protection. The Company encourages and guides employees to start with themselves and practice green

leading to higher total comprehensive energy consumption. The Jinan production base increased its purchase of biomass heat resulting in reduced total natural office and low-carbon living.gas consumption. Multiple production bases purchased renewable electricity (wind power) in 2024; The total comprehensive energy consumption calculated in

tons of standard coal only includes fossil energy consumption. “/”: Not applicable.

6 The statistical caliber covers all of Bloomage Biotech's wholly-owned operational production bases in China. In 2024 multiple production bases purchased

renewable electricity (wind power) and biomass heat. "/": Not applicable.

87 88Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Promoting a Green and Low-Carbon Transition across the Value Chain Environmental Compliance

While focusing on energy conservation and emission reduction in its own operations Bloomage Biotech also pays attention to

energy use and energy-saving achievements in the upstream and downstream of the value chain striving to work with suppliers

and consumers to jointly promote the carbon reduction process across the entire value chain. Management

Upholding the concept of green manufacturing and the management policy of "preventing accidents complying with regulations

Suppliers Logistics and packaging Consumers protecting the environment and continuously improving" Bloomage Biotech has established and continued to improve the environ-

mental management system to ensure environmental compliance while reducing the impact of operations on the environment.We urge suppliers to pay We have optimized the layout of cloud warehouses We have promoted low-carbon

attention to the risks and shortened transportation distances through lifestyles among consumers

opportunities brought by climate multi-warehouse shipping models increased vehicle through initiatives such as empty Environmental Management System

change take conservation and load factors and improved transportation efficiency tube recycling programs product

substitution measures actively while reducing carbon emissions refill core designs supplementary Bloomage Biotech strictly complies with laws and regulations including the Environmental Protection Law of the People’s Republic of

introduce green energy reduce We choose carriers that use renewable energy and packs and large packaging to China and the Law of the People's Republic of China on Environmental Impact Assessment. With reference to the standards and require-

consumption of energy water collaborate with them on emission reduction reduce small packaging usage

and natural resources and ments of ISO 14001 Environmental Management System we have revised internal environmental management systems including measures in the transportation process promoting We have disseminated Bloomage

decrease greenhouse gas the Environmental Protection Management System the Environmental Factor Identification and Evaluation Process as well as manage-a shift from traditional air transport to sea transport Biotech's sustainable development

emissions for overseas business concepts and practices to ment regulations on air emissions wastewater and waste discharge in accordance with its own environmental management

We have collected and assessed consumers through media status. Through systematic management the Company aims to enhance its performance in environmental protection.In 2024 all We have optimized the packaging space design to

suppliers' greenhouse gas reduce void ratio releases and exhibitions guiding major production bases of Bloomage Biotech (Jinan Dongying and Tianjin) obtained ISO 14001 Environmental Management

emission information and them to practice sustainable System certification.reduction measures through We use recyclable insulation boxes and ice packs consumption behaviors

questionnaires

During this reporting period the Company optimized its environmental management organizational structure. At the group level

the newly established Safety and Environmental Protection Management Center is responsible for setting overall EHS goals annual

Emission Performance targets and work plans and for cascading implementing and evaluating these goals to ensure their achievement. At the produc-tion base level the Safety and Environmental Protection Department is tasked with identifying and assessing environmental

In 2024 Bloomage Biotech continued to conduct greenhouse gas emissions review and performed accounting for emissions across factors determining significant environmental factors and related targets and indicators and formulating and supervising the

the value chain (Scope 3) for the first time. implementation of management plans. At the workshop level environmental protection managers are appointed to implement

regional environmental responsibilities and ensure the smooth progress of environmental protection efforts.GHG emissions of Bloomage Biotech7

To further clarify the responsibilities of relevant departments standardize employees' environmental protection and energy-sav-

ing behaviors and ensure that rewards and punishments are well-founded we have formulated the Safety Environmental Protec-

Indicators Unit 2023 2024 tion and Occupational Health Performance Appraisal Management Procedures and an energy efficiency incentive mechanism. We

monthly assess employees of each level based on rationalized suggestions environmental protection and energy-saving technolo-

Total GHG emissions (Scope 1 + Scope 2) gies operations against regulations and relevant penalties.Location-based tCO2e 100902.09 113510.99

Key Performance

Market-based tCO2e / 109785.94

Scope 1 Emissions tCO2e 43554.73 37412.27 Total investment in low-carbon

envrionmental protectiton8 Number of environmental pollution incidents

Scope 2 Emissions 46.74 million RMB 0

Location-based tCO2e 57347.36 76098.72

Market-based tCO2e / 72373.66

Wastewater discharge compliance rate Air emissions compliance rate

GHG emissions per unit of revenue

(Scope 1 + Scope 2) 100 % 100 %

Location-based tCO2e/revenue in RMB 1000000 16.61 21.14

Hazardous waste disposal compliance rate

Market-based tCO2e/revenue in RMB 1000000 / 20.44

Scope 3 Emissions tCO2e / 183852.39 100 % 100 %

National Green Factory Provincial Green Factory

7 The statistical caliber of the Company's Scope 1 and 2 GHG emission data covers all of Bloomage Biotech's wholly-owned operational production bases in China. 1 1

GHG emissions include emissions from natural gas consumption diesel fuel gasoline fugitive methane from wastewater refrigerant charge fire extinguishers (Jinan production base) (Tianjin production base)

purchased electricity and purchased heat; and Scope 3 data include emissions from purchased goods and services capital commodities fuel and energy related

activities upstream transportation and distribution business trips and sold and sold products transportation and distribution. The Company conducts

greenhouse gas accounting in accordance with the requirements set forth in the Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard as well

as the ISO14064-1:2018 Greenhouse gases—Part 1: Specification with Guidance at the Organization Level for Quantification and Reporting of Greenhouse Gas Emissions

and Removals. “/”: Not applicable. 8 The statistical caliber covers all of Bloomage Biotech's wholly-owned operational production bases in China including waste disposal costs environmental

monitoring costs and renewable energy costs.

89 90Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Environmental Risk Management and Control Environmental Supervision and Audit

Bloomage Biotech strictly implements the "three simultaneous" system of environmental protection (environmental protection

Daily Risk Management and Control facilities and the main project must be designed constructed and put into use simultaneously). We conduct timely environmental

impact assessments before project construction to obtain approval and organize acceptance of environmental protection after

To step up its daily environmental risk management and control Bloomage Biotech identifies and evaluates environmental factors project completion to ensure that new projects meet environmental compliance requirements. We regularly conduct internal and

involved in the Company’s production R&D and business operations one by one and controls them effectively. We keep track of external audits to discover problems and deficiencies in environmental management. We also take timely corrective measures to

updates in laws and regulations and the demands of interested parties and regularly identify environmental factors from 3 tempo- prevent potential environmental accidents and pollution incidents and to protect environmental and public interests.ral perspectives 3 states 8 types and 2 aspects to form an environmental factor list. Additionally we regularly evaluate the

effectiveness of control measures for important environmental factors. The Company conducts at least 1 internal environmental audit every year covering all operational sites and business types.Through personnel interviews document reviews and on-site visits we conduct inspections and develop our Audit Report on

Process of environmental factor identification environmental management policies documented information pollutant prevention and control measures and emergency

preparedness and response. For problems discovered in the internal audit the audited department analyzes the causes of the

non-conformities and prepares a report. Subsequently the department makes its rectification plan based on the Corrective and

Preventive Control Procedures and completes rectification within a time limit. Internal auditors are responsible for confirming the

rectification results.Discharge to the atmosphere Discharge to water bodies The Company regularly invites external third-party agencies to conduct ISO 14001 Environmental Management System audits to

Environmental pollution ensure the applicability and effectiveness of the management system. The Company also takes the initiative to accept external

Past present future Raw materials and audits from regulatory authorities and clients to continuously improve resource utilization and pollution prevention and control.Discharge to land natural resource use

Bloomage Biotech’s environmental audit performance for 2024

Normality abnormality Energy emissions Energy release Ecological damage and

and emergency rational use of resources

Waste and by-products Space occupation Audit type Coverage Audit performance

Internal

audit Environmental compliance inspection All production bases 571 times

Jinan Dongying and Tianjin Completed the required ISO 14001

External System certification and oversight audit production bases oversight audit

audit Regulatory and client audits All production bases 57 times

The Company takes effective risk management and control measures including environmental facility inspections environmen-

tal monitoring and emergency management to minimize environmental risks:

Daily inspection

Improving Environmental Protection Capabilities

Conduct regular inspections of environmental protection facilities to check their operation and equipment wear. Carry out

timely maintenance to ensure the safe and effective operation of all kinds of environmental protection facilities Bloomage Biotech regularly conducts environmental knowledge training and provides in-depth interpretations of environmental

laws regulations and standards for all employees to enhance their environmental awareness and create a company-wide participa-

Environmental monitoring tion atmosphere. Furthermore the Company also actively participates in training organized by regulatory authorities to keep

In accordance with the Regulation on the Administration of Permitting of Pollutant Discharges and the requirements of the abreast of the latest environmental regulations and standards ensuring compliance with operations. In addition the Company

pollutant discharge permit we conduct regular environmental monitoring including air emissions wastewater noise and develops detailed operating procedures and provides specialized training for personnel involved in environmental protection to

groundwater to effectively monitor the discharge of pollutants and disclose the environmental monitoring results in a enhance their professional capabilities in environmental management. These efforts ensure compliance with operational

timely manner as required. The results are subject to review by regulators and public supervision standards and effectively prevent violations.Emergency management Environmental protection training of Bloomage Biotech?

We have established and improved the response mechanism for environmental emergencies regularly identified and

assessed environmental risks and prepared documents such as the Emergency Plan for Environmental Emergencies and the Indicators Unit 2023 2024

emergency plan for heavily polluted weather. We have carried out regular emergency drills to ensure that on-site response

to environmental emergencies can be conducted in a quick orderly and efficient manner Number of training sessions on environmental times 43 53

protection and pollution prevention and control

Number of employees trained in environmental

participants

Case Dongying production base conducts a drill for environmental emergency protection and pollution prevention and control 3622 2987

Total hours of training on environmental protection

and pollution prevention and control hour 3313 4806

In 2024 the Dongying production base organized a total of 5 drills for environmental emergencies including 2 drills for on-site hazardous

chemical leakage 2 drills for sewage workshop fire accidents and 1 drill for on-site hazardous waste leakage. These drills tested the

practicality and operability of emergency response plans and improved the coordination capabilities of various departments and

workshop front-line employees ensuring their abilities to properly handle emergencies.

9 The statistical caliber covers all of Bloomage Biotech's wholly-owned operational production bases in China.

91 92Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Biodiversity Assessment

Bloomage Biotech adheres to the baseline of biodiversity conservation in production and operations actively identifying monitor- Pollutant Emissions and

ing and mitigating potential negative impacts on surrounding ecosystems. Based on potential risk sources affected scope proba-

bility of occurrence severity of impact and risk levels the Company formulates corresponding prevention and control measures.Besides the Company integrates biodiversity conservation concepts into product R&D manufacturing and raw material procure- Waste Management

ment leveraging its expertise in synthetic biology to reduce the impact of products on biodiversity.Bloomage Biotech biodiversity conservation measures (partial) Bloomage Biotech strictly complies with pollution prevention regulations and standards including the Law of the People's Republic

of China on the Prevention and Control of Atmospheric Pollution the Law of the People’s Republic of China on Prevention and Control of

Water Pollution and the Law of the People’s Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste.The Company prioritizes pollution prevention as a key initiative of its environmental management strengthens the operational

We adopt fermentation methods to replace traditional extraction methods for

producing various bioactive materials reducing the consumption of rare plant control of environmental protection facilities and establishes internal emission standards based on national local and industry

Product R&D resources standards to ensure compliance with pollutant discharge limits.We have introduced green processes such as membrane filtration and enzymatic

hydrolysis to replace traditional chemical treatment methods Air Emissions

Active

conservation Through measures like source substitution and process optimization we effectively Bloomage Biotech adopts advanced air emission treatment technologies to effectively manage both organized and unorganized Technological

measures innovation reduce the negative impact of the product life cycle on the environment and emissions of air pollutants. Each production base has established systems and management records such as the Air Emission

biodiversity Treatment Management Process and the Operation and Maintenance Procedures for Air Emission Deodorization Systems. Air emissions

are treated through methods including acid washing alkaline washing water spraying activated carbon adsorption and the

installation of low-nitrogen burners. Dedicated personnel are assigned to maintain emission treatment facilities and third-party

We have researched the application of plant-based plastics and purchased

Packaging testing is regularly commissioned. During the reporting period all environmental protection facilities operated normally and

biodegradable plastics and recyclable plastics to use more sustainable packaging

optimization stably effectively ensuring compliance with air emission standards.materials

In terms of air emission reduction the Company continues to improve treatment efficiency and reduce emissions by upgrading

process designs and transforming environmental protection equipment.Project planning We conduct environmental impact assessments and take necessary ecological

and design stage protection measures during construction Air emission reduction measures at Bloomage Biotech

Ethanol collection and treatment：The Jinan production base has added emission treatment facilities in the ethanol

We regularly carry out biodiversity assessments and investigate the surrounding storage area to collect treat and reuse ethanol emissions reducing fugitive emissions

Baseline ecosystems animal and plant species. The Company has conducted biodiversity Boiler exhaust gas reduction：The Dongying production base has adopted natural gas boilers (equipped with low-nitro

conservation assessment whose results have shown that there are no nature reserves scenic gen burners) to lower air emissions -

measures spots national and local key protected wild plants and rare or endangered wild Daily production

animals within 1 km of the area where the Company is located. The Company ：The Company has replaced diesel forklifts with electric forklifts in bulk to reduce emissions

and operations stage

causes no significant negative impacts on biodiversity while maintaining the normal from diesel combustion

and effective operation of environmental protection facilities and detecting and

disinfecting foreign objects. The Company will continue to conduct regular

Each production base has enhanced the management of odor-generating processes by enclosing odor-emitting areas such as

assessments and cautiously manage biodiversity risks

anaerobic reactors anoxic tanks regulating tanks and sludge thickening tanks in wastewater treatment facilities. Collected odors

are treated through the emission treatment system to reduce odors generated during production operations.Bloomage Biotech's odor mitigation measures (partial)

On May 22 2024 the International Day for Biological Diversity Bloomage Biotech launched a knowledge-sharing activity around

the theme “Protecting Biodiversity to Promote Sustainable Development”. This initiative enhanced employees' understanding of -

the connection between the Company’s production & operations and biodiversity motivating their participation in biodiversity

conservation practices. The Dongying production base has replaced valves and manhole covers in the wastewater treatment workshop's air

Emissions of major air pollutants of Bloomage Biotech10

Indicators Unit Total emissions in 2023 Total emissions in 2024

Sulfur oxides ton 2.32 1.75

Nitrogen oxides ton 7.46 6.22

Volatile organic compounds ton 3.30 3.05

10 The Company monitors collects and treats air pollutant emissions in accordance with regulatory requirements including particulate matter

and other emissions which are insignificant in information disclosure. The statistical caliber covers all of Bloomage Biotech's wholly-owned

93 operational production bases in China. 94Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Wastewater Waste

Bloomage Biotech continuously strengthens the management of water pollution prevention and control facilities and effectively Waste Management Policies and Measures

controls various water body risks. The Company has formulated the Wastewater Treatment Management Process to strictly control

Bloomage Biotech adheres to the sustainable development concept of green operation and upholds the principle of "reduction

all aspects of wastewater discharge and treatment. Integrated wastewater treatment facilities are used to treat pollutants such as

recycling and harmlessness" of solid waste to promote comprehensive solid waste management and utilization. The Company has

chemical oxygen demand (COD) and ammonia nitrogen. During the reporting period all environmental protection facilities operat-

formulated systems such as the General Solid Waste Management Process and the Hazardous Waste Management Process to

ed normally and stably effectively ensuring compliance with wastewater discharge standards.standardize the classified management of waste. The Company formulates annual management plans for general solid waste and

hazardous waste and establishes records for the generation transfer and storage of various wastes ensuring full traceability

Production bases listed as key sewage discharge units have established wastewater treatment workshops within their parks to

throughout the waste management process.ensure that wastewater treatment meets the requirements of the Wastewater Quality Standards for Discharge to Municipal Sewers

(GB/T 31962-2015) before being discharged into the municipal sewage pipe network. Besides in accordance with the requirements

of the Management Regulations on Pollutant Discharge Permits they have installed wastewater online monitoring equipment and

networked with the government's environmental protection department to achieve internal and external collaborative and dynam-

ic supervision of wastewater discharge. The wastewater quality of other production bases is regularly tested by the government Waste type

and can be directly discharged into the municipal sewage pipe network. 100% of such wastewater discharged into the municipal Storage Disposal

sewage pipe network meets the discharge requirements.Recycle or hand over to

The company comprehensively monitors wastewater discharge and the operation of wastewater treatment facilities by regularly General solid waste perlite waste activated

inspecting production equipment and pipelines to promptly identify and address any leaks or spills. The Company also sets up waste carbon) sludge waste plastics disposal and reuse after

anti-seepage layers and emergency ponds in key areas such as chemical warehouses and uses enclosed pipelines to transport waste cartons etc.wastewater. Anti-seepage layers are installed in wastewater pipelines and treatment facilities to effectively prevent groundwater

Non-hazard- A general solid waste storage area has

pollution. ous Wastes been built to store general solid waste Entrust a municipal waste

Domestic waste domestic waste and kitchen waste in a

disposal company for

In addition to strengthening water body pollution control the Company reuses wastewater for biogas power generation and imple- dormitory waste etc. transportation and disposal

ments wastewater reduction initiatives. In 2024 the Company further reduced wastewater pollutant emissions by timely mainte-

nance and optimization of wastewater treatment processes. For example the Dongying production base adjusted the CEAB+AAO

Entrust a municipal waste

biological treatment method for wastewater increasing the treatment time in anaerobic tanks thereby reducing COD and sludge Kitchen waste Food waste from cafeterias disposal company for

production. transportation and disposal

Bloomage Biotech has the business of producing pharmaceutical-grade products. The Company's products (hyaluronic acid and

related products) may flow into the wastewater treatment system during production due to container cleaning and other reasons. A storage room for hazardous waste has

been built. In strict accordance with the

Such products discharged meet the pollution discharge requirements. In addition these products themselves are non-toxic relevant requirements of the Standards

biologically inactive and can be used as food ingredients thus posing no substantial negative impact on the environment or for Pollution Control on Hazardous Waste

human health. Hazardous Storage and the Technical Specifications

Wastes for Collection Storage Transportation of

for transportation and disposal

Hazardous waste Chemical containers Hazardous Waste ground anti-seepage in strict accordance with the

gas collection and exhaust pipe Hazardous Waste Transfer

equipment are installed to store various Management Measures

Wastewater discharge of Bloomage Biotech11 hazardous wastes in a classified manner

and prominent warning signs of

hazardous waste are set in the storage

area

Indicators Unit Total emissions in 2023 Total emissions in 2024

Total volume of wastewater discharged 10000 tons 123.85 171.54

Bloomage Biotech focuses on waste reduction at the source and harmless treatment at the end of the waste stream. Each produc-

Chemical oxygen demand (COD) ton 54.01 102.52 tion base reduces waste generation through process optimization and consumables management. For example the Dongying

production base has replaced solid alkali with liquid alkali reducing hazardous waste alkali bags by approximately 700 kg.The

Ammonia nitrogen ton 2.03 0.80 Company aims to reduce the filter residue discharge per ton of pharmaceutical-grade bioactive products at its Jinan production

base by 1% and the sludge discharge per ton of wastewater by 3% by 2025 compared to 2023.Total phosphorus ton 0.79 1.04

Bloomage Biotech's measures to reduce the generation of various wastes mainly include:

Total nitrogen ton 10.10 11.23

Source reduction Harmlessness

Optimize production processes and improve

product quality and productivity to reduce unrecyclable general industrial solid wastes

solid waste generation and hazardous wastes

Recycle cleaning solution to reduce chemical

consumption and hazardous waste

11 The statistical caliber covers all of Bloomage Biotech's wholly-owned operational production bases in China. This year the increased production capacity at production

Bloomage Biotech's Tianjin production bases has led to a rise in total wastewater discharge and COD. Optimize the wastewater treatment process

to reduce the amount of dosing and sludge

generation

95 96Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Waste Recycling and Reuse Resource Utilization and

Bloomage Biotech responds to the national call to accelerate the building of a waste recycling system continuously improving

waste resource utilization and recycling levels in production and product development. The Company explores new pathways for

recycling and reusing waste and expired products from production processes. Circular Economy

Bloomage Biotech's resource recycling measures (partial) management and implements water recycling measures leveraging innovation to advance resource recycling and green alternatives.Waste type Resource recycling measures Water Management

All of Bloomage Biotech’s offices and production are supplied by municipal water. The types of water used mainly include produc-

Classify and recycle by material type (e.g. cardboard mixed paper plastic PET bottles) and hand over to

Scrap packaging materials tion water make-up water for cooling circulating water boiler replenishment water water for environmental protection facilities

specialized agencies for processing into other recycled products and domestic water. The Company has formulated the Energy Management Energy Saving and Consumption Reduction Regulations-

adding water consumption management indicators into the daily indicator management system of each workshop and team and

Waste perlite and sludge clarifying water metering requirements. Each production base formulates an annual water consumption plan based on local water

consumption quotas monitors and analyzes water consumption data in a timely manner and commissions third parties to carry

out water balance tests and industrial water conservation diagnoses. By doing so we have laid a solid foundation for the long-term

Carry out the "Empty Tube Recycling" program. From its initiation in 2020 to the end of the reporting period

Single-use empty tubes improvement of water resource utilization efficiency.The Company aims to continuously improve water efficiency by increasing the more than 15.63 million empty tubes had been recycled with a total of more than 140000 participants and a

recycled weight of 23.45 tons reuse of condensate water and improving production processes.Bloomage Biotech focuses on building water-saving enterprises by improving water metering identifying water management

weaknesses promoting water-saving technologies and processes and replacing old water facilities to prevent water waste such as

leakage and venting in the water supply pipe network. The Dongying production base has been honored as a Water-saving

Enterprise of Shandong Province.Waste discharge of Bloomage Biotech12

Bloomage Biotech’s improvement on water metering and statistical measures

Indicators Unit Total emissions in 2023 Total emissions in 2024

Total waste ton 10923.55 12204.44

The Chaohu production base has strengthened real-time measurement and monitoring of water consumption by installing

Hazardous waste ton 85.01 144.22 8 IoT water meter monitoring devices so as to identify and address water consumption issues in a timely manner

General industrial waste ton 9599.45 10521.68

Case Jinan production base conducts water balance tests to optimize Domestic waste ton 581.09 1184.42 water use efficiency and reduce water waste

Kitchen waste ton 658.00 354.12

Hazardous waste intensity ton/revenue in RMB 1000000 0.01 0.03

pipes water waste due to leakage and spillage was reduced by 10%.Non-hazardous waste intensity ton/revenue in RMB 1000000 1.78 2.25

Recycled waste ton 7331.00 7125.01

Case Dongying production base promotes condensate recycling

In the newly launched aseptic project the Dongying production base uses idle storage tanks to collect chilled water used for cooling in

the production process. After re-cooling the used chilled water can be supplied to the workshop for recycling which is equivalent to

saving 5000 tons of water each year.Indicators Unit Consumption in 2023 Consumption in 2024

Total water consumption 10000 tons 149.33 163.83

Water consumption intensity ton/revenue in RMB 1000000 245.77 305.44

12 The statistical caliber covers all of Bloomage Biotech's wholly-owned operational production bases in China. This year the increased production capacity at

Bloomage Biotech's Tianjin production bases has led to a rise in hazardous waste general industrial waste and total waste.

13 The statistical caliber covers all of Bloomage Biotech's wholly-owned operational production bases in China. This year the increased production capacity at

Bloomage Biotech's Tianjin production bases has led to a rise in total wastewater consumption. The total water consumption for 2023 was recalculated to be 1.49

million tons.

97 98Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Packaging Material Management QuadHA CT50 Skin Dynamic Youth Cream uses card boxes

Case instead of hardcover boxes

Bloomage Biotech strictly follows the requirements of the Product Quality Law of the People’s Republic of China the Food Safety Law

of the People's Republic of China the Drug Administration Law of the People's Republic of China the Regulations on Cosmetics Supervision

and Administration the Regulation on the Supervision and Administration of Medical Devices the Law of the People’s Republic of China Bloomage Biotech's brand QuadHA's new product CT50 Skin Dynamic Youth Cream abandons the previous hardcover pasting process

on the Prevention and Control of Environmental Pollution by Solid Waste and other laws and regulations to carry out packaging design and EVA lining and adopts white cardboard boxes and corrugated folding inner supports reducing packaging weight by nearly 60%. The

procurement and disposal. Besides we comply with national standards including the Requirements of Restricting Excessive use of single paper material facilitates recycling lowers processing complexity and reduces the production process thereby reducing

Package—Foods and Cosmetics and the Sustainable Packaging Initiative for Cosmetics to practice sustainable packaging material energy consumption.management. We actively embrace the principles of the circular economy implementing strategies focused on lightweight design

material substitution and recycling. By reducing pollution and waste at the design stage increasing the use of sustainable raw

materials and recycling and reusing packaging materials at the end of a product's life cycle we promote resource circulation and

sustainability.Case Saving energy and reducing plastic starting from the "core"

Lightweight and Plastic-Reduced Packaging

Bloomage Biotech strictly adheres to relevant regulations reducing packaging material usage and plastic consumption through

design optimization process improvement material substitution and recycling initiatives. Additionally the Company has reducing plastic shell usage by approximately 37.6g per unit (77% of total packaging weight). Bio-Meso Hydrating Cleansing Honey’s

supplementary packaging design reduces plastic shell usage by about 42.2g per unit (82% of total packaging weight)

the use of smaller packaging and glass materials.Bloomage Biotech's key measures to reduce weight and plastic in packaging include: packaging weight)

Green packaging design

Conduct research on the application of sugarcane-based plastics in disposable packaging materials. Compared with

traditional petroleum-based plastics each ton of bio-based plastics can reduce carbon dioxide emissions by about 3 tons

substances contained in PVC on the environment and employees' health

Process improvement

Material substitution

Reduce the use of composite materials and use a single material

Select degradable renewable or recyclable materials. For example use paper-aluminum foil bags in facial mask packag-

Packaging recycling

Recycle waste plastics waste outer packaging cartons and other waste generated during the production process to

minimize the amount of waste packaging

Supply chain enhancement

Reduce packaging for transportation

99 100Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Sustainable Packaging Material Usage

Case BIOHYALUX's "Empty Tube Recycling" program for single-use products

Bloomage Biotech continuously explores and adopts biodegradable and recyclable packaging materials avoiding unsustainable

wood sourcing high-energy-consuming or high-pollution petroleum-based materials.brands. The recycling program encourages green and low-carbon consumption by issuing

Material type Material features Product application second-throw empty tubes will be sent to the recycling factory for processing and made into

recycled environmentally friendly peripherals. As of December 2024 over 140000 participants

During the injection molding process of the have joined the "Empty Tube Recycling" program recycling over 15.63 million empty tubes with a

bottle of the Bio-MESO Saccharomyces Rice

The generation of plastic waste is reduced by total weight of 23.45 tons. In 2024 BIOHYALUX expanded the recycling program to allow

Post-Consumer Recycled Vitality Purifying Balancing Milk 30% of PCR recycling and reusing PCR. Compared with year-round participation without brand restrictions fully integrating sustainable and circular

(PCR) Plastics recycled materials were added fully integrat-traditional materials the production of PCR concepts into consumers' daily lives.ing the concept of environmental protection

materials lowers carbon dioxide emissions.-

ality of the product.Paper-plastic is a natural packaging material

BIOHYALUX's single-use packaging replaces

made from recycled cardboard wood bagasse

Paper-Plastic Inner Supports XPE material inner supports with paper-plastic

options.and biodegradable.Case Turning waste plastic bottles into eco-friendly gifts

FSC (Forest Stewardship Council) FSC-COC (chain of custody) allowed to purchase

that the product is sustainable and environmen-

tally friendly throughout the supply chain. packaging materials. Bloomage Biotech actively practices the concept of resource

recycling customizes canvas bag souvenirs made of waste packag-

ing materials and conveys the concept of sustainable consump-

tion and circular economy to business partners. Each canvas bag is

made from 25 recycled plastic bottles transforming waste through

circular regeneration technology. This not only reduces plastic

pollution but also demonstrates the potential of resource

recycling.Packaging Recycling and Reuse

front back

Bloomage Biotech incorporates recycling considerations into packaging design from the outset upgrading multiple products to

single-material options and implementing waste packaging and product recycling plans to promote material circulation.Case MedRepair uses a single material all-plastic pump and plastic soft packaging

for end-of-line recycling

In 2024 the Bloomage Biotech brand MedRepair upgraded its products including MedRepair Soothing Radiant Essence MedRepair Indicators Unit 2023 2024

Barrier Repairable Hydragel Cream and MedRepair Hydrating Gel Cream. The packaging now features single-material plastic pumps

with all pump components (including springs beads gaskets and straws) made from PP material facilitating recycling and reducing Total procurement of packaging materials14 ton 5270.00 8494.23

manual sorting and disassembly costs. Additionally MedRepair's Soothing Skin Essence Sample packaging uses single-material OPP

plastic soft packaging which is 100% recyclable.ton 846.00 1635.00

packaging materials

14 The packaging materials purchased by the Company mainly include paper plastic glass and aluminum.

101 102Sustainable

2024 Sustainability Report CONTENTS

Chairwoman and

CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

06

Achievements: A Sustainable

Value Chain

A stable and reliable supply chain is crucial for corporate sustainable

development. Bloomage Biotech adheres to the principles of integrity

stable high-quality biomanufacturing supply chain ecosystem. We consis-

tently practice responsible procurement aiming at a positive impact on the

environment and society while product quality is guaranteed.SDGs Addressed in this Chapter:

Major Material Topics of Sustainability Covered in this Chapter:

· Supplier Management

· Product Environmental Impact

· Response to Climate Change and Energy Management

· Product QualityChairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Ensuring Supply Chain Security

Bloomage Biotech has established a rigorous supplier admission mechanism conducting comprehensive assessments of potential

suppliers based on basic qualifications quality assurance scale competitiveness and other factors. Necessary on-site audits are

Bloomage Biotech is committed to building and maintaining a secure stable and sustainable supply chain network. We continu- carried out to select suppliers that meet requirements and include them in the annual List of Qualified Suppliers.supply chain's security. The Company implements classified management of qualified suppliers and the suppliers are classified according to their procure-

ment amount importance of goods and impact on the Company's products and production and other dimensions. By stratifying

Supply Chain Management System and Structure suppliers according to these dimensions we implement supplier management in a tiered manner effectively controlling supplier risks and ensuring high-quality stable and safe operation of the supply chain.Bloomage Biotech continues to improve its supply chain management system. This year the Company comprehensively sorted out As per the Company’s requirements suppliers of raw materials packaging materials and other types must be qualified with certifi-

cates for production and operation necessary management system (eg. quality management system GMP etc.) and for

process supplier access and management. purchased items (such as production process description safety assessment quarantine certificates toxicology and efficacy study

data or inspection reports of raw materials etc.) accompanied with appropriate production conditions. Besides the Company

Bloomage Biotech’s supply chain management initiatives (partial) assesses the performances of suppliers in environmental protection occupational health and safety energy management and

labor rights and rewards additional credits to excellent suppliers with well-established management systems and certifications.Manage procurement needs and plans Supplier Access Flow Chart

Standardize the formulation of medium- and long-term procurement plans and demand applica-

progress of procurement activities

Develop procurement and category management strategies Application and Evaluation and Document Sample Assessment Trial Production

Evaluation Evaluation Regarding Process of

Guide business personnel to formulate procurement category strategies in a systematic manner to Changes Small-batch

reduce procurement costs optimize the Company's operational management and enhance the Samples

Company's competitiveness and sustainable development capabilities On-site Review

Supplier selection and contract management

Standardize the access process selection principles and access rules for various suppliers clarify

the responsibilities of procurement quality production R&D and other personnel in the supplier

selection process and ensure that procurement activities are carried out in compliance and Supplementa-

ry List of

Manage procurement execution Suppliers (to

List of

Supplier Trial Production Quality

Standardize the process from issuing purchase orders to material acceptance and reconciliation Suppliers Approval Agreements

chain while ensuring that the quality quantity and price of the purchased materials are consistent

with the contract requirements to meet production and operation needs

Manage suppliers

Standardize supplier registration evaluation selection the establishment of cooperative relation-

ships performance management exit management and continuous improvement and improve In the reporting period Bloomage Biotech has developed partnerships with 1339 production suppliers distributed as follows:

transparency stability and procurement quality

In 2024 the Company optimized its organizational structure by establishing the "Global Supply Chain Platform" and "Global Shared Region Unit Quantity

Platform." These platforms integrate and optimize production bases enhance the management efficiency of functional depart-

ments coordinate with various business lines ensure stable material supply and continuous product production and boost supply Mainland China count 1333

chain resilience. The Company also strengthened the construction of dedicated teams for procurement bidding and supplier

management to solidify supply chain risk management capabilities. Hong Kong Macao and Taiwan China count 1

Additionally the Company implemented systematized management of procurement and supplier access processes through the Overseas countries or regions count 5

SRM system. This system incorporates supplier qualification review archive information maintenance and dynamic supplier

processes (performance suspension exit) to improve supply chain management efficiency.

105 106CONTENTS Chairwoman and

Sustainable

2024 Sustainability Report CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Bloomage Biotech recognizes that material stability is a key risk in the supply chain. Therefore the Company has developed target-

ed supply chain risk response strategies to ensure high-quality stable and secure operations. These strategies include: Supply Chain Quality Management

Interdepartmental collaboration Bloomage Biotech has established a comprehensive supplier quality management mechanism referencing regulatory require-

ments and standards to develop quality management systems for different categories of suppliers. These include the Regulations

for Sampling Inspection and Retention Management of Cosmetic Packaging Materials the Regulations for Sampling and Retention

forecasts and procurement plans to jointly ensure a stable supply of materials Management of Raw and Auxiliary Materials for Cosmetics the Nonconforming Product and Return Processes the Outsourced Processing

Management Regulations and the Quality Management Regulations for Class A Raw Material Suppliers. The Company also signs the

Quality Assurance Agreements with suppliers to ensure the stability and reliability of the materials provided.Material strategy development Dedicated personnel are assigned to evaluate supplier admission quality assess quality performance and drive continuous quality

improvement. The Company sets annual management targets for supplier delivery quality inspection pass rates regularly collects

and analyzes target completion status and promptly follows up on nonconforming situations to ensure closed-loop handling.Formulate annual material demand forecasts and analysis and formulate supply and demand plans

Supplier Quality Supervision and Review

The Company has established a robust supplier quality audit mechanism based on regulations such as the Cosmetics Supplier Entry

Procurement Plans Optimization Supervision and Management Regulations the Regulations on Selection Evaluation and Management of Raw Material Suppliers the

Supplier Entry Supervision and Management Regulations and the On-Site Supplier Audit Regulations. These documents standardize the

supplier audit process. Each year we develop a supplier supervision and audit plan covering multiple aspects of supplier opera-

For new product procurement needs increase the planned frequency and monitoring frequency of tions including business production logistics and warehousing. For identified nonconformities during audits we assist suppliers

procurement in developing effective corrective action plans regularly communicate the implementation status of these plans and conduct

Identify and analyze procurement risks and comprehensively judge the procurement lead time of materi- necessary re-audits to confirm the effective implementation of corrective actions until issues are closed.als based on material categories supplier production capacity procurement demand forecasts supplier

material arrival time and procurement inventory and formulate appropriate procurement plans

Based on the annual evaluation and assessment results the Company provides feedback to suppliers on areas for improvement

and urges them to enhance their performance. For suppliers identified with critical disqualifying items or deemed "nonconforming"

Supplier collaboration in the evaluation the Company will no longer include them in the annual List of Qualified Suppliers. If such a supplier is to be reacti-

vated they will be assessed through the new supplier introduction process. During this reporting period the Company conducted

Establish strategic partnerships with important suppliers quality audits on 206 direct suppliers 35 indirect suppliers 146 raw and auxiliary material suppliers and 41 contract manufactur-

Pay attention to the overall inventory status or production plan of key material suppliers or provide ers. No "nonconforming" suppliers were identified in the annual evaluation and assessment.suppliers with forecast values to ensure stable and continuous supply

Determine the delivery mechanism and strategy with upstream suppliers based on the supply and

application characteristics of materials Supplier Quality Improvement and Empowerment

Standardized procurement

-

ers continuously improve their quality management capabilities.Simplify internal processes and promote standardization of procurement agreements

Promote standardization of packaging materials reduce the types of purchased packaging materials and

Case Supplier quality support

Strict inventory management

In November 2024 the Bloomage Biotech brand BIOHYALUX in collaboration with packaging R&D supplier quality procurement center

and other departments formed a dedicated project improvement team for customized product projects. The team visited suppliers to

security

conduct in-depth cooperation and communication on key aspects of customized product packaging quality and technology jointly

Set up safety inventory strictly monitor inventory levels and conduct statistics and analysis of deviations

exploring improvement and optimization solutions.between actual consumption and plans

Response to abnormal situations

Implement a diversified supplier strategy self-production substitution and intervene in the R&D

process in advance to identify supply chain risks and improve response capabilities

107 108Sustainable

2024 Sustainability Report CONTENTS

Chairwoman and

CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Case Supplier quality training Supply Chain ESG Management

In 2024 Bloomage Biotech's procurement center in coordination with the quality department conducted supplier quality training and

Promoting ESG management among suppliers is a crucial aspect of Bloomage Biotech's commitment to sustainable development.empowerment activities. The training conveyed the Company's quality standards to approximately 60 suppliers across categories such

The Company has established a foundational ESG management system for the supply chain covering policy development internal

and external empowerment assessment data management and sustainable procurement. This system will continue to deepen

and optimize in future operations working with supply chain partners to advance industry progress.Policy Development

Case Bloomage Biotech successfully hosts inaugural supplier conference

pioneering a new era of industrial collaboration During this reporting period the Company formulated and implemented a revised version of the Bloomage Biotech Supplier Code of

Conduct. This code addresses labor rights and human rights protection health and safety environment business ethics and

management systems requiring suppliers to sign and comply with the Compliance Commitment Letter (including clauses on integrity

On December 14 2024 Bloomage Biotech successfully held its first supplier conference themed "Leading Revolution Embracing cooperation financial compliance and anti-bribery). As of the end of the reporting period 100% of production material suppliers

Brilliance." The event invited 36 suppliers numerous partners and industry experts to jointly explore new opportunities and challenges had signed the above regulations.in supply chain collaboration. Chairwoman Zhao Yan delivered a speech titled Growing Together Achieving Mutual Success—Building a

High-Quality Biomanufacturing Supply Chain Ecosystem. She proposed three cooperation visions: quality sustainable development and

innovative collaboration. Bloomage Biotech aims to reach consensus on cooperation standards with supplier partners to jointly build a

robust industrial supply chain ecosystem contributing to the development of the biomanufacturing industry.Bloomage Biotech Supplier Code of Conduct

Additionally the conference featured a roundtable forum inviting multiple guests to discuss the opportunities and challenges brought

by digitalization and ESG to enterprises. Bloomage Biotech also recognized outstanding supplier partners for their exceptional

performance in product quality innovation capabilities and collaborative synergy. Seven awards were presented including the

Star Award Innovation Pioneer Award and Cost Leadership Award.

109 110CONTENTS Chairwoman and

Sustainable

2024 Sustainability Report CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

The Bloomage Biotech Supplier Internal and External Empowerment

Code of Conduct stipulates that Management System

The Company places emphasis on training the internal procurement team and suppliers in ESG management awareness and

Management responsibilities capabilities aiming to continuously enhance the ESG capabilities of relevant personnel both internally and externally. Therefore

Risk Identification assessment the Company conducts specialized empowerment sessions around ESG management systems policy trends low-carbon transi-

and management tion and labor rights through supplier conferences and internal seminars. Additionally the Company guides internal and external

Performance evaluations personnel in understanding these concepts through practical work in scope 3 greenhouse gas data collection and ESG manage-

Assessment and audit ment evaluation. During this reporting period the Company conducted ESG training for 80% of procurement positions and 50% of

Correction and improvement suppliers.EHS management

Training and communication

Assessment

During this reporting period the Company established a supplier ESG self-assessment management mechanism aiming to

manage the ESG risks of major suppliers through annual inquiries and to encourage suppliers to focus on and strengthen their ESG

capabilities. The assessment content in addition to covering the Bloomage Biotech Supplier Code of Conduct has added require-

ments for low-carbon management sustainable supply chains and information disclosure. This encourages suppliers to systemati-

-

ness. In 2025 the company targets to conduct assessments for over 20% of its production material suppliers.Data Management

Business Ethics Environment

Integrity and compliance Environmental permits and suppliers. During this reporting period the Company conducted organizational-level scope 3 greenhouse gas data accounting and

reporting

Information disclosure life cycle accounting (LCA) for several products collecting data from major suppliers. In the project the Company cooperated with

Prevention of environmental

Intellectual property protection suppliers to jointly establish relevant data statistical capabilities to lay the foundation for future management optimization.pollution

Fair competition

Chemicals management

Whistl-blower protection and

Energy conservation and emission

anonymous teporting

reduction Sustainable Purchasing

Responsible procurement

Green energy

Environmental management system Bloomage Biotech actively practices sustainable procurement aiming to enhance the sustainability of products from multiple

perspectives such as low-carbon environmental protection and circularity. We prioritize suppliers with sustainable characteristics

and advantages to build a sustainable supply chain from the source. In 2024 we deeply promoted the optimization of production

recyclability. For more information please refer to the Section “Packaging Material Management” under Chapter 5.Labor Rights and

Human Rights Protection Health and Safety

Decent work Safe and hygienic working conditions

Protection of juvenile workers Occupational health and safety compliance

Working hours Occupational health and safety manage-

ment

Humane treatment Incident management

Non-discrimination Health and safety information communica-

tion

Freedom of association and collective

bargaining Occupational health and safety

management system

Grievance redress and stakeholder

engagement mechanisms Emergency preparedness and response

Workplace regulations

Living conditions

111 112Sustainable

2024 Sustainability Report CONTENTS

Chairwoman and

CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

07

Responsibility: Community

Care and Contribution

corporate responsibilities and is committed to developing the "In Cloud"

and "Bloomage Health Tour" public welfare activities. We promote the

organic integration of science and technology and art support the compre-

hensive development of medical and educational undertakings give full play

to the Company's own advantages work together with all walks of life and

lay a solid foundation for building a harmonious and beautiful society.SDGs Addressed in this Chapter:

Major Material Topics of Sustainability Covered in this Chapter:

· Social Welfare and Community RelationsChairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Social Welfare and Case “In Cloud” has been ongoing for 14 years to help the development of ethnic and cultural inheritanceCommunity Relations ”Over the years we have continued to carry out two major public welfare activities "In Cloud" and "Bloomage Health Tour" actively “I have always believed that the essence of charity is to inspire passion especially for the protection of national cultures. Only whenexplored and practiced in the fields of medical popularization and cultural inheritance and continuously enriched our public the people of the ethnic group themselves are passionate can the inheritance and promotion be more powerful.”

welfare initiatives to expand social influence.Additionally Bloomage Biotech pays close attention to the welfare of veterans and rural revitalization projects aiming to improve Ms. Zhao Yan Chairwoman and CEO of Bloomage Biotech initiator of "In Cloud"the living standards of veterans and rural residents. In 2024 the company donated facial masks moisturizing lotions personal care “products and case to charitable organizations such as the Jinan City Veterans Care Foundation and the High-Tech Zone Charity

Federation. These donations were used to support social welfare and charity projects with a total value of donated goods reaching

RMB 9.61 million."In Cloud" has lasted for 14 years traveled across more than 10 provinces or autonomous regions penetrated into ethnic minority

settlements in more than 60 cities and helped nearly 400 ethnic culture and intangible cultural heritage inheritors from 41 ethnic groups.In 2023 the project was included in excellent cases at the Pavilion UN SDG Summit 2023 and ESG best practices for Chinese Listed Compa-

nies 2023 by China Association for Public Companies

"Bloomage Health Tour" has been carried out for 11 years with volunteer medical activities covering Yexian County of Henan Province Seda

County of Sichuan Province Yinchuan City of Ningxia Hui Autonomous Region Zibo City of Shandong Province Bole City of Xinjiang Province

and other areas. This project has facilitated the recovery of thousands of patients

Case Bloomage Biotech’s “In Cloud” project launched the theme activity of

"To See Xinjiang—Southern Xinjiang"

Xinjiang" thematic activity to assist in the inheritance and development of

Xinjiang's national culture. While showcasing the beautiful natural scenery

of Xinjiang the activity delved into southern Xinjiang to understand the In 2011 Zhao Yan Chairwoman and CEO of the Company initiated the "In Cloud" project with a mission to protect China's original

musical intangible cultural heritage of ethnic groups such as the Tajik cultures. This project explores how to preserve the intangible cultural heritage of various ethnic groups in China through art exhibitions

Uyghur and Kirgiz and promoted it through promotional videos public immersive experiences singing and dancing performances and culinary events. Additionally it supports rural development by promot-

accounts and video websites. Additionally Bloomage Biotech hosted the ing the inheritance of ethnic cultures and improving local residents' living standards. In general it contributes to rural prosperity.minority compatriots in spreading the true and diverse culture of Xinjiang Since its establishment "In Cloud" has conducted 14 series of activities visiting more than 10 provinces autonomous regions and

and promoting the profound inheritance of ethnic minority musical municipalities directly under the central government and passing through over 60 ethnic minority settlements in cities with a total

culture and song and dance art. journey of more than 160000 kilometers. It has helped nearly 400 cultural and intangible cultural heritage inheritors from 41 ethnic

groups to take the stage in China and abroad. As of the end of 2024 "In Cloud" has launched 127 related series works in the form of short

and strive to preserve more brilliant national cultures contributing to the continuity of Chinese culture.Bloomage Biotech collaborated with "Light Up Action Charity Plan"

Case to care for autistic children

In 2024 Bloomage Biotech strengthened its support and care for children with autism. Its brands BIOHYALUX and BLOOMCARE collabo-

rated with the “Light Up Action Charity Plan” to jointly create the "Vitality Gift Box" incorporating the paintings of children with autism

into BIOHYALUX’s product Collagen Vitality Boost Essence. A portion of the sales revenue was applied to the care for children with autism

autism and providing more tangible help to these children and their families.Bloomage Biotech's "In Cloud" Series of Thematic Activities

115 116Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Appendices GRI Index

GRI Standard Disclosure Index

2-1 Organizational details P3-4

Index of Indicators 2-2 Entities included in the organization's sustainability reporting About This Report

2-3 Reporting period frequency and contact point About This Report

2-4 Restatements of information P98

SSE Sustainability Report Disclosure Guidelines 2-5 External assurance N/A

2-6 Activities value chain and other business relationships About This Report，P105-112

Dimension Disclosure Topics Index 2-7 Employees P51-78

Addressing Climate Change P81-85 2-8 Workers who are not employees P67-68105-112

Pollutant Emissions P94-97 2-9 Governance structure and composition P19

Waste Management P96-97 2-10 Nomination and selection of highest governance body P19

Ecosystem and Biodiversity Conservation P93 2-11 Chair of the highest governance body P19

Environment

Environmental Compliance Management P90-92 2-12 Role of the highest governance body in overseeing the management of impacts P19

Energy Utilization P86-88 2-13 Delegation of responsibility for managing impacts P19

Water Utilization P95 P98 2-14 Role of the highest governance body in sustainability reporting P11 19

Circular Economy P98-102 P25-26

Rural Revitalization P115 GRI 2: General Disclosures 2-16 Communication of critical concerns P10

Social Contribution P115-116 2-17 Collective knowledge of the highest governance body P19

Innovation Drive P33-41 2-18 Evaluation of the performance of the highest governance body -

Ethics in Technology P38 2-19 Remuneration policies P75

Society Supply Chain Security P105-112 2-20 Process to determine remuneration P75

Equal Treatment of Small and Medium-sized Enterprises During the reporting period no instances of overdue unpaid 2-21 Annual total compensation ratio -

amounts to small and medium-sized enterprises were found

Product and Service Safety and Quality P42-50 2-22 Statement on sustainable development strategy P9

Data Security and Customer Privacy Protection P28-2949 2-23 Policy commitments P19-30 57 90

Employee P51-78 2-24 Embedding policy commitments P19-30 57 90

Due Diligence P23-24106111 2-25 Processes to remediate negative impacts P27

Governance Related to Stakeholders Engagement P10 2-26 Mechanisms for seeking advice and raising concerns P27

Sustainable Development Anti-commercial Bribery and Corruption P25-27 P20-243738404248

2-27 Compliance with laws and regulations

5365909499

Anti-unfair Competition P25

2-28 Membership associations P39

2-29 Approach to stakeholder engagement P10

2-30 Collective bargaining agreements P78

3-1 Process to determine material topics P11

GRI 3：Material Topics 3-2 List of material topics P12-14

3-3 Management of material topics P11-14

117 118CONTENTS Chairwoman and

Sustainable

2024 Sustainability Report CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

GRI Standard Disclosure Index GRI Standard Disclosure Index

201-1 Direct economic value generated and distributed P132 304-1 Operational sites owned leased managed in or adjacent to protected areas P93

and areas of high biodiversity value outside protected areas

201-2 Financial implications and other risks and opportunities due to climate change P84-85

GRI 201: Economic Performance 304-2 Significant impacts of activities products and services on biodiversity P93

201-3 Defined benefit plan obligations and other retirement plans P75-77 GRI 304: Biodiversity

304-3 Habitats protected or restored N/A

201-4 Financial assistance received from government -

304-4 IUCN Red List species and national conservation list

202-1 Ratios of standard entry level wage by gender compared to local minimum wage P75 129 species with habitats in areas affected by operations P93

GRI 202: Market Presence

202-2 Proportion of senior management hired from the local community P55-56

305-1 Direct (Scope 1) GHG emissions P89

203-1 Infrastructure investments and services supported N/A

305-2 Energy indirect (Scope 2) GHG emissions P89

GRI 203: Indirect Economic Impacts

203-2 Significant indirect economic impacts P115-116

305-3 Other indirect (Scope 3) GHG emissions P89

GRI 204: Procurement Practices 204-1 Proportion of spending on local suppliers -

GRI 305: Emissions 305-4 GHG emissions intensity P89

205-1 Operations assessed for risks related to corruption P26

305-5 Reduction of GHG emissions P89

GRI 205: Anti-corruption 205-2 Communication and training about anti-corruption policies and procedures P27 305-6 Emissions of ozone-depleting substances (ODS) P89

205-3 Confirmed incidents of corruption and actions taken P27

305-7 Nitrogen oxides (NOx) sulfur oxides (SOx) and other significant air emissions P94

GRI 206: Anti-competitive Behavior 206-1 Legal actions for anti-competitive behavior anti-trust and monopoly practices P25 306-1 Waste generation and significant waste-related impacts P96

207-1 Approach to tax P22

306-2 Management of significant waste-related impacts P96

207-2 Tax governance control and risk management P22

GRI 306: Waste 306-3 Waste generated P96-97

GRI 207: Tax

207-3 Stakeholder engagement and management of concerns related to tax P22

306-4 Waste diverted from disposal P97

207-4 Country-by-country reporting N/A

306-5 Waste directed to disposal P97

301-1 Materials used by weight or volume P99-102

308-1 New suppliers that were screened using environmental criteria P111-112

GRI 308: Supplier Environmental

GRI 301: Materials 301-2 Recycled input materials used P99-102 Assessment 308-2 Negative environmental impacts in the supply chain and actions taken P112

301-3 Reclaimed products and their packaging materials P99-102

401-1 New employee hires and employee turnover P54

302-1 Energy consumption within the organization P87-88

401-2 Benefits provided to full-time employees that are not provided to temporary or

GRI 401: Employment part-time employees P75-77

302-2 Energy consumption outside of the organization P89

401-3 Parental leave P76

GRI 302: Energy 302-3 Energy intensity P87-88

GRI 402: Labor/Management Relations 402-1 Minimum notice periods regarding operational changes N/A

302-4 Reduction of energy consumption P87-88

403-1 Occupational health and safety management system P65

302-5 Reductions in energy requirements of products and services P86-89

403-2 Hazard identification risk assessment and incident investigation P67-72

303-1 Interactions with water as a shared resource P98

403-3 Occupational health services P73-74

303-2 Management of water discharge-related impacts P95

403-4 Worker participation consultation and communication on occupational health

GRI 303: Water and Effluents 303-3 Water withdrawal P125 and safety P73-74

303-4 Water discharge P125 403-5 Worker training on occupational health and safety P73-74

GRI 403: Occupational Health and Safety

303-5 Water consumption P125 403-6 Promotion of worker health P73-74

403-7 Prevention and mitigation of occupational health and safety impacts directly

linked by business relationships P73-74

403-8 Workers covered by an occupational health and safety management system P73-74

403-9 Work-related injuries P66

403-10 Work-related ill health P74-74

119 120CONTENTS Chairwoman and

Sustainable

2024 Sustainability Report CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

IFRS S2 Index

GRI Standard Disclosure Index

404-1 Average hours of training per year per employee P128 Suggested Disclosure Index

GRI 404: Training and Education 404-2 Program for upgrading employee skills and transition assistance programs P57-62

Disclose the governing body (which may include the board of directors committees or equivalent bodies

P81

404-3 Percentage of employees receiving regular performance and career development reviews P63 responsible for governance) or individuals responsible for overseeing climate-related risks and opportunities.

Governance

405-1 Diversity of governance bodies and employees P55-56131 Disclose the role of management in the oversight management and supervision of the governance

P81

GRI 405: Diversity and Equal Opportunity processes controls and procedures related to monitoring climate-related risks and opportunities.

405-2 Ratio of basic salary and remuneration of women to men P129

Disclose how climate-related risks and opportunities may reasonably impact the prospects of the entity. P8284-85

GRI 406: Non-discrimination 406-1 Incidents of discrimination and corrective actions taken P53-55 63

Disclose the current and expected impacts of climate-related risks and opportunities on the entity's business

406-1 Freedom of Association and 407-1 Operations and suppliers in which the right to freedom of association and collective bargaining model and value chain. P8284-85

Collective Bargaining P78may be at risk

Disclose the impact of climate-related risks and opportunities on the entity's strategies and decisions

GRI 408: Child Labor 408-1 Operations and suppliers at significant risk for incidents of child labor P54 including information on transition plans related to climate. P8284-85

Strategy

GRI 409: Forced or Compulsory Labor 409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor P54

Disclose the impact of climate-related risks and opportunities on the entity's financial position financial

performance and cash flows during the reporting period as well as the expected impact on the entity's

GRI 410：Security Practices 410-1 Security personnel trained in human rights policies or procedures P67-68 P8284-85short-term medium-term and long-term financial position financial performance and cash flows

considering how climate-related risks and opportunities are incorporated into the entity's financial planning.GRI 411：Rights of Indigenous Peoples 411-1 Incidents of violations involving rights of indigenous peoples N/A

413-1 Operations with local community engagement impact assessment and development programs P115-116 Consider the entity's ability to adapt to climate-related changes developments and uncertainties and P8284-85

GRI 413: Local Communities disclose the entity's strategies and its business model's adaptability to climate-related changes.

413-2 Operations with significant actual and potential negative impacts on local communities P115-116

Disclose the processes and related policies used by the entity to identify assess prioritize address and

P83

414-1 New suppliers that were screened using social criteria P111 monitor climate-related risks.

GRI 414: Supplier Social Assessment

414-2 Negative social impacts in the supply chain and actions taken P111 Disclose the procedures used by the entity to identify assess prioritize and monitor climate-related

Risk opportunities including whether and how the entity uses climate scenario analysis to identify climate-related P84

GRI 415：Public Policy 415-1 Political contributions N/A Management opportunities.

416-1 Assessment of the health and safety impacts of product and service categories P38 Disclose to what extent the processes for identifying assessing prioritizing and monitoring climate-related

GRI 416: Customer Health and Safety risks and opportunities are integrated into the entity's overall risk management process and how they are P83

416-2 Incidents of non-compliance concerning the health and safety impacts of products and services P36-38 incorporated and reported.

417-1 Requirements for product and service information and labeling P45 48

Disclose information related to cross-industry metric categories. P125-126

GRI 417：Marketing and Labeling 417-2 Incidents of non-compliance concerning product and service information and labeling P48

Disclose industry-specific metrics related to specific business models activities or other common

P125-126

417-3 Incidents of non-compliance concerning marketing communications P48 Directions characteristics of participating industries.

and Targets

GRI 418: Customer Privacy 418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data P49 Disclose the targets set by the entity to mitigate or adapt to climate-related risks or to leverage climate-relat-

ed opportunities as well as any targets required by laws or regulations for the entity to achieve including P82

indicators used by the governing body or management to measure progress towards these targets.Table of the Ten Principles of the United Nations Global Compact (UNGC)

Category Principles Index

Principle 1: Businesses should support and respect the protection of internationally proclaimed human rights; and P53-54

Human Rights

Principle 2: Make sure that they are not complicit in human rights abuses P53-54

Principle 3: Businesses should uphold the freedom of association and the effective recognition of the right to

collective bargaining P78

Principle 4: The elimination of all forms of forced and compulsory labour P54

Labour

Principle 5: The effective abolition of child labour; and P54

Principle 6: The elimination of discrimination in respect of employment and occupation P54

Principle 7: Businesses should support a precautionary approach to environmental challenges P81-102

Environment Principle 8: Undertake initiatives to promote greater environmental responsibility; and P81-102

Principle 9: Encourage the development and diffusion of environmentally friendly technologies P81-102

Anti-Corruption Principle 10: Businesses should work against corruption in all its forms including extortion and bribery P25-27

121 122Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

GHG Verification Statement待补充证书

123 124Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

ESG Key Performance Tables Indicators Unit 2023 2024

Total water consumption 10000 tons 149.33 163.83

Water

Water usage per unit of revenue ton/million revenue in RMB 245.77 305.04

Environmental Performance15 Total procurement of packaging materials ton 5270.00 8494.23

Packaging materials

Purchase volume of FSC-certified paper

ton 846.00 1635.00

Indicators Unit 2023 2024 packaging materials

Total waste discharged ton 10923.55 12204.44

Location-based tCO?e 100902.09 113510.99

Total GHG emissions

(Scope 1 and 2) General industrial waste ton 9599.45 10521.68

Market-based tCO?e / 109785.94

Hazardous waste ton 85.01 144.22

Location-based tCO?e/million revenue in RMB 16.61 21.14

GHG emissions per unit of

revenue (Scope 1 and 2) Domestic waste ton 581.09 1184.42

Market-based tCO?e/million revenue in RMB / 20.44 Wastes

Greenhouse gases Kitchen waste ton 658.00 354.12

Scope 1 emissions tCO?e 43554.73 37412.27

Recycled waste ton 7331.00 7125.01

Location-based tCO?e 57347.36 76098.72

Scope 2 emissions Non-hazardous waste emission intensity ton/million revenue in RMB 1.78 2.25

Market-based tCO?e / 72373.66

Hazardous waste emission intensity ton/million revenue in RMB 0.01 0.03

Scope 3 emissions tCO?e / 183852.39

Sulfur oxides ton 2.32 1.75

Natural gas cubic meter 15686836 13073453

Air emissions Nitrogen oxides ton 7.46 6.22

Gasoline litre 21706 30112

Volatile organic compounds ton 3.30 3.05

Diesel oil litre 8939 7934

Total volume of wastewater discharged 10000 tons 123.85 171.54

Purchased electricity (thermal power) kWh 66931210 77625771

Chemical oxygen demand (COD) ton 54.01 102.52

Purchased renewable electricity (wind power) kWh / 13375618

Wastewater Ammonia nitrogen ton 2.03 0.80

Total amount kWh 3521913 3745485

Energy Self-generated Photovoltaic Total phosphorus ton 0.79 1.04

renewable electricity generation kWh 2401725 2312192

electricity

Biogas electricity Total nitrogen ton 10.10 11.23

generation kWh 1120188 1433293

Number of training sessions times 43 53

Purchased heat from fossil fuels GJ 174331.73 245503.80 Training on environmental

protection and pollution Number of employees trained participants 3622 2987

Purchased heat from biomass fuel GJ 38282.69 153263.05 prevention and control

Total training duration hour 3313 4806

Total comprehensive energy consumption tons of standard coal 35071.79 35346.54

Comprehensive energy consumption intensity tons of standard coal/million revenue in RMB 5.77 6.58

15 The scope of statistics includes all operational production bases of Bloomage Biotech located within China. The total comprehensive energy consumption (in

tons of standard coal) is calculated based solely on the comprehensive energy consumption of fossil fuel energy. Due to the increased production volume at

Bloomage Biotech's Tianjin production base this year the total consumption of fossil energy for heat and electricity as well as the total water usage have all

increased. The symbol "/" indicates that the item is not applicable.

125 126Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Social Performance16

Indicators Unit 2023 2024

Indicators Unit 2023 2024 Total employee turnover rate % 28.46 28.75

Male % - 26.80

Total number of employees person 4655 4444 Turnover rate by

gender

Female % - 30.76

Male person 2344 2268

Number of

employees by gender Aged 51 or above % - 17.52

Female person 2311 2176

Employee turnover rate

T u r n i n g r a t e b y a g e Aged 31 to 50 % - 18.00

Aged 51 or above person 70 67

Nu Aged 30 or below % - 38.51 m b e r o f Aged 31 to 50 person 2017 2172

employees by age

Mainland China % - 28.75

Aged 30 or below person 2568 2205

Employment Turning rate by

r e g i o n Regions or countries outside the mainland

Senior management person 8 8 % - 29.41 (including Hong Kong Macao and Taiwan)

N u m b e r o f Middle Management person 663 193

Employees by rank P r o p o r t i o n o f Male % 53.39 48.97

trained employees

General staff person 3984 4243 b y g e n d e r Female % 46.61 51.03

Mainland China person 4637 4428

Number of Management % 20.72 11.51Training participation

employees by

g e o g r a p h i c l o c a t i o n Regions or countries outside the mainland

rate by rank

person 18 16 General staff % 79.28 88.49

(including Hong Kong Macao and Taiwan)

Male hour 22.19 29.17

Female senior management (executives) person 4 4 Average training

hours by gender

Female hour 23.15 24.16

N u m b e r a n d Proportion of women in senior management % 50.00 50.00

proportion of Management hour 38.52 32.52

w o m e n i n Female middle management Average training

managemen person 328 80 t (above the manager level) hours by rank

General staff hour 18.49 25.84

Proportion of women in middle management % 49.47 41.45

Total number of employees trained participants - 6279

Number of R&D employees person 926 920

Average hours of employee trained hour 22.83 26.61

N u m b e r a n d Proportion of R&D employees % 19.87 20.70 Total investment in employee training RMB 10000 506.57 267.25

proportion of R&D

e m p l o y e e s Number of female R&D employees person 576 577

Employee Development Proportion of employees receiving performance appraisals % 100 100

Proportion of female R&D employees % 62.20 62.72

Employee Diversity Total number of promotions person / 322

N u m b e r o f General staff person 4643 4427 Internal promotion rate % / 7.25

employees by

p h y s i c a l c o n d i t i o n Disabled employees person 12 17

Number of male employees promoted internally person / 114

N u m b e r o f Number of employees of ethnic minorities person 131 120 N u m b e r o f Proportion of male employees promoted internally % / 35.40employees by ethnic

promotions by

g r o u p Number of employees of non-ethnic minorities person 4524 4324

g e n d e r Number of female employees promoted internally person / 208

Doctor's degree and Professor person 36 43

Proportion of female employees promoted internally % / 64.60

N u m b e r o f Master's degree person 654 633

Internal promotions

Senior management person / 4

employees by

e d u c a t i o n Bachelor's degree person 1712 1699

N u m b e r o f

%/1.24

Proportion of senior management promoted internally

Below bachelor's degree person 2253 2069 promotions by rank

Middle management person / 25

Proportion of middle management promoted internally % / 7.76

Aged 51 or above person / 3

Number of

p r o m o t i o n s b y a g e Aged 31 to 50

person / 147

Aged 30 or below person / 172

16 "-" indicates the item was not counted; "/" indicates the item is not applicable.

127 128Chairwoman and Sustainable

2024 Sustainability Report CONTENTS CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Indicators Unit 2023 2024 Indicators Unit 2023 2024

Unadjusted average gender pay gap % - -7.71 Cumulative number of invention patents authorized item 296 392

Employee Compensation17 Average gender pay gap % - 92.84 Cumulative number of design patents authorized item 58 73

Medium gender pay gap % - 78.46 C u m u l a t iv e Cumulative number of utility model patents authorized item 98 122

number of

Number of employees covered person 339 339 i n t e l l e c t u a l Cumulative number of trademark rights authorized item 4346 5057

property rights

E m p l o y e e s t o c k Number of stocks covered share 4800000 4800000 Cumulative number of software and copyright authorizations item 100 113

ownership plan

Proportion of the amount of stocks covered % 1 1 Cumulative number of invention patents applied to main business item 296 392

Employee Benefits

Proportion of employees' social security contributions % 100 100 Cumulative number of domestic patent authorizations item 445 572

Cumulative number

Supplementary medical insurance for regular employees % 100 100 o f i n t e l l e c t u a l Cumulative number of overseas patent authorizations item 7 15

property

Physical examination coverage rate for regular employees % 100 100 a u t h o r i z a t i o n s b y Cumulative number of domestic trademark authorizations item 3749 4180

region

Number of occupational health and safety training times 640 1755 Cumulative number of overseas trademark authorizations item 597 877

Intellectual property rights

Number of employees trained on occupational health and safety participants 16675 34080 Annual number of invention patent authorizations item 87 96

Occupational

h e a l t h a n d s a f e t y Number of safety education for suppliers contractors etc. times - 467 Annual number of design patent authorizations item 16 15

training

Number of participants in safety education for suppliers contractors etc. participants - 27823 A n n u a l n u m b e r Annual number of utility model patent authorizations item 12 24

of intellectual

Total hours of occupational health and safety training hour 23533 36629 p r o p e r t y r i g h t s Annual number of trademark right authorizations item 585 711

Number of work-related injuries count 3 0 Annual number of software and work copyright authorizations item 17 13

Employee Health and Safety Number of work-related deaths person 0 0 Annual number of invention patents authorized for main business item 87 96

Work-related

i n j u r y i n c i d e n t s Number of working days lost due to work-related injuries day 53 0 Annual number of domestic patent authorizations item 112 127

Annual number

Work-related accidents per million work hours % 0.32 0 o f i n t e l l e c t u a l Annual number of overseas patent authorizations item 3 8

property

I n v e s t m e n t i n Total investment RMB 10000 935.05 1082.22 a u t h o r i z a t i o n s b y Annual number of domestic trademark authorizations item 530 431

occupational region

h e a l t h a n d s a f e t y Investment in employee safety liability insurance RMB 10000 13.76 13.52 Annual number of overseas trademark authorizations item 55 280

Internal safety audit rate % 100 100 Participants in training participants 8585 22243

Safety audit Responsible Marketing

Rectification rate of safety audit % 100 100 Cumulative Duration of responsible marketing training hour 2714 15312

Total number of suppliers count 712 1339

Mainland China count 601 1333

Responsib

Suppliers

l e Hong Kong Macao and Taiwan China count 2 1

Marketing

Overseas countries or regions count 109 5

Signing rate of compliance commitment letters of suppliers of production materials % 94 100

Cybersecurity Network and data security violations count 0 0

Social welfare Total investment in public welfare RMB million 2.68 9.61

17 The unadjusted average gender pay gap = (Average male pay - Average female pay) ÷ Average male pay × 100%. The male/female average wage ratio is the

difference in average hourly wages between male full-time relevant employees and female full-time relevant employees expressed as a ratio of male/female.The male/female median wage ratio is the difference in median hourly wages between male full-time relevant employees and female full-time relevant employ-

ees expressed as a ratio of male/female.

129 130Sustainable

2024 Sustainability Report CONTENTS

Chairwoman and

CEO's Message About Us Development Safeguard Driving Forces Growth Symbiosis Achievements Responsibility AppendicesManagement

Governance Performance Economic Performance

Indicators Unit 2023 2024 Indicators Unit 2023 2024

Number of directors person 9 9 Operating revenue RMB 100 million 60.76 53.71

Number of female directors in the Board person 3 3 Net income attributable to parent RMB 100 million 5.93 1.74

Proportion of female directors in the Board % 33.33 33.33 R&D investment RMB 100 million 4.46 4.66

Number of independent directors in the Board person 3 3 Proportion of R&D investment to total revenue % 7.35 8.68

Proportion of independent directors in the Board % 33.33 33.33

Number of directors with industry experience person 5 5

Number of directors with risk management experience person 6 6

Number of directors with financial management experience person 3 3

Proportion of independent directors of the Audit Committee % 66.67/100 100

Proportion of independent directors of the Nomination Committee % 66.67 66.67

Board composition and Proportion of independent directors of the Remuneration and

governance overview Assessment Committee % 66.67 66.67

Proportion of independent Directors of the Strategy Committee % 20 20

Proportion of independent directors in the ESG Committee % 66.67 66.67

Number of supervisors person 3 3

Number of female supervisors person 3 3

Number of employee supervisors in the Board of Supervisors person 1 1

Proportion of employee supervisors in the Board of Supervisors % 33.33 33.33

Number of the Board meetings held times 6 5

Number of the Supervisory Board meetings held times 4 3

Number of the Shareholders' meetings held times 1 2

Number of meetings of each committee times 7 10

Number of compliance training times 6 3

Coverage rate of key personnel in compliance training % 100 100

Special training on

corporate governance Number of anti-bribery training times 2 4

Coverage rate of key personnel in anti-bribery training % 100 100

131132